As
filed with the Securities and Exchange Commission on April 17,
2017
Registration
No. 333-__________
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington
D.C. 20549
REGISTRATION STATEMENT ON
FORM S-1
UNDER THE SECURITIES ACT OF 1933
WRAP TECHNOLOGIES,
INC.
(Exact
name or Registrant as specified in its charter)
Delaware
|
|
3480
|
|
98-0551945
|
(State
or Other Jurisdiction of Incorporation or
Organization)
|
|
(Primary Standard
Industrial Classification Number)
|
|
(IRS
Employer Identification Number)
|
4620
Arville Street, Suite E
Las
Vegas, Nevada 89103
(800)
583-2652
|
(Address,
including zip code, and telephone number, including area code, of
registrant’s principal executive offices)
|
James
A. Barnes
President
and Chief Financial Officer
Wrap
Technologies, Inc.
4620
Arville Street, Suite E
Las
Vegas, Nevada 89103
(800) 583-2652
(Name,
address including zip code, and telephone number, including area
code, of agent for service)
Copies of all communications to:
Daniel W. Rumsey, Esq.
Jessica R. Sudweeks, Esq.
Disclosure Law Group,
|
a Professional Corporation
|
600 West Broadway, Suite 700
|
San Diego, California 92101
|
Tel: (619) 272-7050
|
Fax: (619) 330-2101
|
APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE
PUBLIC:
As
soon as practicable after the effective date of the Registration
Statement
If any
of the securities being registered on this form are to be offered
on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933, check the following
box. [X]
If this
form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, check the
following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same
offering. [ ]
If this
form is a post-effective amendment filed pursuant to
Rule 462(c) under the Securities Act, check the following box
and list the Securities Act registration statement number of the
earlier effective registration statement for the same
offering. [ ]
If this
form is a post-effective amendment filed pursuant to
Rule 462(d) under the Securities Act, check the following box
and list the Securities Act registration statement number of the
earlier effective registration statement for the same
offering. [ ]
Indicated
by check mark whether the Registrant is large accelerated filer, an
accelerated filer, a non-accelerated filer or a small reporting
company as defined in Rule 12b-2 of the Securities Exchange Act of
1934. (Check one unless a smaller reporting
company.)
Large
Accelerated Filer [ ]
|
|
Accelerated
Filer [ ]
|
|
|
|
Non-accelerated
Filer [ ]
|
|
Smaller
Reporting Company [X]
|
CALCULATION OF REGISTRATION FEE
Title
Of Each Class Of
Securities
To Be Registered
|
Amount to be
Registered
(1)
(2)
|
Proposed
Maximum
Offering
Price
Per
Share
(1)
|
Proposed
Maximum
Aggregate
Offering
Price
(2)
|
Amount
of
Registration
Fee
(1)
|
Common Stock, par
value, $0.0001 per share $
|
|
|
$
|
$
|
Shares of common
stock to be distributed as a dividend to shareholders of Petro
River Oil Corp.
|
400,838
|
|
|
|
Total
|
|
|
$
4,000,000
|
$
463.60
|
(1)
Estimated solely
for purposes of calculating the registration fee pursuant to Rule
457(o) of the Securities Act of 1933, as amended (the
“
Securities Act
”).
(2)
Pursuant to Rule
416 under the Securities Act, there is also being registered such
indeterminable additional securities as may be issued to prevent
dilution as a result of stock splits, stock dividends or similar
transactions.
(3)
Estimated solely for the purpose of calculating the registration
fee pursuant to Rule 457(g) under the Securities Act.
The Registrant hereby amends this Registration Statement on such
date or dates as may be necessary to delay its effective date until
the Registrant shall file an amendment which specifically states
that this Registration Statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933 or
until the Registration Statement shall become effective on such
date as the Securities and Exchange Commission, acting pursuant to
said Section 8(a), may determine.
EXPLANATORY NOTE
This registration statement contains two forms of
prospectus. One form of prospectus, which we refer to as the
primary public offering prospectus, is to be used in connection
with a public offering of up to _________ shares of our common
stock. The other form of prospectus, which we refer to as the
resale prospectus, is to be used in connection with the
distribution by Petro River Oil Corp. of 400,838 shares of our
common stock upon the effectiveness of the registration statement
of which such prospectus forms a part. The primary public offering
prospectus and the resale prospectus will be identical in all
respects except for the alternate pages for the resale prospectus
included herein, which are labeled “
Alternate Page for Resale
Prospectus
.”
The information in this preliminary prospectus is not complete and
may be changed. These securities may not be sold until the
registration statement filed with Securities and Exchange
Commission is effective. This prospectus is not an offer to sell
these securities and is not soliciting an offer to buy these
securities in any state or other jurisdiction where the offer or
sale is not permitted.
Prospectus
|
|
____________, 2017
|
_________ shares of Common Stock
Wrap Technologies, Inc. (the “
Company
”) is offering up to ________ shares of
common stock, par value of $0.0001(“
Common
Stock
”)
(“
Shares
”). There is currently no public market for
our Common Stock. In addition:
1.
This
is a "self-underwritten" public offering, with no minimum purchase
requirement;
2.
The
Company is not using an underwriter for this offering;
and
3.
There
is no arrangement to place the proceeds from this offering in an
escrow, trust or similar account.
The offering will commence on the effective date of this prospectus
and will terminate on or before _______, 2017. We will not
extend the offering beyond the termination date. In our sole
discretion, we may terminate the offering before all of Shares are
sold.
We will sell the Shares ourselves, on a best efforts basis for a
period of up to twelve months from the effective date of this
prospectus. We do not plan to use underwriters or pay any
commissions. There is no minimum number of Shares we must
sell. As such, no funds raised from the sale of Shares will
go into escrow, trust or another similar arrangement. Because
there is no minimum to our offering, if we fail to raise sufficient
capital to execute our business plan, investors could lose their
entire investment and will not be entitled to a
refund.
There is currently no established public trading market for our
Common Stock and an active trading market in our Common Stock may
not develop or, if it is developed, may not be sustained. We
anticipate having a market maker file an application with the
Financial Industry Regulatory Authority (“
FINRA
”) on our behalf so that our Common Stock
may be quoted on an inter-dealer quotation system such as the OTC
Markets or the Nasdaq OMX; however, to date, we do not have a
market maker who has agreed to file an
application.
Due to the uncertainty of our ability to meet our current operating
and capital expenses, our independent auditors have included a
going concern opinion in their report on our audited financial
statements for the period ending December 31, 2016. The notes to
our financial statements contain additional disclosure describing
the circumstances leading to the issuance of a going concern
opinion by our auditors.
An investment in
our securities involves a high degree of risk.
We urge you to read carefully
the “Risk Factors” section beginning on page 5 where we
describe specific risks associated with an investment in Wrap
Technologies, Inc. and our securities before you make your
investment decision. You should purchase our securities only if you
can afford a complete loss of your purchase.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved these securities,
or determined if this prospectus is truthful or
complete. Any representation to the contrary is a
criminal offense.
|
|
Offering
Expenses
($)
(1)
|
|
Net
Proceeds
to
Us if 25% of
Shares
Sold
(_______
Shares) ($)
|
Net
Proceeds
to
Us if 50% of
Shares
Sold
(________
Shares) ($)
|
Net
Proceeds
to
Us if 75% of
Shares
Sold
(________
Shares) ($)
|
Net
Proceeds
to
Us if 100% of
Shares
Sold
(________
Shares) ($)
|
|
|
|
|
|
|
|
|
Per
Share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
(2)
|
|
|
(3)
|
|
|
|
|
(1)
The total amount of offering expenses is
estimated to be $50,000. See “
Use of
Proceeds
” for
additional information.
(2)
There are no underwriting discounts or commissions being paid in
connection with this offering. Our officers and directors will not
receive any compensation for their role in offering or selling the
Shares in this offering.
(3)
Net Proceeds includes the deduction of offering expenses estimated
to be $50,000.00.
The information in this prospectus is not complete and may be
changed. The Company may not sell the Shares until the registration
statement filed with the Securities and Exchange Commission (the
“
SEC
”) is effective. This prospectus is not an
offer to sell the Shares nor is it a solicitation of an offer to
buy the Shares in any state where the offer or sale is not
permitted.
We are an “emerging growth company” under the Federal
securities laws and will therefore be subject to reduced public
company reporting requirements. Investment in the Shares offered by
this prospectus involves a high degree of risk. You may lose your
entire investment.
The date of this Prospectus is __, 2017
|
|
|
Generation 2
Pre-Production Functioning Version of BolaWrap™ Model
100
|
|
Artist Rendering of
Planned Production Version of the BolaWrap 100
|
|
Illustration of
Hand-Held Size of BolaWrap 100
|
TABLE OF CONTENTS
Descriptive
Title
|
|
Page
|
|
|
|
PROSPECTUS
SUMMARY
|
|
2
|
RISK
FACTORS
|
|
5
|
JUMPSTART
OUR BUSINESS STARTUPS ACT
|
|
11
|
SPECIAL
NOTE ABOUT FORWARD-LOOKING STATEMENTS
|
|
12
|
USE OF
PROCEEDS
|
|
14
|
MARKET
PRICE OF COMMON STOCK AND RELATED
MATTERS
|
|
15
|
ABSENCE
OF PUBLIC MARKET AND DIVIDEND POLICY
|
|
15
|
CAPITALIZATION
AND FINANCING
|
|
16
|
DILUTION
|
|
17
|
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
|
|
18
|
BUSINESS
|
|
23
|
MANAGEMENT
|
|
31
|
EXECUTIVE
COMPENSATION
|
|
32
|
SECURITY
OWNERSHIP BY CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
|
|
33
|
CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
|
|
34
|
DESCRIPTION
OF OUR SECURITIES
|
|
35
|
SHARES
ELIGIBLE FOR FUTURE SALES
|
|
37
|
PLAN OF
DISTRIBUTION
|
|
38
|
DETERMINATION
OF OFFERING PRICE
|
|
38
|
LEGAL
MATTERS
|
|
39
|
EXPERTS
|
|
39
|
WHERE
YOU CAN FIND MORE INFORMATION
|
|
39
|
INDEX
TO FINANCIAL STATEMENTS
|
|
F-1
|
|
|
|
|
ABOUT THIS PROSPECTUS
You
should rely only on the information contained in or incorporated by
reference into this prospectus and any prospectus supplement or
free writing prospectus authorized by us. To the extent the
information contained in this prospectus differs or varies from the
information contained in any document filed prior to the date of
this prospectus and incorporated by reference, the information in
this prospectus will control. We have not authorized any other
person to provide you with different information. If anyone
provides you with different or inconsistent information, you should
not rely on it. The information in this prospectus is accurate only
as of the date it is presented. You should read this prospectus,
and any prospectus supplement or free writing prospectus that we
have authorized for use in connection with this offering, in their
entirety before investing in our securities.
We
are offering to sell, and seeking offers to buy, the securities
offered by this prospectus only in jurisdictions where offers and
sales are permitted. The distribution of this prospectus and the
offering of the securities offered by this prospectus in certain
jurisdictions may be restricted by law. This prospectus does not
constitute, and may not be used in connection with, an offer to
sell, or a solicitation of an offer to buy, any securities offered
by this prospectus in any jurisdiction in which it is unlawful for
such person to make such an offer or solicitation.
Unless the context
otherwise requires, the words “
Wrap
Technologies, Inc.,
”
“
Wrap
Technologies
,”
“
Wrap
Tech
,”
“
we
,”
“
the
Company
,”
“
us
”
and “
our
”
refer to Wrap Technologies, Inc., a Delaware
corporation.
|
|
|
|
|
|
|
|
|
PROSPECTUS
SUMMARY
The following is a summary of the material terms of the offering
described in this prospectus. This summary is qualified
in its entirety by the more detailed information set forth
elsewhere in this prospectus, including our financial statements
and notes thereto. We urge you to read carefully the entire
prospectus, especially the risks discussed under “Risk
Factors” and our financial statements.
Our Company
We are a development stage security technology company focused on
delivering innovative solutions to customers, primarily law
enforcement and security personnel. We plan to introduce our first
product, the BolaWrap
™
100, during 2017.
The
BolaWrap™ 100 is a hand-held remote restraint device that
discharges an eight-foot bola style Kevlar
®
tether to
entangle an individual at a range of 10-25 feet. Inspired by law
enforcement professionals, the small but powerful BolaWrap™
100 assists law enforcement to safely and effectively control
encounters. Law enforcement agencies authorize a continuum of force
options:
●
physical control
– soft techniques of grabs and holds progressing to hard
techniques such as punches and kicks;
●
less-lethal weapons
- batons, pepper spray, impact munitions and CEWs (conducted
electrical weapons); and
●
lethal force
– deadly weapons such as firearms.
BolaWrap™
100 offers law enforcement a new tool to remotely and temporarily
control an individual or impede flight by targeting and wrapping an
individual’s legs.
The
small, light but rugged BolaWrap™ 100 is designed for weak
hand operation to provide remote restraint while other use of force
continuum options remain open. The design offers wide latitude of
accuracy to engage and restrain targeted legs of a subject. Quick
eject and rapid reload of bola cartridges allows one device to be
reused in a single encounter or in multiple
encounters.
There
are limited effective options for remote engagement so when verbal
commands go unheeded law enforcement is faced with either hands on
engagement or other potentially injurious less lethal or lethal
force. We believe our new tool is essential to meet modern policing
requirements with individuals frequently not responding to verbal
commands and to assuage public demands for less lethal policing. We
believe our device minimizes the need to employ other uses of force
including combat and less-lethal weapons. Many less-lethal weapons
rely on “pain compliance” often escalating encounters
with potential for injury.
We intend to commercialize the BolaWrap™ 100 by initially
targeting sales to the approximate 18,000 United States law
enforcement agencies with approximately 765,000 full time officers
and to the United States Border Patrol with 21,000 border patrol
agents. Thereafter we intend to target law enforcement agencies and
security personnel worldwide.
Our Strengths and Challenges
We believe the following competitive strengths position us for
future operating success, growth and ultimately,
profitability:
●
We
are pioneering the BolaWrap™ 100 device. There has been no
restraint or less-lethal product broadly accepted by law
enforcement since the 1994 introduction of the Taser CEW (conducted
electrical weapon also referred to as CED, or conducted energy
device);
●
We
believe we are creating important intellectual property around our
product;
|
|
|
|
|
|
|
|
|
●
Our
initial focus on BolaWrap™ 100 affords us great sales and
marketing flexibility to respond to and meet customer requirements;
and
●
Our
management team has developed a strong technical base in this
technology and is experienced in innovating and bringing products
to market. We plan to develop a line of BolaWrap™
entanglement products and develop additional security technology
products.
We expect to face significant challenges and uncertainties in
executing our business plan, including but not limited to the
following:
●
We
need to rapidly, profitably and successfully commercialize the
BolaWrap™ 100 product and develop additional versions of the
technology, and develop new technologies and products;
●
Our
products must meet the needs of customers and we need to generate
sufficient revenues to sustain profitable operations;
●
We
have limited personnel and financial resources to develop required
business functions, including development, production, marketing,
sales, distribution, service and administration;
●
We
will be required to obtain additional financing until we are able
to produce sufficient revenues and profitability to sustain future
operations; and
●
We face the uncertainties and risks facing any
development stage company, including but not limited to, the risk
factors described in the section entitled
“
Risk
Factors
” starting on page
5.
Our Strategy
Our goal is to realize the potential of a new remote restraint
device targeting law enforcement and security personnel. We aim to
produce a product line starting with the BolaWrap™ 100 to
meet the requirements of these customers. The key elements of our
strategy include:
●
Produce
a product line meeting customer requirements as a new tool to aid
in the retention of individuals to make encounters more effective
and less dangerous to law enforcement and the public;
●
Develop
a robust production and supply system to support our customers;
and
●
Develop
relationships with customers requiring large numbers of products,
mainly larger city police departments and large
agencies.
We also plan to explore markets for use by security and related
personnel and develop international distribution.
Corporate Information
Our
principal executive offices are located at 4620 Arville Street,
Suite E, Las Vegas, Nevada 89104, and our telephone number is
(800) 583-2652. Our website addresses are
www.wraptechnologies.com and www.bolawrap.com. Information
contained on, or that can be accessed through, our websites, is not
incorporated by reference into this prospectus, and you should not
consider information on our website to be part of this
prospectus.
|
|
|
|
|
|
|
|
|
The Offering
Securities we are
offering
______
shares of Common
Stock
Common Stock outstanding after this
offering
__________ shares
of Common Stock.
Use of proceeds
We estimate that
the maximum net proceeds to us from this offering, after deducting
the estimated offering expenses payable by us, and based on the
assumed combined public offering price of $____ per Share will be
approximately $____ million. We intend to use the net proceeds of
this offering principally for research, development and tooling,
and sales and marketing. See “
Use of Proceeds
” for a more
complete description of the intended use of proceeds from this
offering.
|
|
|
|
|
RISK FACTORS
In addition to the information contained elsewhere in this
prospectus, you should consider carefully the following risk
factors related to Wrap Tech. If any of the risks described below
actually occur, our business, financial condition, results of
operations, cash flows and stock price could be materially
adversely affected. This prospectus also contains forward-looking
statements that involve risks and uncertainties. Our actual results
could differ materially from those anticipated in these
forward-looking statements as a result of certain factors,
including the risks faced by us described below and elsewhere in
this prospectus. See “Special Note About Forward-Looking
Statements
”
on page
12
.
Risk Factors Relating to Our Business
We have a history of operating losses, expect additional losses and
may not achieve or sustain profitability.
We have a history of operating losses and expect additional losses
as we introduce our new product line and until we achieve revenues
and resulting margins to offset our operating costs. Our net
loss for the period from inception (March 2, 2016) to December 31,
2016 was $234,356 and for the three months ended March 31, 2017 was
$201,755. Our ability to achieve future profitability is dependent
on a variety of factors, many outside our control. Failure to
achieve profitability or sustain profitability, if achieved, may
require us to continue to raise additional financing which could
have a material negative impact on the market value of our Common
Stock.
Our independent auditors have expressed substantial doubt about our
ability to continue as a going concern.
In their audit opinion issued in connection with our balance sheet
as of December 31, 2016 and our related statements of operations,
changes in owners equity and cash flows for the period then ended,
our independent registered public accounting firm stated that our
net losses and our requirement to secure additional financing
raised substantial doubt about our ability to continue as a going
concern. We have prepared our financial statements on a
going concern basis which contemplates the realization of assets
and the satisfaction of liabilities in the normal course of
business for the foreseeable future. Our financial statements do
not include any adjustments that would be necessary should we be
unable to continue as a going concern and, therefore, be required
to liquidate our assets and discharge our liabilities in other than
the normal course of business, and at amounts different from those
reflected in our financial statements. If we are unable
to continue as a going concern, our shareholders may lose a
substantial portion or all of their investment.
We need additional capital to execute our business plan, and
raising additional capital, if possible, by issuing additional
equity securities may cause dilution to existing shareholders. In
addition, raising additional capital by issuing additional debt
financing may restrict our operations.
While
we may be able to generate some funds from product sales, existing
working capital will not be sufficient due to product introduction
costs, operating losses and other factors. Principal factors
affecting the availability of internally generated funds
include:
●
failure of product
sales to meet planned projections;
●
working capital
requirements to support business growth;
●
our ability to
control spending; and
●
acceptance of our
product in planned markets.
In the
event we are required to raise additional capital through the
issuance of equity or convertible debt securities, the percentage
ownership of our shareholders could be diluted significantly, and
these newly issued securities may have rights, preferences or
privileges senior to those of our existing shareholders. In
addition, the issuance of any equity securities could be at a
discount to the market price.
If we
incur debt financing, the payment of principal and interest on such
indebtedness may limit funds available for our business activities,
and we could be subject to covenants that restrict our ability to
operate our business and make distributions to our
shareholders. These restrictive covenants may include
limitations on additional borrowing and specific restrictions on
the use of our assets, as well as prohibitions on our ability to
create liens, pay dividends, redeem stock or make
investments. There is no assurance that any equity or debt
financing transaction will be available on acceptable terms, or at
all.
Our principal product remains under development, and has not yet
been produced in any commercial quantities. We we may incur
significant and unpredictable warranty costs as our products are
introduced and produced.
Our principal product remains under development, and has not been
formally introduced into the marketplace. No assurance can be
provided that we can successfully produce commercial quantities of
our principal product. We generally expect to warrant our products
to be free from defects in materials and workmanship for a period
of up to one year from the date of purchase. We may incur
substantial and unpredictable warranty costs from post-production
product or component failures. Future warranty costs could further
adversely affect our financial position, results of operations and
business prospects.
We are materially dependent on the acceptance of our product by the
law enforcement market. If law enforcement agencies do not purchase
our product, our revenues will be adversely affected and we may not
be able to expand into other markets, or otherwise continue as a
going concern.
A
substantial number of law enforcement agencies may not purchase our
remote restraint product. In addition, if our product is not widely
accepted by the law enforcement market, we may not be able to
expand sales of our product into other markets. Law enforcement
agencies may be influenced by claims or perceptions that our
product is not effective or may be used in an abusive manner. Sales
of our product to these agencies may be delayed or limited by such
claims or perceptions.
We will be dependent on sales of the BolaWrap™ 100 product,
and if this product is not widely accepted, our growth prospects
will be diminished.
We
expect to depend on sales of the BolaWrap™ 100 and related
cartridges for the foreseeable future. A lack of demand for this
product, or its failure to achieve broad market acceptance, would
significantly harm our growth prospects, operating results and
financial condition.
If we are unable to manage our projected growth, our growth
prospects may be limited and our future profitability may be
adversely affected.
We
intend to expand our sales and marketing programs and our
manufacturing capability. Rapid expansion may strain our
managerial, financial and other resources. If we are unable to
manage our growth, our business, operating results and financial
condition could be adversely affected. Our systems, procedures,
controls and management resources also may not be adequate to
support our future operations. We will need to continually improve
our operational, financial and other internal systems to manage our
growth effectively, and any failure to do so may lead to
inefficiencies and redundancies, and result in reduced growth
prospects and profitability.
We may face personal injury and other liability claims that harm
our reputation and adversely affect our sales and financial
condition.
Our
product is intended to be used in confrontations that could result
in injury to those involved, whether or not involving our product.
Our product may cause or be associated with such injuries. A person
injured in a confrontation or otherwise in connection with the use
of our product may bring legal action against us to recover damages
on the basis of theories including personal injury, wrongful death,
negligent design, dangerous product or inadequate warning. We may
also be subject to lawsuits involving allegations of misuse of our
product. If successful, personal injury, misuse and other claims
could have a material adverse effect on our operating results and
financial condition. Although we carry product liability insurance,
significant litigation could also result in a diversion of
management’s attention and resources, negative publicity and
an award of monetary damages in excess of our insurance
coverage.
Our future success is dependent on our ability to expand sales
through direct sales or distributors, and our inability to grow our
sales force or recruit new distributors would negatively affect our
sales.
Our
distribution strategy is to pursue sales through multiple channels
with an emphasis on direct sales and, in the future, independent
distributors. Our inability to recruit and retain sales personnel
and police equipment distributors who can successfully sell our
products could adversely affect our sales. If we do not
competitively price our products, meet the requirements of any
future distributors or end-users, provide adequate marketing
support, or comply with the terms of any distribution arrangements,
such distributors may fail to aggressively market our product or
may terminate their relationships with us. These developments would
likely have a material adverse effect on our sales. Should we
employ distributors our reliance on the sales of our products by
others also makes it more difficult to predict our revenues, cash
flow and operating results.
We expect to expend significant resources to generate sales due to
our lengthy sales cycle, and such efforts may not result in sales
or revenue.
Generally,
law enforcement agencies consider a wide range of issues before
committing to purchase a product, including product benefits,
training costs, the cost to use our product in addition to, or in
place of other use of force products, product reliability and
budget constraints. The length of our sales cycle may range from
30 days to a year or more. We may incur substantial selling
costs and expend significant effort in connection with the
evaluation of our product by potential customers before they place
an order. If these potential customers do not purchase our product,
we will have expended significant resources without corresponding
revenue.
Most of our intended end-users are subject to budgetary and
political constraints that may delay or prevent sales.
Most of
our intended end-user customers are government agencies. These
agencies often do not set their own budgets and therefore have
little control over the amount of money they can spend. In
addition, these agencies experience political pressure that may
dictate the manner in which they spend money. As a result, even if
an agency wants to acquire our product, it may be unable to
purchase due to budgetary or political constraints. Some government
agency orders may also be canceled or substantially delayed due to
budgetary, political or other scheduling delays which frequently
occur in connection with the acquisition of products by such
agencies.
Government regulation of our products may adversely affect
sales.
Our
device may be a firearm regulated by the Bureau of Alcohol, Tobacco
and Firearms involving substantial regulatory compliance. Our
device may also face state restrictions especially regarding sales
to security agencies. Our product sales may be significantly
affected by federal, state and local regulation. Failure to comply
with regulations could also result in the impostion of fines,
penalties and other actions that could adversely impact our
financial position, cash flows and operating results.
Our
product may also be controlled by the United States Department of
Commerce (“
DOC
”), for export directly from
the United States. Consequently, we may need to obtain an export
license from the DOC for the export of our product from the United
States other than to Canada. Compliance with or changes in U.S.
export regulations could significantly and adversely affect any
future international sales.
Certain
foreign jurisdictions may restrict the sale of our device limiting
our international sales opportunities.
If we are unable to protect our intellectual property, we may lose
a competitive advantage or incur substantial litigation costs to
protect our rights.
Our
future success depends in part upon our proprietary technology. Our
protective measures, including pending patents, trademarks and
trade secret laws, may prove inadequate to protect our proprietary
rights. There can be no assurance we will be granted any patent
rights from pending patents. The scope of any possible patent
rights may not prevent others from developing and selling competing
products. The validity and breadth of claims covered in any
possible patents involve complex legal and factual questions, and
the resolution of such claims may be highly uncertain, lengthy, and
expensive. In addition, any patents, if granted, may be held
invalid upon challenge, or others may claim rights in or ownership
of our patents.
Our competitive position will be seriously damaged if our products
are found to infringe on the intellectual property rights of
others.
Other companies and our competitors may currently own or obtain
patents or other proprietary rights that might prevent, limit or
interfere with our ability to make, use or sell our
products.
Any intellectual property infringement claims
against us, with or without merit, could be costly and
time-consuming to defend and divert our management’s
attention from our business.
In the
event of a successful claim of infringement against us and our
failure or inability to license the infringed technology, our
business and operating results could be adversely affected. Any
litigation or claims, whether or not valid, could result in
substantial costs and diversion of our resources. An adverse result
from intellectual property litigation could force us to do one or
more of the following:
●
cease
selling, incorporating or using products or services that
incorporate the challenged intellectual property;
●
obtain
a license from the holder of the infringed intellectual property
right, which license may not be available on reasonable terms, if
at all; and
●
redesign
products or services that incorporate the disputed
technology.
If we are forced to take any of the foregoing actions, we could
face substantial costs and shipment delays and our business could
be seriously harmed. Although we carry general liability insurance,
our insurance may not cover potential claims of this type or be
adequate to indemnify us for all liability that may be
imposed.
In addition, it is possible that our customers may seek indemnity
from us in the event that our products are found or alleged to
infringe the intellectual property rights of others. Any such claim
for indemnity could result in substantial expenses to us that could
harm our operating results.
Competition in the law enforcement market could reduce our sales
and prevent us from achieving profitability.
The law
enforcement market is highly competitive. We face competition from
numerous larger, better capitalized and more widely known companies
that make restraint devices, less-lethal weapons and other law
enforcement products. Increased competition could result in greater
pricing pressure, lower gross margins and reduced sales, and
prevent us from achieving profitability.
We cannot predict our future operating results. Our quarterly and
annual results will likely be subject to fluctuations caused by
many factors, any of which could result in our failure to achieve
our expectations.
We currently expect our BolaWrap™ 100 product will be the
source of all of any future revenues. Revenues, if any, are
expected to vary significantly due to a number of factors. Many of
these factors are beyond our control. Any one or more of these
factors, including those listed below, could cause us to fail to
achieve our revenue expectations. These factors
include:
●
our
ability to develop and supply product to customers;
●
market
acceptance of, and changes in demand for, our
products;
●
gains
or losses of significant customers, distributors or strategic
relationships;
●
unpredictable
volume and timing of customer orders;
●
the
availability, pricing and timeliness of delivery of components for
our products;
●
fluctuations
in the availability of manufacturing capacity or manufacturing
yields and related manufacturing costs;
●
timing
of new technological advances, product announcements or
introductions by us and by our competitors;
●
unpredictable
warranty costs associated with our product;
●
budgetary
cycles and order delays by customers or production delays by us or
our suppliers;
●
regulatory
changes affecting the marketability of our products;
●
general
economic conditions that could affect the timing of customer orders
and capital spending and result in order cancellations or
rescheduling; and
●
general
political conditions in this country and in various other parts of
the world that could affect spending for the products that we
intend to offer.
Some or all of these factors could adversely affect demand for our
products and, therefore, adversely affect our future operating
results.
As a result of these and other factors, we believe
that period-to-period comparisons of our operating results may not
be meaningful in the near term and accordingly you should not rely
upon our performance in a particular period as indicative of our
performance in any future period.
Our expenses may vary from period to period, which could affect
quarterly results and our stock price.
If we incur additional expenses in a quarter in which we do not
experience increased revenue, our results of operations will be
adversely affected and we may incur larger losses than anticipated
for that quarter. Factors that could cause our expenses to
fluctuate from period to period include:
●
the
timing and extent of our research and development
efforts;
●
investments
and costs of maintaining or protecting our intellectual
property;
●
the
extent of marketing and sales efforts to promote our products and
technologies; and
●
the
timing of personnel and consultant hiring.
Our dependence on third-party suppliers for key components of our
product could delay shipment of our products and reduce our
sales.
We will
depend on certain domestic and foreign suppliers for the delivery
of components used in the assembly of our product. Our reliance on
third-party suppliers creates risks related to our potential
inability to obtain an adequate supply of components or
subassemblies and reduced control over pricing and timing of
delivery of components and subassemblies. Specifically, we will
depend on suppliers of sub-assemblies, machined parts, injection
molded plastic parts, and other miscellaneous custom parts for our
product. We do not have any long-term supply agreements with any
planned suppliers. Any interruption of supply for any material
components of our products could significantly delay the shipment
of our products and have a material adverse effect on our revenues,
profitability and financial condition.
Foreign currency fluctuations may reduce our competitiveness and
sales in foreign markets.
The
relative change in currency values creates fluctuations in product
pricing for future potential international customers. These changes
in foreign end-user costs may result in lost orders and reduce the
competitiveness of our products in certain foreign markets. These
changes may also negatively affect the financial condition of some
foreign customers and reduce or eliminate their future orders of
our products.
Loss of key management and other personnel could impact our
business.
Our business is substantially dependent on our officers and other
key personnel. The loss of an officer or any key personnel could
materially adversely affect our business, financial condition,
results of operations and cash flows. In addition, competition for
skilled and non-skilled employees among companies like ours is
intense, and the future loss of skilled or non-skilled employees or
an inability to attract, retain and motivate additional skilled and
non-skilled employees required for the operation and expansion of
our business could hinder our ability to conduct research
activities successfully, develop new products, attract customers
and meet customer shipments.
Inadequate internal controls and accounting practices could lead to
errors, which could negatively impact our business, financial
condition, results of operations and cash flows.
We will need to establish internal controls and management
oversight systems. Our small size and limited personnel and
consulting resources will make doing so more challenging than for
more established entities. We may not be able to prevent or detect
misstatements in our reported financial statements due to system
errors, the potential for human error, unauthorized actions of
employees or contractors, inadequacy of controls, temporary lapses
in controls due to shortfalls in transition planning and oversight
resource contracts and other factors. In addition, due to their
inherent limitations, such controls may not prevent or detect
misstatements in our reported financial results as required under
SEC rules, which could increase our operating costs or impair our
ability to operate our business. Controls may also become
inadequate due to changes in circumstances. It will be necessary to
replace, upgrade or modify our internal information systems from
time to time. If we are unable to implement these changes in a
timely and cost-effective manner, our ability to capture and
process financial transactions and support our customers as
required may be materially adversely impacted, which could harm our
business, financial condition, results of operations and cash
flows.
Risk Factors Relating to Our Common Stock
There may not be an active trading market for shares of our Common
Stock.
There is no public trading market for shares of our Common Stock.
We cannot predict the extent to which investor interest in the
Company will lead to the development of an active trading market in
our Common Stock or how liquid such a market might become. It is
possible that, after the offering, an active trading market will
not develop or continue, and there can be no assurance as to the
price at which our Common Stock will trade. The initial share price
of our Common Stock may not be indicative of prices that will
prevail in the future.
We do not expect to be the subject of research analyst coverage.
The absence of research analyst coverage can adversely affect the
market value and liquidity of an equity security.
We cannot predict the price range or volatility of our Common
Stock, and sales of a substantial number of shares of our Common
Stock may adversely affect the market price of our Common
Stock.
From time to time, the market price and volume of shares traded of
companies in the industy in which we operate experience periods of
significant volatility. Company-specific issues and developments
generally affecting our industries or the economy may cause this
volatility. The market price of our Common Stock may fluctuate in
response to a number of events and factors, including:
●
general
economic, market and political conditions;
●
quarterly
variations in results of operations or results of operations that
are below public market analyst and investor
expectations;
●
changes
in financial estimates and recommendations by securities
analysts;
●
operating
and market price performance of other companies that investors may
deem comparable;
●
press
releases or publicity relating to us or our competitors or relating
to trends in our markets; and
●
sales
of Common Stock or other securities by insiders.
In addition, broad market and industry fluctuations, investor
perception and the depth and liquidity of the market for our Common
Stock may adversely affect the trading price of our Common Stock,
regardless of actual operating performance.
Sales or distributions of a substantial number of shares of our
Common Stock in the public market or otherwise following the
distribution, or the perception that such sales could occur, could
adversely affect the market price of our Common Stock. Many of the
shares of our Common Stock, other than the shares held by executive
officers and directors, will be eligible for immediate resale in
the public market following the effectiveness of the registration
statement, of which this prospectus is a part. Investment criteria
of certain investment funds and other holders of our Common Stock
may result in the immediate sale of our Common Stock after such
effectiveness to the extent such stock no longer meets these
criteria. Substantial selling of our Common Stock, whether as a
result of the effectiveness of the registration statement or
otherwise, could adversely affect the market price of our Common
Stock.
We cannot assure you as to the price at which our Common Stock will
trade as a result of the offering. Until our Common Stock is fully
distributed and an orderly market develops in our Common Stock, the
price at which our Common Stock trades may fluctuate significantly
and may be lower or higher than the price that would be expected
for a fully distributed issue.
We may issue additional Common Stock in the future. The issuance of
additional Common Stock may reduce the value of your Common
Stock.
We may issue additional shares of Common Stock without further
action by our shareholders. Moreover, the economic and voting
interests of each stockholder will be diluted as a result of such
issuances. Although the number of shares of Common Stock that
shareholders presently own will not decrease, such shares will
represent a smaller percentage of the total shares that will be
outstanding after the issuance of additional shares. The
issuance of additional shares of Common Stock may cause the market
price of our Common Stock to decline.
Sales of Common Stock issuable on the exercise of any future
options or warrants may lower the price of our Common
Stock.
We adopted a stock option plan on March 31, 2017, which will
authorize the grant of options or restricted stock awards to
purchase up to 2.0 million shares of our Common Stock to our
employees, directors and consultants. The issuance of shares of
Common Stock issuable upon the exercise or conversion of options
could cause substantial dilution to existing holders of Common
Stock, and the sale of those shares in the market could cause the
market price of our Common Stock to decline. The potential dilution
from the issuance of these shares could negatively affect the terms
on which we are able to obtain equity financing.
We may issue preferred stock in the future, and the terms of the
preferred stock may reduce the value of your Common
Stock.
We are authorized to issue up to 5,000,000 shares of preferred
stock in one or more series. Our Board of Directors may determine
the terms of future preferred stock offerings without further
action by our shareholders. If we issue preferred stock, it could
affect your rights or reduce the value of your Common Stock. In
particular, specific rights granted to future holders of preferred
stock could be used to restrict our ability to merge with or sell
our assets to a third party. Preferred stock terms may include
voting rights, preferences as to dividends and liquidation,
conversion and redemption rights and sinking fund
provisions.
The payment of dividends will be at the discretion of our Board of
Directors.
The declaration and amount of future dividends, if any, will be
determined by our Board of Directors and will depend on our
financial condition, earnings, capital requirements, financial
covenants, regulatory constraints, industry practice and other
factors our Board deems relevant. See “
Dividend
Policy
” on page 15
for additional information
on our dividend policy following the
distribution.
JUMPSTART OUR BUSINESS STARTUPS ACT
We
qualify as an “emerging growth company” as defined in
Section 101 of the Jumpstart our Business Startups Act
(“
JOBS Act
”) as
we do not have more than $1.0 billion in annual gross revenue and
did not have such amount as of December 31, 2016, our last fiscal
year. We are electing to use the extended transition period for
complying with new or revised accounting standards under Section
102(b)(1) of the JOBS Act.
We may
lose our status as an emerging growth company on the last day of
our fiscal year during which (i) our annual gross revenue exceeds
$1.0 billion or (ii) we issue more than $1.0 billion in
non-convertible debt in a three-year period. We will lose our
status as an emerging growth company (i) if at any time we are
deemed to be a large accelerated filer. We will lose our status as
an emerging growth company on the last day of our fiscal year
following the fifth anniversary of the date of the first sale of
common equity securities pursuant to an effective registration
statement.
As an
emerging growth company we are exempt from Section 404(b) of the
Sarbanes-Oxley Act of 2002 and Section 14A(a) and (b) of the
Securities Exchange Act of 1934. Such sections are provided
below:
●
Section 404(b) of
the Sarbanes-Oxley Act of 2002 requires a public company’s
auditor to attest to, and report on, management’s assessment
of its internal controls.
●
Sections 14A(a) and
(b) of the Securities and Exchange Act, implemented by Section 951
of the Dodd-Frank Act, require companies to hold shareholder
advisory votes on executive compensation and golden parachute
compensation.
As long
as we qualify as an emerging growth company, we will not be
required to comply with the requirements of Section 404(b) of the
Sarbanes-Oxley Act of 2002 and Section 14A(a) and (b) of the
Securities Exchange Act of 1934.
SPECIAL NOTE ABOUT FORWARD-LOOKING STATEMENTS
This prospectus and other materials filed or to be filed by us, as
well as information in oral statements or other written statements
made or to be made by us, contain statements, including in this
document under the captions
“Executive
Summary,” “Questions and Answers About the
Distribution,” “Risk Factors,” “The
Distribution,” “Capitalization and Financing,”
“Management’s Discussion and Analysis of Financial
Condition and Results of Operations,”
and
“Business”,
that are, or may be considered to be,
forward-looking statements. All statements that are not historical
facts, including statements about our beliefs or expectations, are
forward-looking statements. You can identify these forward-looking
statements by the use of forward-looking words such as
“outlook,” “believes,”
“expects,” “potential,”
“continues,” “may,” “will,”
“should,” “seeks,”
“approximately,” “predicts,”
“intends,” “plans,”
“estimates,” “anticipates,”
“foresees” or the negative version of those words or
other comparable words and phrases. Any forward-looking statements
contained in this information statement are based on our historical
performance and on current plans, estimates and expectations. The
inclusion of this forward-looking information should not be
regarded as a representation by us or any other person that the
future plans, estimates or expectations contemplated by us will be
achieved. There may be events in the future that we are not able to
predict accurately or control. The factors listed under
“
Risk
Factors
,” as well as any
cautionary language in this information statement, provide examples
of risks, uncertainties and events that may cause our results to
differ materially from the expectations we describe in our
forward-looking statements. You should be aware that the occurrence
of the events described in these risk factors and elsewhere in this
information statement could have a material adverse effect on our
business, results of operations and financial
position.
Forward-looking statements, whether express or implied, are not
guarantees of future performance and are subject to risks and
uncertainties that can cause actual results to differ materially
from those currently anticipated due to a number of factors, which
include, but are not limited to:
●
risks
that we may not have sufficient capital in the amounts and at the
times needed to finance our business;
●
risks
associated with our future revenue source dependent on a new
product line not yet in production;
●
risks
that any future potential revenue opportunities from customers may
not materialize to any meaningful degree or at all;
●
risks
of delays or unforeseen technical obstacles in arranging production
and bringing our new product line to market;
●
absence
of a public market for our Common Stock;
●
our
ability to attract and retain qualified personnel and key
employees;
●
our
ability to establish financial, administrative and other support
functions;
●
difficulty
in predicting the timing or outcome of new product development
efforts;
●
the
amount and timing of costs associated with research and development
of our product line;
●
our
ability to generate operating revenue;
●
market
adoption of our principal product;
●
the
competitive nature of the industry in which we
compete;
●
the
availability and price of acceptable raw materials and components
from third-party suppliers;
●
volatility
in the financial markets;
●
any
adverse outcome in litigation to which we may become a
party;
●
general
economic, political and business conditions that adversely affect
our company or our suppliers or any company to which we sell our
products;
●
changes
in costs, including changes in labor costs and raw material
prices;
●
the
impact on our product development of patents and other proprietary
rights licensed or owned by us; and
●
the
ability to successfully have our products manufactured in an
efficient, time-sensitive and cost-effective manner.
You should read this information statement completely and with the
understanding that actual future results may be materially
different than expectations. All forward-looking statements made in
this prospectus are qualified by these cautionary statements. These
forward-looking statements are made only as of the date of this
prospectus, and we do not undertake any obligation (and we
expressly disclaim any such obligation), other than as may be
required by law, to update or revise any forward-looking statements
to reflect changes in assumptions, the occurrence of unanticipated
events or changes in future operating results over time or
otherwise.
USE OF PROCEEDS
Any
proceeds received from the sale of the Shares will be deposited
directly into the operating account of the Company. We will be
attempting to raise up to $4 million, minus expenses of
approximately $50,000 from the sale of the Shares. These proceeds
will be used as follows:
|
|
|
|
|
Gross
Proceeds
|
$
4,000,000
|
$
3,000,000
|
$
2,000,000
|
$
1,000,000
|
Less Offering
Expenses
|
(50,000
)
|
(50,000
)
|
(50,000
)
|
(50,000
)
|
NET OFFERING
PROCEEDS
|
$
3,950,000
|
$
2,950,000
|
$
1,950,000
|
$
950,000
|
Research,
Development and Tooling
|
$
435,000
|
$
435,000
|
$
435,000
|
$
435,000
|
Sales and
Marketing
|
$
410,000
|
$
410,000
|
$
410,000
|
$
210,000
|
General Corporate
Expense
|
$
305,000
|
$
305,000
|
$
305,000
|
$
305,000
|
Working
Capital
|
$
2,800,000
|
$
1,800,000
|
$
800,000
|
$
-0-
|
Our
offering expenses are comprised of legal and accounting
expenses. Our officers and directors will not receive
any compensation for their efforts in selling the
Shares.
Research
and development expense primarily relates to developing new
security products while tooling costs consist primarily of upfront
tooling costs to reduce the cost of BolaWrap™ 100 components.
Sales and marketing expense includes staffing costs, product
promotion costs and travel and customer support activities. General
corporate expense includes staffing and Working capital may also
consist of capacity and staffing expansion and administrative
expense.
In the
event we are not successful in selling Shares resulting in gross
proceeds of at least $1.0 million, we would utilize any available
funds raised in the following order of priority:
●
For general and
administrative expenses, including legal and accounting fees and
administrative support expenses incurred in connection with our
reporting obligations with the Securities and Exchange Commission
(“
SEC
”);
●
For research,
development and tooling;
●
For general
corporate expenses.
We
estimate the need to raise a minimum of $1.5 million to implement
our plan of operations and provide sufficient working capital for
production and to finance sales operations.
MARKET PRICE OF COMMON STOCK AND RELATED MATTERS
Market Information
There
has been no public trading market for the shares of the
Company’s Common Stock. We intend to apply to list
our Common Stock on the OTCBB such that a secondary market will
commence following the offering.
Holders
As of
April 14, 2017, there were approximately 14 shareholders of record
of the Company’s Common Stock and no holders of
record of its preferred stock.
Our
transfer agent is
_____________, ________.
Their telephone number is
_________.
ABSENCE OF PUBLIC MARKET AND DIVIDEND POLICY
Public Market
While
not currently a reporting company, we will become a Section 15(d)
reporting company as a result of the consummation of the
offering.
Dividend Policy
The payment of dividends is subject to the discretion of our board
of directors and will depend, among other things, upon our
earnings, our capital requirements, our financial condition and
other relevant factors. We have not paid or declared any dividends
upon our Common Stock since our inception and, by reason of our
present financial status and our contemplated financial
requirements do not anticipate paying any dividends upon our Common
Stock in the foreseeable future. Therefore, there can be no
assurance that any dividends on the Common Stock will ever be
paid.
CAPITALIZATION AND FINANCING
The
following sets forth our capitalization as of March 31, 2017 that
is derived from our unaudited financial information included
elsewhere in this prospectus:
●
On an actual basis;
and
●
On a pro forma
basis, giving affect to the sale and issuance by us of ______
shares of Common Stock in this offering, at an assumed offering
price of $__ per share,, and after deducting estimated offering
expenses payable by us.
|
|
|
|
|
|
|
|
|
Cash
|
$
344,629
|
$
________
|
|
|
|
Stockholders’
equity:
|
|
|
Preferred
stock
|
-0-
|
-0-
|
Common
stock
|
2,000
|
________
|
Additional
paid-in capital
|
665,500
|
________
|
Accumulated
deficit
|
(436,111)
|
________
|
Total
stockholders’ equity
|
$
231,389
|
$
________
|
|
|
|
|
$
231,389
|
$
________
|
This
table should be read in conjunction with “
Management’s Discussion and Analysis of
Financial Condition and Results of Operations
” and our
historical financial statements, notes and pro forma information
included elsewhere in this prospectus.
DILUTION
Dilution
represents the difference between the offering price and the net
tangible book value per share immediately after completion of this
offering. Net tangible book value is the amount that results from
subtracting total liabilities and intangible assets from total
assets. Dilution arises mainly as a result of our arbitrary
determination of the offering price of the shares of Common Stock
being offered. Dilution of the value of the Common Stock you
purchase is also a result of the lower book value of the shares
held by our existing shareholders.
As of March 31, 2017, the net tangible book value of our Common
Stock was $231,389 or approximately $0.01 per share based upon 20.0
million shares of Common Stock issued and outstanding.
If 100% of the Shares Are Sold:
Upon
completion of this offering, in the event all of the shares are
sold, the net tangible book value of the _________ shares of Common
Stock to be outstanding will be (______) or approximately $______
per share. The net tangible book value of the shares of Common
Stock held by our existing shareholders will be increased by $____
per share without any additional investment on their part.
Investors in the offering will incur an immediate dilution from
$_____ per share of Common Stock to $______ per share.
After
completion of this offering, if _______ shares of Common Stock are
sold, investors in the offering will own __% of the total number of
shares then outstanding for which they will have made cash
investment of $____ million, or $_____ per share. Our existing
shareholders will own ___% of the total number of shares of Common
Stock then outstanding, for which they have made contributions of
cash totaling $0.00 per share.
Upon
completion of this offering, in the event all Shares are not sold,
the following table details the range of possible outcomes from the
offering assuming the sale of 100%, 75%, 50% and
25%.
Funding
Level
|
|
$
4,000,000
|
|
$
3,000,000
|
|
$
2,000,000
|
$
|
$
1,000,000
|
|
|
|
|
|
|
|
|
Offering
price
|
|
$
|
|
$
|
|
$
|
|
$
|
Net tangible book
value per common share before offering
|
|
$
(0.01
)
|
|
$
(0.01
)
|
|
$
(0.01
)
|
|
$
(0.01
)
|
Pro forma net
tangible book value per common share after
|
|
$
|
|
$
|
|
$
|
|
$
|
Dilution to
investors
|
|
$
|
|
$
|
|
$
|
|
$
|
Dilution as a
percentage of offering price
|
|
|
|
|
|
|
|
|
Based
on 20,000,000 shares of Common Stock outstanding as of March 31,
2017 and total stockholder's equity of $231,389 utilizing unaudited
financial statements.
Since
inception, the officers, directors, promoters and affiliated
persons have paid an aggregate average price of $.034 per share of
Common Stock in comparison to the offering price of $____ per share
of Common Stock.
Further Dilution
The
Company may issue equity and debt securities in the future.
These issuances and any sales of additional Common Stock may
have a depressive effect upon the market price of the Company's
Common Stock and investors in this offering.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
You should read the following discussion in conjunction with the
financial statements and other financial information included
elsewhere in this information statement. The following discussion
may contain forward-looking statements that reflect our plans,
estimates and beliefs. Our actual results could differ materially
from those discussed in these forward-looking statements. Factors
that could cause or contribute to these differences include, but
are not limited to, those discussed below and elsewhere in this
information statement, particularly in “Risk Factors”
and “Special Note About Forward-Looking
Statements.”
We are a security technology company organized in March 2016
focused on delivering solutions to customers, primarily law
enforcement and security personnel. We plan to introduce our first
product, the BolaWrap
™
100, during 2017. We do not expect to report
revenues until production quantities are available for sale to
customers. There can be no assurance regarding the timing or amount
of future revenues from this product, if any.
Organization and Reverse Capitalization
Our
Company resulted from the March 31, 2017 merger of Wrap
Technologies, LLC (“
Wrap
LLC
”) with and into our wholly-owned subsidiary
MegaWest Energy Montana Corp. (“
MegaWest
”). Wrap LLC ceased
separate existence with MegaWest continuing as the surviving
entity. MegaWest changed its name to Wrap Technologies, Inc. and
amended and restated new articles of incorporation authorizing
150,000,000 shares of Common Stock, par value $0.0001, and
5,000,000 shares of preferred stock, par value $0.0001. All issued
and outstanding 835.75 membership units of Wrap LLC were exchanged
for 20.0 million shares of Common Stock of the
Company.
Wrap
LLC acquired privately held MegaWest from Petro River Oil Corp.
(“
Petro River
”)
on March 22, 2017 through the issuance of 16.75 membership units,
representing a 2% membership interest in Wrap LLC. Petro River is
owned 11% by Scot Cohen, its Executive Chairman, who also was a
Manager and the owner of a 26% membership interest in Wrap LLC, and
is a director and officer of the Company. MegaWest had no assets or
liabilities at the date of acquisition nor at December 31, 2016,
and is not considered an operating business.
Wrap
LLC’s acquisition of MegaWest and its subsequent merger with
and into MegaWest as a wholly-owned subsidiary of the Company, and
exchange of membership interests for Common Stock has been
accounted for as a reverse recapitalization of Wrap LLC (the
“
Recapitalization
”). Wrap LLC, now
the Company as a result of the Recapitalization, is deemed the
accounting acquirer with MegaWest the accounting acquiree. Our
financial statements are in substance those of Wrap LLC and are
deemed to be a continuation of its business from its inception date
of March 2, 2016. The Company’s balance sheet continues at
historical cost as the accounting acquiree had no assets or
liabilities and no goodwill or intangible assets were recorded as
part of the Recapitalization.
To reflect the Recapitalization, historical shares of Common Stock
and additional paid-in capital have been retroactively adjusted
using the exchange ratio of approximately 23,930.60 shares of
Common Stock for each membership unit of Wrap LLC.
Basis of Presentation – Going Concern
Since
inception in March 2016, we have generated significant losses from
operations and anticipate that we will continue to generate
significant losses from operations for the foreseeable future. In
order to continue as a going concern, our business will require
substantial additional investment that has not yet been
secured. Our loss from operations was $234,356 for the period
ended December 31, 2016 and $201,755 for the three months ended
March 31, 2017. The net cash used from operations and investing was
$187,428 for the period ended December 31, 2016 and $135,443 for
the three months ended March 31, 2017. On March 31, 2017, we had
$344,629 in cash. As of March 31, 2017, our obligations
included $155,050 of current liabilities and lease commitments of
approximately $48,300.
Our
management has concluded that due to the conditions described
above, there is substantial doubt about our ability to continue as
a going concern through April 17, 2018.
Management
has evaluated the significance of the conditions in relation to our
ability to meet our obligations and believes that the current cash
balance will provide sufficient capital to continue operations
through approximately June 2017. While we plan to raise capital to
address our capital deficiencies and meet our operating cash
requirements, there is no assurance that our plans will be
successful. Management cannot assure you that financing will be
available on favorable terms or at all. Additionally, if additional
capital is raised through the sale of equity or convertible debt
securities, the issuance of such securities would result in
dilution to our existing shareholders. Furthermore, despite
management’s optimism regarding our technology and planned
products, even in the event that the Company is adequately funded,
there is no guarantee that any products or product candidates will
perform as hoped or that such products can be successfully
commercialized.
Equity Compensation Plan
On
March 31, 2017, the Company approved the 2017 Equity Compensation
Plan (the “
Plan
”). The Plan provides for the
granting of nonqualified stock options, incentive stock options,
and restricted stock grants and units. The Plan allows for an
issuance of a maximum of 2,000,000 shares of Common Stock, with
awards made at the discretion of the board of directors. No awards
have been made to date. The Company plans to issue stock options in
the future to executive officers, directors, employees and
consultants.
Challenges, Opportunities, and Uncertainties
We will be required to establish and grow business functions
including production, marketing, sales, distribution, service and
administration. Until we generate revenues and margins or obtain
additional financing, we expect to have limited personnel to
accomplish these functions and will primarily rely on our
executives along with outside consultants and suppliers we intend
to engage for production and certain other services. Given our
limited personnel, there is risk and uncertainty whether we can
timely accomplish required functional activities and achieve
important milestones, including introducing new products and
obtaining orders from new customers.
We are unable to predict the market acceptance of our new product
or the level of future sales, if any. We have not yet commenced
marketing our new product and have no orders or customers for our
products.
We will be reliant on existing financial resources to provide
initial working capital. We will need additional capital to finish
development and marketing of our new product line and working
capital to produce product for sale to customers. Obtaining any
required additional financing in the future could be a significant
management challenge and failure to secure necessary financing
would have a material adverse affect on our operations. Our ability
to continue as a going concern is dependent upon achieving a
profitable level of operations and until then obtaining additional
financing.
Given our limited personnel and financial resources we face
significant challenges in establishing, operating and growing our
new business. We expect we will need to continue to innovate new
applications for our security technology, develop new products and
technologies to meet diverse customer requirements and identify and
develop new markets for our products.
Critical Accounting Policies and Estimates
The preparation of financial statements in accordance with
accounting principles generally accepted in the United States,
which we refer to as U.S. GAAP, requires us to make estimates and
judgments that affect the reported amounts of assets, liabilities,
revenue and expenses, and related disclosure of contingent assets
and liabilities. On an on-going basis, we evaluate our estimates,
including those related to recognition and measurement of
contingencies and accrued costs. We base our estimates on
historical experience and on various other assumptions we believe
to be reasonable under the circumstances. Actual results may differ
from these estimates under different assumptions or
conditions.
Until
consummation of the Recapitalization on March 31, 2017, we were
treated as a partnership for federal and state income tax purposes
and did not incur income taxes. Instead, our losses were included
in the income tax returns of the member partners. Following the
Recapitalization, we will be responsible for federal, state and
foreign taxes for jurisdictions in which we conduct business. As
part of the process of preparing our financial statements we will
be required to estimate our provision for income taxes. Significant
management judgment will be required in determining our provision
for income taxes, deferred tax assets and liabilities, tax
contingencies, unrecognized tax benefits, and any required
valuation allowance, including taking into consideration the
probability of the tax contingencies being incurred. Management
expects to assess this probability based upon information provided
by its tax advisers, its legal advisers and similar tax cases. If
at a later time its assessment of the probability of these tax
contingencies changes, its accrual for such tax uncertainties may
increase or decrease. Our effective tax rate for annual and interim
reporting periods could be impacted if uncertain tax positions that
are not recognized are settled at an amount which differs from our
estimates.
Operating Expense
Our operating expenses have included (i) selling, general and
administrative expense, and (ii) research and development expense.
Research and development expense comprises the costs incurred in
performing research and development activities on our behalf,
including compensation and consulting, design and prototype costs,
contract services, patent costs and other outside expenses. The
scope and magnitude of our future research and development expense
is difficult to predict at this time and will depend on elections
made regarding research projects, staffing levels and outside
consulting and contract costs. The actual level of future selling,
general and administrative expense will be dependent on staffing
levels, elections regarding the use of outside resources, public
company and regulatory costs, and other factors, some outside our
control
.
Our operating costs could increase rapidly as we
introduce our product and expand our research and development,
production, distribution, service and administrative functions in
future months. We may also incur future financing costs and
substantial noncash stock-based compensation costs depending on
future option grants that are impacted by stock prices and other
valuation factors. Historical expenditures are not indicative of
future expenditures.
Results of Operations
Three Months Ended March 31, 2017 Compared to the Period from
Inception (March 2, 2016) to March 31, 2016
We had no revenues or product costs for the three months ended
March 31, 2017 nor for the prior period including from inception
(March 2, 2016) to March 31, 2016 (“
prior short
period
”).
Selling, General and Administrative Expense.
Selling, general and administrative expense for
the three month period ended March 31, 2017 were $75,792 compared
to $3,690 for the prior short period ended March 31, 2016. The most
recent period included legal, merger and audit costs of $36,893,
compensation of $11,000, occupancy costs of $4,640 and trade show
preparation and marketing costs of $8,507. The prior short period
included startup legal and organization costs of
$3,390.
Research and Development Expense.
Research and development expense for the period
ended March 31, 2017 was $125,963 and included $14,000 of deferred
related party research costs, consulting and contract research
costs of $75,063, patent costs of $15,337, and prototype and supply
costs of $13,489. This compared to $27,909 for the prior short
period ended March 31, 2016 including $7,000 of deferred related
party research costs, $4,711 of prototype and supply costs and
$14,043 of patent costs.
Net Loss.
Our net loss for the
three-month period ended March 31, 2017 was $201,755 compared to a
net loss of $31,599 for the prior short period ending March 31,
2016 when development activities were just
beginning.
Period from Inception (March 2, 2016) to December 31,
2016
The following is a discussion of the results of our operations for
the period from inception (March 2, 2016) to December 31, 2016. Due
to the inception date there is no prior comparable period. We had
no revenues or product costs during the period.
Selling, General and Administrative Expense.
Selling, general and administrative expense for
the period ended December 31, 2016 was $17,112, and included
startup legal and organization costs of $11,207, marketing costs of
$2,300, and administrative costs of $3,605.
Research and Development Expense.
Research and development expense for the period
ended December 31, 2016 was $217,244, and included $70,000 of
deferred related party research costs, consulting and contract
research costs of $95,525, patent costs of $33,141, and prototype
and supply costs of $15,313.
Net Loss.
Our net loss for the
period ended December 31, 2016 was $234,356.
Liquidity and Capital Resources
Overview.
Our sole source of
liquidity has been funding from our shareholders. We expect our
primary source of future liquidity will be from the sale of future
product, if any, and any future equity or debt
financings.
Capital Requirements.
Other
than $344,629 cash on hand at March 31, 2017, we have no additional
sources of liquidity. We cannot currently estimate our future
liquidity requirements or future capital needs which will depend on
capital required to introduce our new product and the staffing and
support required along with the timing and amount of future
revenues and product costs. We anticipate that demands for
operating and working capital could grow rapidly based on decisions
regarding staffing, development, production, marketing and other
functions and based on factors outside our control. Accordingly
additional capital will be required during the next twelve months.
No assurances can be provided that any future debt or equity
capital will be available to us. Failure to quickly produce and
sell our new product and timely obtain any required additional
capital in the future will have a material adverse affect on the
Company. Our ability to continue as a going concern is in
substantial doubt and is dependent upon achieving a profitable
level of operations and until then obtaining additional
capital.
Our future capital requirements, cash flows and results of
operations could be affected by and will depend on many factors
that are currently unknown to us, including:
●
the
timing of the availability of our new product line for sale to
customers;
●
decisions
regarding staffing, development, production, marketing and other
functions;
●
the
timing and extent of any market acceptance of our
products;
●
the
costs, timing and outcome of planned production and required
customer and regulatory compliance of our new
products;
●
the
costs of preparing, filing and prosecuting our patent applications
and defending any future intellectual property-related
claims;
●
the
costs and timing of additional product development;
●
the
costs, timing and outcome of any future warranty claims or
litigation against us associated with any of our products;
and
●
the
timing and costs associated with any new financing.
Cash Flow
Operating Activities.
During
the period ended March 31, 2017, net cash used in operating
activities was $131,347.
The net loss of $201,755 was reduced by $26,000 of
deferred and accrued officer compensation and $44,085 of accounts
payable and accruals.
During the period ended December 31, 2016, net cash used in
operating activities was $177,890. The net loss of
$234,356 was increased by $29,811 of prepaid expenses and deposits
and reduced by $70,000 of deferred officer compensation and $14,965
of accounts payable and accruals.
Investing Activities.
We used
$4,096 and $9,538 of cash for the purchase of property and
equipment during the three month period ended March 31, 2017 and
the period from inception to December 31, 2016,
respectively.
Financing Activities.
We
obtained $442,500 of cash from our shareholders during the period
ended December 31, 2016. During the period ended March 31, 2017 we
obtained an additional $225,000 of cash from our
shareholders.
Contractual Obligations
Other than our facility lease of approximately $18,100 per year, we
have no contractual obligations. We are obligated to pay to
Syzygy Licensing, LLC (“
Syzygy
”)
a 4% royalty on future product sales up to an
aggregate of $1.0 million in royalties.
Effects of Inflation
We do not believe that inflation has had a material impact on our
business, revenues or operating results during the period
presented.
Recent Accounting Pronouncements
There have been no recent accounting pronouncements or changes in
accounting pronouncements during the period ended March 31, 2017,
or subsequently thereto, that we believe are of potential
significance to our financial statements.
BUSINESS
Overview
We are a security technology company focused on delivering
innovative solutions to customers, primarily law enforcement and
security personnel. We plan to introduce our first product, the
BolaWrap
™
100, during
2017.
Our
BolaWrap™ 100 product is a hand-held remote restraint device
that discharges an eight-foot bola style Kevlar® tether to
entangle an individual at a range of 10-25 feet. Inspired by law
enforcement professionals, the small but powerful BolaWrap™
100 assists law enforcement to safely and effectively control
encounters. Law enforcement agencies authorize a continuum of force
options:
●
physical control
– soft techniques of grabs and holds progressing to hard
techniques such as punches and kicks;
●
less-lethal weapons
- batons, pepper spray, impact munitions and CEWs (conducted
electrical weapons); and
●
lethal force
– deadly weapons such as firearms.
BolaWrap™
100 offers law enforcement a new tool to remotely and temporarily
control an individual or impede flight by targeting and wrapping an
individual’s legs.
The
small, light but rugged BolaWrap™ 100 is designed for weak
hand operation to provide remote restraint while other use of force
continuum options remain open. The design offers wide latitude of
accuracy to engage and restrain targeted legs of a subject. Quick
eject and rapid reload of bola cartridges allows one device to be
reused in a single encounter or in multiple
encounters.
|
|
|
Illustration of
Bola Wrapping and Wide Latitude of Accuracy
|
|
Entanglement
Wrapping Illustration
|
There
are limited effective options for remote engagement so when verbal
commands go unheeded law enforcement is faced with either hands on
engagement or other potentially injurious less lethal or lethal
force. We believe our new tool is essential to meet modern policing
requirements with individuals frequently not responding to verbal
commands and to assuage public demands for less lethal policing. We
believe our device minimizes the need to employ other uses of force
including combat and less-lethal weapons. Many less-lethal weapons
rely on “pain compliance” often escalating encounters
with potential for injury.
Primary
use cases fall into the two broad categories routinely encountered
by law enforcement and security personnel:
●
Remotely retain and
limit the mobility of an individual attempting to evade arrest or
questioning. Individuals increasingly ignore law enforcement verbal
commands; and
●
Assist in subduing
individuals actively resisting arrest by limiting mobility,
possibly making other engagement options less risky to officers and
less injurious to individuals.
We intend to commercialize the BolaWrap™ 100 by initially
targeting sales to the approximately 18,000 United States law
enforcement agencies with approximately 765,000 full time officers
and to the United States Border Patrol with 21,000 border patrol
agents. Thereafter, we intend to target law enforcement agencies
and security personnel worldwide.
History
We were organized as Wrap Technologies, LLC, a Delaware limited
liability company on March 2, 2016 by our founders Elwood G.
Norris, Scot Cohen and James A. Barnes. We are headquartered in Las
Vegas, Nevada. Our formation followed several months of research
into ensnarement techniques by our Chief Technology Officer and
primary inventor, Mr. Norris. Mr. Norris has been granted over 80
U.S. patents, and with Mr. Barnes, founded LRAD Corporation
(Nasdaq:LRAD), a company engaged in directed sound technologies
including non-lethal acoustic hailing and warning devices sold
worldwide for law enforcement, military, government and security
markets.
On March 22, 2017, we acquired MegaWest Energy Montana Corp., a
wholly-owned subsidiary, from Petro River Oil Corp.
(“
MegaWest
”), and on March 31, 2017, we merged with
MegaWest, and changed our name to Wrap Technologies, Inc., a
Delaware corporation (the “
Merger
”). Our original members retained
approximately 98% ownership interest following the Merger and Petro
River Oil Corp. retained an approximate 2% ownership interest in
the Company following the Merger.
Industry Background
The
market for use of force related products and devices includes law
enforcement agencies, correctional facilities, military agencies,
private security guard companies and retail consumers. We believe
law enforcement officials are the opinion leaders regarding market
acceptance of new security products. We therefore intend to focus
on the law enforcement agency segment of the market for our first
product, the BolaWrap™ 100.
According
to the Department of Justice, from 2002 to 2011 an annual average
of 44 million U.S. residents age 16 or older - about 19% of all
persons of this age - had at least one face-to-face contact with a
police officer. About 1.6% or 715,500 involved threats of or use of
force. And about 1.3 million were handcuffed during their encounter
with police. Nearly all local police departments and all federal
law enforcement agencies have a use-of-force policy that dictates
the level of force its officers can use to respond to various
situations. In January 2017, a collaborative effort among 11
significant law enforcement leadership and labor organizations in
the United States resulted in the publication of a National
Consensus Policy on Use of Force. This policy states, among other
information:
●
Officers shall use
only the force that is objectively reasonable to effectively bring
an incident under control, while protecting the safety of the
officer and others;
●
Officers shall use
force only when no reasonably effective alternative appears to
exist and shall use only the level of force which a reasonably
prudent officer would use under the same or similar
circumstances;
●
An officer shall
use de-escalation techniques and other alternatives to higher
levels of force consistent with his or her training whenever
possible and appropriate before resorting to force and to reduce
the need for force; and
●
When de-escalation
techniques are not effective or appropriate, an officer may
consider the use of less lethal force to control a non-compliant or
actively resistant individual. An officer is authorized to use
agency-approved, less lethal force techniques and issued
equipment:
o
to protect the
officer or others from immediate physical harm;
o
to restrain or
subdue an individual who is actively resisting or evading arrest;
or
o
to bring an
unlawful situation safely and effectively under
control.
A
police officer is trained to use only the minimum force necessary
to overcome the threat of injury or violence posed by a suspect.
For example, under most policies, an officer may not use lethal
force unless a subject poses a threat of significant bodily injury
or fatality to the officer or other persons.
Studies
have concluded that most police officers never deploy lethal force
in the course of their careers. While the vast majority of law
enforcement officers around the world are armed with firearms, only
a small percentage will actually ever use them. Officers, however,
use less lethal force on a regular basis. Traditional tactics such
as using a control hold, baton, club, or combat to control a
suspect may result not only in a risk of injury to the suspect, but
also a risk that the officer will be injured. Other force options
including chemical spray, impact munitions and CEWs not only risk
injury but are often controversial. Each weapon available to law
enforcement has distinct advantages and disadvantages, and we
believe law enforcement agencies require different tools for
different situations.
We
believe a new remote restraining device is necessary to meet modern
policing requirements with individuals frequently not responding to
verbal commands and public demands for less lethal policing. A tool
to restrain at a distance may offer reduced frequency of deployment
of other control techniques including CEWs. We believe that the
following characteristics for our new restraining product are the
most important to law enforcement and security
agencies:
●
Effectiveness:
remote restraint of individuals while keeping all other use of
force options available;
●
Range:
variable distance over which the device is effective;
●
Safety: minimal
risk of injury or death;
●
Ease
of use: simple operation and low maintenance;
●
Dependability:
reliability in many environments, product durability;
●
Accountability:
tracking to reduce misuse of the weapon; and
●
Cost:
low cost per use and possible reduction of insurance and litigation
expense.
The BolaWrap™ 100 Solution
The
BolaWrap™ 100 is designed to perform well in terms of all of
the above characteristics. We believe the BolaWrap™ 100 is a
unique new device to restrain subjects safely and without
eliminating any other use of force options necessary for the
protection of law enforcement and the public. While no use of force
technique or device is 100% effective, in our opinion, unique
performance could make the BolaWrap™ 100 a tool of choice in
a range of encounters for law enforcement agencies and other
security services.
Effectiveness
Without
an effective remote restraint device to assist controlling an
encounter, law enforcement often defaults to less-lethal weapons
that rely upon a pain response or electrical induced incapacitation
for effect. These methods along with lethal force may be necessary
for the most dangerous and aggressive suspects. However, there are
many encounters where remote restraint may be an option in lieu of
or before physical contact with an individual to reduce possibility
for flight or the possibility for injury to the individual and the
officer. In volunteer testing, the BolaWrap™ 100 has shown to
be effective in restraining individuals hindering the flight
ability and crippling the ability to fight allowing effective
further officer action.
Range
Batons
and chemical sprays can only be used from close distances, usually
less than five feet. Rubber bullets, beanbag rounds, and similar
less-lethal impact weapons must be used at distances greater than
30 feet to minimize suspects’ injuries. Combat, come along
and wrist locks require intimate contact with suspects. The
BolaWrap™ 100 is designed to engage a suspect at 10 to 25
feet operable by the weak hand allowing other force options to
remain available. The design of the device makes it ineffective and
it is not recommended for use at close distances, less than five
feet.
Safety
The
BolaWrap™ 100 is not intended as a weapon. It does not rely
on pain or electrical induced incapacitation for effectiveness. The
wrapping effect is intended to impede flight while not inducing
uncontrolled falls or injury. There is no issue of recovery time as
the case with CEW, impact munitions or chemical
devices.
Ease of Use
The
BolaWrap™ 100 is small, light and rugged. It is designed to
be operated as a weak hand device. It is simple to use, activate
and deploy. It can be reloaded and deployed again as quickly as a
spent cartridge can be removed and a replacement cartridge
inserted, typically in less than five seconds. Further, the weapon
requires no maintenance, there are no electronic components. The
BolaWrap™ 100 also does not leave contaminating residues,
unlike chemical sprays that may contaminate buildings, vehicles or
other closed facilities or officer uniforms.
Dependability
The
BolaWrap™ 100 as a mechanical device operates effectively
under a variety of unfavorable conditions, such as wind and rain,
and is rugged and durable.
Accountability
The
BolaWrap™ 100 is designed for professional use and not
consumer use. Each device and each cartridge is identified with a
serial number for recordkeeping purposes.
Cost
The
BolaWrap™ 100 is intended to be sold to law enforcement
agencies at a price per unit not yet established. The single use
bola cartridge ammunition is intended to be priced at a per
cartridge price to allow use in both training and active
deployment. While we do not believe there is a directly competitive
remote restraint device, and we expect prices to be competitive
with CEWs, impact munitions and most other specialized less-lethal
weapons, with the exception of the least expensive chemical sprays.
However, the indirect costs of decontaminating buildings, vehicles,
and uniforms resulting from the use of chemical sprays can place
these sprays at an overall cost disadvantage per use.
In
addition, litigation and insurance costs for law enforcement
agencies can be significant. Reducing the need for other use of
force tools and the number of injuries and fatalities caused by law
enforcement officers may reduce the number of suits filed against
agencies for excessive use of force, wrongful death and
injury.
We
believe the addition of a new remote restraint device may have the
benefit of increasing goodwill between law enforcement agencies and
their communities. Community relations considerations can be
particularly important at a time when almost any interaction with
police can be recorded and scrutinized by the media and the
public.
Product
Our
BolaWrap™ 100 product is a hand-held remote restraint device
that discharges an eight-foot bola style Kevlar® tether to
entangle an individual at a range of 10-25 feet. BolaWrap™
100 offers law enforcement a new tool to remotely engage and
temporarily control individuals.
The
small, light but rugged BolaWrap™ 100 is designed for weak
hand operation to provide remote restraint while other use of force
continuum options remain open. The design offers wide latitude of
accuracy to engage and restrain targeted legs of a subject. Quick
eject and rapid reload of bola cartridges allows one device to be
reused in a single encounter or in multiple
encounters.
The
bola cartridge contains two sockets that discharge two small
pellets at a thirty degree angle. The pellets are linked by the
eight-foot Kevlar tether such that the tether first engages an
individual’s legs then the force of the pellets causes the
tether to wrap. Small barbs on each pellet engage clothing to
retard the unwinding of the bola tether wrap. The bola cartridge
contains a 9 mm fractional charge blank cartridge (as used in prop
guns) to discharge the tether.
The
durable body of the BolaWrap™ 100 contains a receptacle for
the bola cartridge along with the activation, deployment and safety
mechanisms. Bola cartridges are quickly ejected allowing rapid
reloading, activation and deployment.
We
demonstrated our first prototype device in December 2016 and
developed pre-manufacturing demonstration units in early April 2017
for planned production and sales in the third quarter of
2017.
Markets
Law Enforcement and Corrections
Federal,
state and local law enforcement agencies in the United States
currently represent the primary target market for the
BolaWrap™ 100. According to United States Bureau of Justice
statistics, there were nearly 18,000 of these agencies in the
United States in 2008 that employed about 765,000 full-time, sworn
law enforcement officers. In 2005, the United States Bureau of
Justice statistics estimated that there were 295,000 correctional
officers in over 1,800 federal and state correctional facilities in
the United States.
United States Border Patrol (USBP)
With
over 21,000 agents, this is one of the largest law enforcement
agencies in the United States with a large number of encounters
with individuals requiring soft engagement techniques. We believe
the BolaWrap™ 100 can be an effective tool to safely assist
in detention of individuals subject to the agency’s
jurisdiction. The BolaWrap™ 100 offers an additional tool for
frontline agents to de-escalate encounters while effecting agent
responsibilities.
Private Security Firms and Guard Services
According
to 2015 Bureau of Labor Statistics there were approximately 1.1
million privately employed security guards in the United States.
They represent a broad range of individuals, including
investigation and security services, hospitals, schools, local
government, and others. We believe that some security personnel
armed with BolaWrap™ 100 could be effective to de-escalate
some encounters without eliminating other tools available today.
Providing guards with BolaWrap™ 100 may reduce the potential
liability of private security companies and personnel in such
encounters.
Although
there are use cases in correctional facilities and by certain
military policing personnel we are initially targeting
BolaWrap™ 100 for law enforcement and security personnel
markets. We do not currently plan a consumer version of the
device.
Selling and Marketing
Law
enforcement agencies represent our primary target market. In this
market, we expect that the decision to purchase the BolaWrap™
100 will normally be made by a group of people including the agency
head, his training staff, and use of force and weapons experts. The
decision sometimes involves political decision-makers such as city
council members. While we expect the decision-making process for a
remote restraint device will be less controversial than that for
less-lethal products such as CEWs, we still expect the process to
take as little as a few weeks or as long as a year or more
partially due to budgeting reasons.
While
initial sales will be made by our executive and sales employees, we
may determine to utilize existing networks of independent regional
police equipment distributors compensated on a commission and
incentive basis.
Most
law enforcement and corrections agencies will not purchase new use
of force devices until a training program is in place to certify
officers in their proper use. We are developing and intend to offer
training and class materials that certify law enforcement trainers
as instructors in the use and limitations of the BolaWrap™
100.
In
addition to our planned training, we plan to participate in a
variety of trade shows and conferences. We expect our marketing
efforts will also benefit from significant free media coverage.
Other marketing communications may include video e-mails, press
releases, and conventional print advertising in law enforcement
trade publications. We are designing a website to contain similar
marketing information and are developing social media outreach and
communications.
Our Strategy
Our goal is to realize the potential of a new remote restraint
device targeting law enforcement and security personnel. We aim to
produce a product line starting with the BolaWrap™ 100 to
meet the requirements of these customers. The key elements of our
strategy include:
●
Produce
a product line meeting customer requirements as a new tool to aid
in the retention of individuals to make encounters more effective
and less dangerous to law enforcement and the public;
●
Develop
a robust production and supply system to support our customers;
and
●
Develop
relationships with customers requiring large numbers of products
mainly larger city police departments and larger
agencies.
We also plan to explore markets for use by security and related
personnel and develop international distribution.
Related Party License and Royalties
We are
obligated to pay royalties pursuant to an exclusive Amended and
Restated Intellectual Property License Agreement, dated as of
September 30, 2016, with Syzygy Licensing, LLC (“
Syzygy
”), a company owned and
controlled by Elwood G. Norris and James A. Barnes, both officers
and shareholders of the Company. The agreement provides for the
payment of royalties of 4% of revenues from products employing the
licensed device technology up to the earlier to occur of (i) the
payment by the Company of an aggregate of $1.0 million in royalies,
or (ii) September 30, 2026. All patent applications and the
technology related to the BolaWrap™ 100 have been assigned to
the Company, subject to the royalty obligation.
Manufacturing and Suppliers
We have substantially completed the design and component selection
for the BolaWrap™ 100. We expect to source components from a
variety of suppliers with final assembly, testing and shipping
occurring in our facility in Las Vegas, Nevada. We believe
arranging and maintaining quality manufacturing capacity will be
essential to the performance of our products and the growth of our
business.
Warranties
We expect to warrant our products to be free from defects in
materials and workmanship for a period up to one year from the date
of purchase. The warranty will be generally a limited warranty, and
in some instances impose certain shipping costs on the customer. We
expect in most cases it will be more economical and effective to
replace the defective device rather than repair.
Competition
While we are targeting the BolaWrap™ 100 as a new solution
for law enforcement and not as a replacement for other tools
currently in use, we will still compete with other use of force
products for budgets. Law enforcement agencies may also determine
that we are an alternative to other solutions in spite of such
positioning.
Other
use of force devices including CEWs sold by Taser International,
Inc., and pepper spray, batons, impact weapons sold by companies
such as Defense Technology will compete with the BolaWrap™
100 indirectly. Many law enforcement and corrections personnel
consider such less-lethal weapons to be distinct tools, each
best-suited to a particular set of circumstances. Consistent with
this tool kit approach, purchasing any given tool does not preclude
the purchase of one or several more. In other cases, budgetary
considerations and limited space on officers’ belts dictate
that only a limited number of devices will be purchased and
carried. We believe the BolaWrap™ 100’s unique remote
restraint use, effectiveness, and low possibility of injury will
enable it to compete effectively against other
alternatives.
Many of our present and potential future competitors have, or may
have, substantially greater resources to devote to compete in the
law enforcement market and to further technological and new product
developments. Also, these competitors or others may introduce
products with features and performance competitive to our
product.
Seasonality
We do not expect to experience any significant seasonality trends.
Seasonality trends may occur in the future.
Government Regulation
The
BolaWrap™ 100 may be considered to be a “firearm”
by the U.S. Bureau of Alcohol, Tobacco, Firearms and Explosives. We
are seeking a ruling to determine the appropriate classification.
We are operating assuming the BolaWrap™ 100 falls under the
definition of a “firearm” and is, therefore, subject to
federal firearms-related regulations. Many states have regulations
restricting the sale and use of certain firearms. In many cases,
the law enforcement and corrections market is subject to different
regulations. Where different regulations exist, we assume the
regulations affecting the private citizen market also apply to the
private security markets, except as the applicable regulations
otherwise specifically provide.
BolaWrap™ 100 may also be
considered a firearm or a
crime control product by the U.S. government. Accordingly, the
export of our devices will be regulated under export administration
regulations. As a result, we must obtain export licenses from the
Department of Commerce for all shipments to foreign countries other
than Canada. We do not expect the need to obtain these licenses
will cause a material delay in any future foreign shipments. Export
regulations also prohibit the further shipment of our products from
foreign markets in which we hold a valid export license to foreign
markets in which we do not hold an export license for our
products.
Foreign
regulations, which may affect our device, and sale thereof, are
numerous and often unclear. We expect to work with a distributor or
advisor who is familiar with the applicable import regulations in
each of any future foreign markets.
Intellectual Property
We intend to protect our intellectual property assets including
pending patents, trademarks and trade craft and trade secrets such
as know-how.
In addition, we use confidentiality agreements
with employees and some suppliers to ensure the safety of our trade
secrets. We have three U.S. patents pending and intend to extend
protection in certain other foreign jurisdictions.
We have filed for trade name protection for
“BolaWrap” and expect to employ a combination of
registered and common law trade names, trademarks and service marks
in our business.
We expect to rely on
a variety of intellectual property protections for our products and
technologies, including contractual obligations, and we intend to
pursue a policy of vigorously enforcing such
rights.
We have an ongoing policy of filing patent applications to seek
protection for novel features of our products and technologies.
Prior to the filing and granting of patents, our policy is to
disclose key features to patent counsel and maintain these features
as trade secrets prior to product introduction. Patent applications
may not result in issued patents covering all important claims and
could be denied in their entirety.
The use of force product industry is characterized by frequent
litigation regarding patent and other intellectual property rights.
Others, including academic institutions and competitors, hold
numerous patents in less-lethal and related technologies. Although
we are not aware of any existing patents that would materially
inhibit our ability to commercialize our technology, others may
assert claims in the future. Such claims, with or without merit,
may have a material adverse effect on our financial condition,
results of operations or cash flows.
The failure to obtain patent protection or the loss of patent
protection on our existing and future technologies or the
circumvention of our patents by competitors could have a material
adverse effect on our ability to compete successfully.
Our policy is to enter into nondisclosure agreements with each
employee and consultant or third party to whom any of our
proprietary information is disclosed. These agreements prohibit the
disclosure of confidential information to others, both during and
subsequent to employment or the duration of the working
relationship. These agreements may not prevent disclosure of
confidential information or provide adequate remedies for any
breach.
Research and Development
Our
research and development initiatives are led by our
internal personnel and make use of specialized consultants when
necessary. These initiatives include basic research, mechanical
engineering design and testing. Future development projects will
focus on new versions of the BolaWrap™ technology and new
security technologies. Total research and development expenditures
were $217,244 in 2016.
Employees and Executive Officers
We have three executive officers. We have one other employee
engaged in marketing and distribution.
Properties
We lease approximately 1,890 square feet of office, assembly and
warehousing space at 4620 Arville Street, Suite E, Las Vegas,
Nevada 89103, pursuant to a three-year lease expiring December 2019
at a monthly rate of $1,512. We expect that this property will be
sufficient to meet our needs for at least the next 12
months.
Legal Proceedings
We are
not aware of any pending or threatened legal proceedings in which
we are involved. In addition, we are not aware of any pending or
threatened legal proceedings in which entities affiliated with our
officers, directors or beneficial owners are involved with respect
to our operations.
MANAGEMENT
Directors and Executive Officers
Set
forth below is information regarding the executive officers and
directors of the Company:
Name
|
Age
|
Position(s)
|
James A. Barnes
|
62
|
Director, President and Chief Financial Officer
|
|
Elwood G. Norris
|
78
|
Director and Chief Technology Officer
|
|
Scot Cohen
|
48
|
Director and Secretary
|
|
When and as business requires and funds are available, we may hire
or appoint additional executive officers. We have no understanding
or arrangements regarding any additional executive officers to be
appointed on or after the consummation of the
offering.
James A. Barnes
cofounded the
Company with Mr. Norris and Mr. Cohen in March 2016 and currently
serves as a director, President and Chief Financial Officer. He
served as Manager until the Company’s incorporation in March
2017. He has been President of Sunrise Capital, Inc., a private
venture capital and financial and regulatory consulting firm since
1984. He was Chief Financial Officer of Parametric Sound
Corporation (now Turtle Beach Corporation) from 2010 to February
2015, and from February 2015 to February 2017 served as Vice
President Administration at Turtle Beach Corporation.
Since
1999, he has been Manager of Syzygy Licensing LLC
(“
Syzygy
”), a
private technology invention and licensing company he owns with Mr.
Norris. He previously practiced as a certified public accountant
and management consultant with Ernst & Ernst (1976-1977),
Touche Ross & Co. (1977-1980), and as a principal in J.
McDonald & Co. Ltd., Phoenix, Arizona (1980-1984). He graduated
from the University of Nebraska with a B.A. Degree in Business
Administration in 1976 and is a certified public accountant
(inactive).
Mr.
Barnes possesses substantial financial, regulatory and management
experience, and such experience is extremely valuable to the Board
of Directors and the Company as it executes its business
plan.
Elwood G. Norris
cofounded the
Company with Mr. Barnes and Mr. Cohen in March 2016 and currently
serves as a director and Chief Technology Officer. He was a
director and President of Parametric Sound Corporation (now Turtle
Beach Corporation) from 2010 to February 2015 and from February
2015 to September 2016 served as Chief Scientist, a non-executive
position, at Turtle Beach.
He was a director of LRAD
Corporation from August 1980 to June 2010. He served as Chairman of
LRAD Corporation’s Board of Directors, an executive position,
in which he served in a technical advisory role and acted as a
product spokesman from September 2000 to April 2009.
He is an inventor, and has authored more than 80
U.S. patents, primarily in the fields of electrical and acoustical
engineering, and has been a frequent speaker on innovation to
corporations and government organizations.
He is the
inventor of our BolaWrap™ technology.
Mr. Norris is a majority owner of Syzygy, but has
no employment or management relationship with
Syzygy.
Mr.
Norris brings to the Company and the Board of Directors
demonstrated product innovation ability and years of public company
executive experience. As a result, the Board of Directors values
the input provided by Mr. Norris, and believe his contributions to
the deliberations of the Board and management are very
valuable.
Scot Cohen
cofounded the Company with Mr. Barnes and Mr.
Norris in March 2016 and currently serves as a director and
Secretary. He served as a Manager until the Company’s
incorporation in March 2017. He has over 20 year’s experience
in institutional asset management, wealth management, and capital
markets. He currently serves as Executive Chairman of the
Board of Petro River Oil Corp. since 2012. Scot is the founder and
serves as a principal of the Iroquois Capital Opportunity Fund, a
closed end private equity fund focused on investments in North
American oil and gas assets. He is also the co-founder
of Iroquois Capital, a New York based hedge fund. In addition,
he manages several operating and non-operating partnerships, which
actively invest in the energy sector.
Prior
to founding Iroquois Capital, Scot founded a merchant bank based
out of New York, which was one of the most active participants in
structured investments in public companies (PIPES) in the United
States over the four-year period he was actively managing the
business. Scot began his career at Oppenheimer and
Company in a sales capacity and transitioned from there to a
boutique investment-banking firm where he spent two years. Scot
currently sits on the board of directors of True Drinks Holding,
Inc. (OTCBB:TRUU), as well as several private companies, and is
involved a number of charitable ventures. Scot earned a
Bachelor of Science degree from Ohio University in
1991.
The Board of Directors believes Mr. Cohen’s success with
multiple private investment firms, his extensive contacts within
the investment community and financial expertise will assist the
Company’s efforts to raise capital to fund the continued
implementation of the Company’s business plan.
Director Independence
For a director to be considered “independent,” the
Board must affirmatively determine that the director has no
material relationship with the Company (directly or as a partner,
stockholder or officer of an organization that has a relationship
with the Company). In each case, the Board considers all relevant
facts and circumstances. We currently have no independent
directors.
Committees of the Board of Directors
During 2017, we plan to add at least two additional Board members
and then we expect our Board of Directors will establish an Audit
Committee and a Compensation Committee to assist it with its
responsibilities. We expect all members of the Audit and
Compensation Committees will meet the criteria for
independence.
DIRECTOR COMPENSATION
We have not yet established arrangements to compensate our
directors for their services.
EXECUTIVE COMPENSATION
Compensation of our Named Executive Officers
We have identified Elwood G. Norris and James A. Barnes as our
named executive officers. Our named executive officers for 2017
could change, as we may hire or appoint new executive
officers.
Effective March 2016 through February 2017, the Company accrued
monthly deferred compensation for the services of Messrs. Norris
and Barnes in the aggregate amount of $7,000 per month payable to
Syzygy. The balance as of December 31, 2016 was $70,000, and at
February 28, 2017 was $84,000 and accrues without interest. There
is currently no established repayment schedule or timing for
payment. Commencing March 1, 2017, Messrs. Norris and Barnes are
each being paid compensation of $6,000 per month for their
services.
Syzygy, an entity controlled by Messrs. Norris and Barnes, will
receive a royalty as described above in “
Business—Related Party
License and Royalties
” in
consideration for the license of certain technology necessary for
the development of BolaWrap™ 100. We expect that Messrs.
Norris and Barnes will continue to be compensated in their roles as
officers as determined by our Board of
Directors.
Description of the 2017 Equity Compensation Plan
The 2017 Equity Compensation Plan (the “
2017
Plan
”) was adopted by
the Company’s Board of Directors on March 31, 2017, and
approved by a majority of the Company’s shareholders on March
31, 2017. The 2017 Plan reserves for issuance 2.0 million shares of
the Company’s Common Stock for issuance as one of four types
of equity incentive awards: (i) stock options, (ii) restricted
stock, and (iii) stock units. The 2017 Plan permits the
qualification of awards under the plan as “performance-based
compensation” within the meaning of
Section 162(m) of the Internal Revenue
Code.
Potential Payments Upon Termination, Death, Disability, or
Retirement
We have no executive employee contracts at this time. Every officer
and employee is an at will employee. The royalties payable to
Syzygy, controlled by Messrs. Norris and Barnes, are unrelated to
employment or their roles as officers, and will continue upon any
termination, death, disability or retirement.
SECURITY OWNERSHIP BY CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT
The following table sets forth information concerning shares of our
Common Stock beneficially owned as of April 10, 2017,
by:
●
each
person or entity known by us to be the beneficial owner of 5% or
more of the outstanding shares of Common Stock;
●
each
person is currently serving as director; and
●
each
of our named executive officers.
The share amounts in the table below are based on 20.0 million
shares of Common Stock issued and outstanding as of April 14, 2017.
To our knowledge, except as otherwise indicated in the footnotes
below, each person or entity has sole voting and investment power
with respect to the shares of Common Stock set forth opposite such
person’s or entity’s name. Beneficial ownership is
determined in accordance with the rules of the SEC and generally
includes voting or investment power with respect to the
securities.
Title of Class
|
|
Name and Address of Beneficial Owner
|
|
Amount and Nature of Beneficial Ownership
|
|
Percent of Class
|
|
|
|
|
|
|
|
|
Common Stock
|
|
Elwood G. Norris
|
|
6,221,956
|
(1)
|
|
31.1%
|
|
|
4620 Arville Street, Suite E
|
|
|
|
|
|
|
Las Vegas, Nevada 89103
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock
|
|
Scot Cohen
|
|
5,251,548
|
(2)
|
|
26.3%
|
|
|
4620 Arville Street, Suite E
|
|
|
|
|
|
|
Las Vegas, Nevada 89103
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock
|
|
James A. Barnes
|
|
2,632,366
|
(3)
|
|
13.2%
|
|
|
4620 Arville Street, Suite E
|
|
|
|
|
|
|
Las Vegas, Nevada 89103
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock
|
|
David Norris
|
|
1,7994,795
|
(4)
|
|
9.0%
|
|
|
31101 via
Peralta
|
|
|
|
|
|
|
|
Coto de Caza, CA
92679
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
Stock
|
|
Twenty-Two Franklin
Street Group, LLC
|
|
1,196,530
|
|
|
6.0%
|
|
|
11
Arthur Ct.
|
|
|
|
|
|
|
|
Jackson, NJ
08527
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All directors and executive
|
|
|
|
|
|
|
|
officers as a group (3 persons)
|
|
14,105,870
|
|
|
70.5
%
|
______________________
(1)
|
Consists of shares of Common Stock beneficially owned by Mr. Norris
and his family trust.
|
(2)
|
Includes 5,204,906 shares owned by Mr. Cohen and 46,642 shares to
be distributed by Petro River based on his ownership in Petro
River.
|
(3)
|
Includes 2,273,407 shares held by a family trust and 358,959 shares
held by Sunrise Capital, Inc. Mr. Barnes is President of Sunrise
Capital, Inc.
|
|
|
(4)
|
Consists of shares of
Common Stock held in family trust.
|
|
|
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Effective March 2016, we began accruing monthly compensation for
the services of Messrs. Norris and Barnes in the aggregate amount
of $7,000 per month payable to Syzygy. The balance as of December
31, 2016 was $70,000 and accrues without interest. This arrangement
ended in February 2017 with a balance of $84,000
accrued.
We are
obligated to pay royalties pursuant to an exclusive Amended and
Restated Intellectual Property License Agreement, dated as of
September 30, 2016, with Syzygy, a company owned and controlled by
Messrs. Norris and Barnes, both officers and shareholders of the
Company. The agreement provides for the payment of royalties of 4%
of revenues from products employing the licensed device technology
up to the earlier to occur of (i) the payment by the Company of an
aggregate of $1.0 million in royalies, or (ii) September 30, 2026.
All patent applications and the technology related to the
BolaWrap™ 100 have been assigned to the Company, subject to
the royalty obligation.
During
the period ended December 31, 2016 we paid $25,409 of patent legal
costs incurred by Syzygy for the device technology pursuant to the
license agreement.
Mr. Barnes owns 35% of Syzygy and as its managing member may also
be considered a promoter as he was active with Messrs. Norris and
Cohen in founding the Company.
DESCRIPTION OF OUR SECURITIES
We are authorized to issue 150,000,000 shares of our Common Stock,
$0.0001 par value per share, and 5,000,000 shares of preferred
stock, $0.0001 par value per share. The following description of
our capital stock is subject to and qualified in its entirety by
our Certificate of Incorporation and Bylaws, which are included as
exhibits to the registration statement of which this prospectus is
a part, and by the provisions of applicable Delaware
law.
Issued and Outstanding Capital Stock
We have 20.0 million shares of Common Stock issued and outstanding.
We have no shares of preferred stock issued and
outstanding.
Common Stock
There are 20.0 million shares of our Common Stock issued and
outstanding and held of record by 14 shareholders. The holders of
our Common Stock are entitled to one vote per share on all matters
to be voted upon by our shareholders. Subject to preferences that
may be applicable to any future outstanding preferred stock, the
holders of our Common Stock are entitled to receive ratably such
dividends, if any, as may be declared from time to time by our
Board of Directors out of funds legally available for that purpose.
See “
Dividend
Policy
” on page 15. In
the event of our liquidation, dissolution or winding-up, the
holders of our Common Stock are entitled to share ratably in all
assets remaining after payment of liabilities, subject to prior
distribution rights of preferred stock, if any, then outstanding.
The holders of our Common Stock have no preemptive or conversion
rights or other subscription rights. There are no redemption or
sinking fund provisions applicable to our Common
Stock.
Preferred Stock
Our Board of Directors has the authority, without action by our
shareholders, to designate and issue preferred stock in one or more
series and to designate the rights, preferences and privileges of
each series, which may be greater than the rights of our Common
Stock. It is not possible to state the actual effect of the
issuance of any shares of our preferred stock upon the rights of
holders of our Common Stock until our Board of Directors determines
the specific rights of the holders of our preferred stock. However,
the effects might include, among other things:
●
restricting
dividends on our Common Stock;
●
diluting
the voting power of our Common Stock;
●
impairing
the liquidation rights of our Common Stock; or
●
delaying
or preventing a change in control of our company without further
action by our shareholders.
We
have no present plans to issue any shares of our preferred
stock.
Authorized but Unissued Capital Stock
Delaware law does not require stockholder approval for any issuance
of authorized shares. These additional shares may be used for a
variety of corporate purposes, including future public offerings,
to raise additional capital or to facilitate acquisitions. One of
the effects of the existence of unissued and unreserved Common
Stock or preferred stock may be to enable our Board of Directors to
issue shares to persons friendly to current management, which
issuance could render more difficult or discourage an attempt to
obtain control of our company by means of a merger, tender offer,
proxy contest or otherwise, and thereby protect the continuity of
our management and possibly deprive the shareholders of
opportunities to sell their shares of Common Stock at prices
higher
than prevailing market
prices.
Certificate of Incorporation; Bylaws
Our certificate of incorporation and bylaws contain provisions that
could make more difficult the acquisition of the Company by means
of a tender offer, a proxy contest or otherwise. These provisions
are summarized below.
Undesignated Preferred Stock
.
The authorization of our undesignated preferred stock makes it
possible for our Board of Directors to issue our preferred stock
with voting or other rights or preferences that could impede the
success of any attempt to change control of us. These and other
provisions may have the effect of deferring hostile takeovers or
delaying changes of control of our management.
Size of Board and Vacancies
.
Newly created directorships resulting from any increase in our
authorized number of directors or any vacancies on the Board of
Directors resulting from death, resignation, disqualification,
removal or other causes and any newly created directorships
resulting from any increase in the number of directors, shall
unless the Board of Directors determines by resolution that any
such vacancies or newly created directorships shall be filled by
stockholder vote, be filled only by the affirmative vote of a
majority of the directors then in office, even though less than a
quorum of the Board of Directors.
No Cumulative Voting.
Our
certificate of incorporation and bylaws do not provide for
cumulative voting in the election of directors.
Stockholder Meetings.
Our
bylaws
provide that special meetings of the shareholders
may be called only by our our President or by our Board of
Directors or by the President at the request of holders of not less
than 51% of all outstanding shares of our voting
stock.
Delaware Laws
We are subject to Section 203 of the DGCL
(“
Section 203
”). In general, Section 203 prohibits a
publicly held Delaware corporation from engaging in “business
combination” transactions with any “interested
stockholder” for a period of three years following the time
that the stockholder became an interested stockholder,
unless:
●
prior
to the time the stockholder became an interested stockholder,
either the applicable business combination or the transaction which
resulted in the stockholder becoming an interested stockholder is
approved by the corporation’s board of
directors;
●
upon
consummation of the transaction which resulted in the stockholder
becoming an interested stockholder, the interested stockholder
owned at least 85% of the voting stock of the corporation
outstanding at the time the transaction commenced, excluding for
purposes of determining the voting stock outstanding (but not the
voting stock owned by the interested stockholder) shares owned by
directors who are also officers of the corporation and shares owned
by employee stock plans in which the employee participants do not
have the right to determine confidentially whether shares held
subject to the plan will be tendered in a tender or exchange offer;
or
●
at or
subsequent to the time that the stockholder became an interested
stockholder, the business combination is approved by the
corporation’s board of directors and authorized at an annual
or special meeting of stockholders by the affirmative vote of at
least 66
2
⁄
3
% of the outstanding
voting stock which is not owned by the interested
stockholder.
A “business combination” is defined to include, in
general and subject to exceptions, a merger of the corporation with
the interested stockholder; a sale of 10% or more of the market
value of the corporation’s consolidated assets to the
interested stockholder; certain transactions that result in the
issuance of the corporation’s stock to the interested
stockholder; a transaction that has the effect of increasing the
proportionate share of the corporation’s stock owned by the
interested stockholder; and any receipt by the interested
stockholder of loans, guarantees or other financial benefits
provided by the corporation. An “interested
stockholder” is defined to include, in general and subject to
exceptions, a person that (1) owns 15% or more of the outstanding
voting stock of the corporation or (2) is an
“affiliate” or “associate” (as defined in
Section 203) of the corporation and was the owner of 15% or more of
the corporation’s outstanding voting stock at any time within
the prior three year period.
A Delaware corporation may opt out of Section 203 with an express
provision in its original certificate of incorporation or by an
amendment to its certificate of incorporation or bylaws expressly
electing not to be governed by Section 203 and approved by a
majority of its outstanding voting shares. We have not opted out of
Section 203. As a result, Section 203 could delay, deter or prevent
a merger, change of control or other takeover of our company that
our stockholders might consider to be in their best interests,
including transactions that might result in a premium being paid
over the market price of our common stock, and may also limit the
price that investors are willing to pay in the future for our
common stock.
SHARES ELIGIBLE FOR FUTURE SALE
Assuming
we sell ______ Shares in this offering, there will be approximately
_______ shares of Common Stock issued and outstanding, based upon
the number of shares of Common Stock outstanding on ____________,
2017. No preferred shares are outstanding. All of the
shares of Common Stock will be freely transferable without
restriction under the Securities Act of 1933, as amended
(“
Securities
Act
”) except for shares that are owned by our
“affiliates,” as that term is defined in Rule 144
under the Securities Act, which includes our directors and our
significant shareholders. Shares of our Common Stock held by
affiliates may not be sold unless they are registered under the
Securities Act or are sold pursuant to an exemption from
registration, including an exemption contained in Rule 144
under the Securities Act. Further, as described below, we plan to
file a registration statement to cover the shares issued under
our equity incentive plans.
Rule 144
In
general, under Rule 144 as currently in effect, a person (or
persons whose shares are aggregated), including an affiliate, who
beneficially owns “restricted securities” of a
“reporting company” may not sell these securities until
the person has beneficially owned them for at least six months.
Thereafter, affiliates may not sell within any three-month period a
number of shares in excess of the greater of: (i) one
percent of the shares of Common Stock issued and outstanding, or
(ii) the average weekly trading volume during the four calendar
weeks preceding the filing of a Form 144, or if no such notice is
required, the date of receipt of the order to execute the
transaction.
Sales
under Rule 144 by our affiliates also will be subject to
restrictions relating to manner of sale, notice and the
availability of current public information about us and may be
effected only through unsolicited brokers’
transactions.
Persons
not deemed to be our affiliates who have beneficially owned
“restricted securities” for at least six months but for
less than one year may sell these securities, provided that current
public information about us is “available,” which means
that, on the date of sale, we have been subject to the reporting
requirements of the Securities Exchange Act of 1934, as amended
(“
Exchange
Act
”) for at least ninety days and are current in our
Exchange Act filings. After beneficially owning “restricted
securities” for one year, our non-affiliates may engage in
unlimited resales of such securities.
Shares
received by our affiliates in the spin-off or upon exercise of
stock options or upon vesting of other equity-linked awards may be
“controlled securities” rather than “restricted
securities.” “Controlled securities” are subject
to the same volume limitations as “restricted
securities” but are not subject to holding period
requirements.
Stock Plans
The
Company has adopted the 2017 Equity Compensation Plan
(“
2017 Plan
”).
The 2017 Plan provides for the issuance of up to 2,000,000 shares
of Common Stock pursuant to awards granted under the terms of the
2017 Plan. As of April 14, 2017, no awards providing for the
issuance of shares of Common Stock have been issued. No prediction
can be made as to the effect, if any, that market sales of
restricted or freely trading shares of Common Stock issued under
the terms of the 2017 Plan will have on the market price of our
Common Stock prevailing from time to time. Nevertheless, sales of
substantial amounts of Common Stock, or the perception that such
sales could occur, could adversely affect prevailing market prices
for our Common Stock and could impair our future ability to raise
capital through an offering of our equity securities.
PLAN OF DISTRIBUTION
This prospectus relates to the sale of ________ shares of Common
Stock.
There is currently no market for our securities. Our Common
Stock is not traded on any exchange or on the over-the-counter
market. After the effective date of the registration
statement relating to this prospectus, we hope to have a market
maker file an application with the Financial Industry Regulatory
Authority for our Common Stock to be eligible for trading on the
over-the-counter market. We do not yet have a market maker
who has agreed to file such application.
We intend to sell the Shares ourselves and do not intend to use
underwriters or pay any commissions for these sales. We will
be selling the Shares using the best efforts of our officers and
directors. No officer or director will receive any
compensation for sales made.
In accordance with Rule 3(a)(4)(ii) of the Securities Exchange Act,
our officers and directors primarily perform substantial duties on
behalf of the issuer that have no connection to securities
transactions.
None of our officers or directors are a broker or dealer or and
associated person of a broker or dealer, nor have they been within
the preceding 12 months. They will not participate in selling
an offering of securities for any issuer more than once every
twelve months other than in reliance on Rule 3(a)(4)(i) and
(iii).
There is no plan or arrangement to enter into any contracts or
agreements to sell the Shares with a broker or dealer. Our
officers and directors will sell the Shares and intend to offer
them to friends, family members and business acquaintances.
There is no minimum number of Shares we must sell so no money
raised from the sale of the Shares will go into escrow, trust or
another similar arrangement.
Under the rules of the Securities and Exchange Commission, our
Common Stock will come within the definition of a “penny
stock” because the price of our Common Stock on the OTC
Bulletin Board is below $5.00 per share. As a result, our
Common Stock will be subject to the "penny stock" rules and
regulations. Broker-dealers who sell penny stocks to certain
types of investors are required to comply with the
Commission’s regulations concerning the transfer of penny
stock. These regulations require broker-dealers
to:
●
Make
a suitability determination prior to selling penny stock to the
purchaser;
●
Receive
the purchaser’s written consent to the transaction;
and
●
Provide
certain written disclosures to the purchaser.
DETERMINATION OF OFFERING PRICE
Our
Common Stock is presently not traded on any market or securities
exchange and we have not applied for listing or quotation on any
public market. We are offering the Shares at a price of $___
per Share. Such offering price does not have any relationship
to any established criteria of value, such as book value or
earnings per share of Common Stock. The price of our Common
Stock is not based on past earnings, nor is the price of our Common
Stock indicative of the current market value of the assets owned by
us. No valuation or appraisal has been prepared for our business
and potential business expansion.
LEGAL MATTERS
Disclosure Law
Group, a Professional Corporation, has issued an opinion that the
shares of Common Stock being issued pursuant to this offering are
duly authorized and validly issued, fully paid and
non-assessable.
EXPERTS
The
financial statements included in this Prospectus and in the
registration statement have been audited by Rosenberg Rich Baker
Berman & Company, independent registered public accounting
firm, to the extent and for the periods set forth in their report,
appearing in the financial statements beginning on Page F-1 in this
prospectus, and are included in reliance upon such report given
upon the authority of said firm as experts in auditing and
accounting.
WHERE YOU CAN FIND MORE INFORMATION
We have
filed a registration statement on Form S-1 with the Securities and
Exchange Commission (“
SEC
”). This prospectus, which
forms a part of that registration statement, does not contain all
of the information included in the registration statement and the
exhibits and schedules thereto as permitted by the rules and
regulations of the SEC. For further information with respect to us
and the shares of our Common Stock offered hereby, please refer to
the registration statement, including its exhibits and schedules.
Statements contained in this prospectus as to the contents of any
contract or other document referred to herein are not necessarily
complete and, where the contract or other document is an exhibit to
the registration statement, each such statement is qualified in all
respects by the provisions of such exhibit, to which reference is
hereby made. You may review a copy of the registration statement at
the SEC’s public reference room at 100 F Street, N.E.,
Washington, DC 20549. Please call the SEC at 1-800-SEC-0330 for
further information on the operation of the public reference rooms.
The registration statement can also be reviewed by accessing the
SEC’s website at
http://www.sec.gov
. We are subject to
the information and reporting requirements of the Exchange Act and,
in accordance therewith, file periodic reports, proxy statements or
information statements, and other information with the SEC. These
reports can also be reviewed by accessing the SEC’s
website.
You should rely only on the information provided in this
prospectus, any prospectus supplement or as part of the
registration statement filed on Form S-1 of which this prospective
is a part, as such registration statement is amended and in effect
with the Securities and Exchange Commission. We have not authorized
anyone else to provide you with different information. We are not
making an offer of these securities in any state where the offer is
not permitted. You should not assume that the information in this
prospectus, any prospectus supplement or any document incorporated
by reference is accurate as of any date other than the date of
those documents.
WRAP TECHNOLOGIES, LLC
INDEX TO FINANCIAL STATEMENTS
|
|
Page
|
|
|
|
Report of Independent Registered Public Accounting
Firm
|
|
F-2
|
|
|
|
Balance Sheet as of December 31, 2016
|
|
F-3
|
|
|
|
Statement of Operations for the Period from Inception (March 2,
2016) to December 31, 2016
|
|
F-4
|
|
|
|
Statement of Members’ Equity for the Period from Inception
(March 2, 2016) to December 31, 2016
|
|
F-5
|
|
|
|
Statement of Cash Flows for the Period from Inception (March 2,
2016) to December 31, 2016
|
|
F-6
|
|
|
|
Notes to Financial Statements
|
|
F-7
|
|
|
|
|
|
|
Condensed Balance Sheets of Wrap Technologies, Inc. as of March 31,
2017 (unaudited) and December 31,
2016
|
|
F-13
|
|
|
|
Condensed Statements of Operations of Wrap Technologies, Inc. for
the three months ended March 31, 2017 and the Period from Inception
(March 2, 2016) to March 31, 2016 (unaudited)
|
|
F-14
|
|
|
|
Condensed Statement of Stockholders’ Equity of Wrap
Technologies, Inc. for the Period from Inception (March 2, 2016) to
March 31, 2017 (unaudited)
|
|
F-15
|
|
|
|
Condensed Statements of Cash Flows of Wrap Technologies, Inc. for
the three months ended March 31, 2017 and the Period from Inception
(March 2, 2016) to March 31, 2016 (unaudited)
|
|
F-16
|
|
|
|
Notes to Unaudited Condensed Interim Financial Statements of Wrap
Technologies, Inc
|
|
F-17
|
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the
Members of Wrap Technologies, LLC
We have
audited the accompanying balance sheet of Wrap Technologies, LLC as
of December 31, 2016 and the related statements of operations,
members’ equity, and cash flows for period from Inception
(March 2, 2016) to December 31, 2016. Wrap Technologies,
LLC’s management is responsible for these financial
statements. Our responsibility is to express an opinion on these
financial statements based on our audit.
We
conducted our audit in accordance with the standards of the Public
Company Accounting Oversight Board (United States). Those standards
require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of
material misstatement. The company is not required to have, nor
were we engaged to perform, an audit of its internal control over
financial reporting. Our audit included consideration of internal
control over financial reporting as a basis for designing audit
procedures that are appropriate in the circumstances, but not for
the purpose of expressing an opinion on the effectiveness of the
company’s internal control over financial reporting.
Accordingly, we express no such opinion. An audit also includes
examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the accounting
principles used and significant estimates made by management, as
well as evaluating the overall financial statement presentation. We
believe that our audit provides a reasonable basis for our
opinion.
In our
opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of Wrap
Technologies, LLC as of December 31, 2016, and the results of its
operations and its cash flows for the period from Inception (March
2, 2016) to December 31, 2016, in conformity with accounting
principles generally accepted in the United States of
America.
The
accompanying financial statements have been prepared assuming that
the Company will continue as a going concern. As discussed in Note
1 to the financial statements, the Company has generated
significant losses since inception and anticipates that it will
continue to generate significant losses and require substantial
additional investment. These conditions raise substantial doubt
about its ability to continue as a going concern.
Management’s plans regarding those matters also are described
in Note 1. The financial statements do not include any adjustments
that might result from the outcome of this uncertainty. Our opinion
is not modified with respect to that matter.
/s/
Rosenberg Rich Baker Berman & Company
Somerset,
New Jersey
March
29, 2017
Wrap Technologies, LLC
Balance Sheet
December 31, 2016
ASSETS
|
|
Current assets:
|
|
Cash
|
$
255,072
|
Prepaid
expenses and other assets
|
28,299
|
Total current assets
|
283,371
|
Property and equipment, net
|
8,226
|
Other assets, net
|
1,512
|
Total assets
|
$
293,109
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
|
Current liabilities:
|
|
Accounts
payable
|
$
12,065
|
Deferred
officer compensation
|
70,000
|
Accrued
liabilities
|
2,900
|
Total current liabilities
|
84,965
|
|
|
Commitments and contingencies (Note 6)
|
|
|
|
Members' equity:
|
|
Members'
equity, 729 units issued and outstanding
|
208,144
|
Total liabilities and members' equity
|
$
293,109
|
See
accompanying notes to financial statements.
Wrap Technologies, LLC
Statement of Operations
For the Period from Inception (March 2, 2016) to December 31,
2016
Operating expenses:
|
|
Selling,
general and administrative
|
$
17,112
|
Research
and development
|
217,244
|
Total
operating expenses
|
234,356
|
Loss
from operations
|
(234,356
)
|
|
|
Net loss
|
$
(234,356
)
|
|
|
Loss
per unit
|
$
(703.77
)
|
Weighted
average units outstanding
|
333
|
See
accompanying notes to financial statements.
Wrap Technologies, LLC
Statement of Members’ Equity
|
|
|
|
|
|
Balance at Inception (March 2, 2016)
|
|
$
-
|
Member
capital contributions
|
729
|
442,500
|
Net
loss for the period
|
|
(234,356
)
|
Member
distributions
|
|
-
|
Balance at December 31, 2016
|
729
|
$
208,144
|
See
accompanying notes to financial statements.
Wrap Technologies, LLC
Statement of Cash Flow
For the Period from Inception (March 2, 2106) to December 31,
2016
Cash Flows From Operating Activities:
|
|
Net
loss
|
$
(234,356
)
|
Adjustments
to reconcile net loss to net cash
used
in operating activities:
|
Depreciation
|
1,312
|
Changes
in assets and liabilities:
|
|
Prepaid
expenses and other assets
|
(29,811
)
|
Accounts
payable
|
12,065
|
Deferred
officer compensation
|
70,000
|
Accrued
liabilities
|
2,900
|
Net
cash used in operating activities
|
(177,890
)
|
|
|
Cash Flows From Investing Activities:
|
|
Capital
expenditures for property and equipment
|
(9,538
)
|
Net
cash used in investing activities
|
(9,538
)
|
|
|
Cash Flows From Financing Activities:
|
|
Member
capital contributions
|
442,500
|
Net
cash provided by financing activities
|
442,500
|
Net increase in cash and cash equivalents
|
255,072
|
Cash and cash equivalents, beginning of period
|
-
|
Cash and cash equivalents, end of year
|
$
255,072
|
See
accompanying notes to financial statements.
Wrap Technologies, LLC
Notes to Financial Statements
1.
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES
Organization and Business Description
Wrap Technologies, LLC (“
Wrap
” or the “
Company
”)
is a developer of security
products designed for use by law enforcement and security
personnel. The Company plans to introduce its first product, the
BolaWrap™ 100 remote restraint device, during
2017.
The
Company was organized as a Delaware limited liability company on
March 2, 2016 and is headquartered in Las Vegas,
Nevada.
Basis of Presentation and Use of Estimates
The
accompanying financial statements have been prepared in conformity
with accounting principles generally accepted in the United States
of America (“
U.S.
GAAP
”).
The preparation
of financial statements in conformity with accounting principles
generally accepted in the United States of America requires
management to make estimates and assumptions (e.g., recognition and
measurement of contingencies and accrued costs) that affect the
reported amounts of assets and liabilities, and disclosure of
contingent assets and liabilities at the date of the financial
statements and affect the reported amounts of revenues and expenses
during the reporting period. Actual results could materially differ
from those estimates.
Going Concern
Since
inception in March 2016, the Company has generated significant
losses from operations and anticipates that it will continue to
generate significant losses from operations for the foreseeable
future, and that in order to continue as a going concern, the
business will require substantial additional investment that has
not yet been secured. The Company’s loss from
operations was $234,356 for the period ended December 31, 2016. The
net cash used from operations and investing was $187,428 for the
period ended December 31, 2016. On December 31, 2016 the Company
had $255,072 in cash and in January 2017 received additional
$225,000 cash from the sale of membership units. As of
December 31, 2016, the Company’s obligations included $84,965
of current liabilities and lease commitments of approximately
$51,000.
Management has
concluded that due to the conditions described above, there is
substantial doubt about the entity’s ability to continue as a
going concern through March 29, 2018
Management has
evaluated the significance of the conditions in relation to the
Company’s ability to meet its obligations and believes that
the current cash balance will provide sufficient capital to
continue operations through approximately June 2017. While the
Company plans to raise capital to address its capital deficiencies
and meet its operating cash requirements, there is no assurance
that its plans will be successful. Management cannot assure you
that financing will be available on favorable terms or at all.
Additionally, if additional capital is raised through the sale of
equity or convertible debt securities, the issuance of such
securities would result in dilution to the Company’s existing
members. Furthermore, despite management’s optimism regarding
the Company’s technology and planned products, even in the
event that the Company is adequately funded, there is no guarantee
that any products or product candidates will perform as hoped or
that such products can be successfully commercialized.
Net Loss per Membership Unit
Basic
net loss per unit is computed by dividing net loss by the weighted
average number of membership units outstanding during the period.
Diluted net loss per unit is computed by dividing net loss by the
weighted average number of membership units and membership unit
equivalents outstanding during the period. There were no membership
unit equivalents outstanding during the period presented;
accordingly, the Company’s basic and diluted net loss per
unit are the same.
Wrap Technologies, LLC
Notes to Financial Statements
1.
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(continued)
Fair Value of Financial Instruments
The
carrying amounts of cash, accounts payable and accrued liabilities
approximate fair values due to the short maturity of these
instruments.
Concentrations of Credit Risk
Financial
instruments, which potentially subject the Company to
concentrations of credit risk, consist primarily of cash. Due to
the relative short nature of such instrument, the carrying amount
approximates fair value. The Company places its cash in a demand
deposit account at one bank and such balances may at times be in
excess of amounts insured by federal agencies, which is $250,000 as
of December 31, 2016. The Company does not believe that it is
subject to any unusual financial risk beyond the normal risk
associated with commercial banking relationships. The Company
performs periodic evaluations of the relative credit standing of
these financial institutions. The Company has not experienced any
significant losses on its cash equivalents.
Property, Equipment and Depreciation
Property
and equipment is stated at cost. Depreciation on property and
equipment is computed over the estimated useful lives of three
years using the straight-line method. The Company intends, on any
retirement or disposition of property and equipment, that the
related cost and accumulated depreciation or amortization will be
removed and a gain or loss recorded.
Impairment of Long-Lived Assets
Long-lived
assets and identifiable intangibles held for use are reviewed for
impairment whenever events or changes in circumstances indicate
that the carrying amount may not be recoverable. If the sum of
undiscounted expected future cash flows is less than the carrying
amount of the asset or if changes in facts and circumstances
indicate, an impairment loss is recognized and measured using the
asset’s fair value. The Company did not recognize any
impairment loss during the period ended December 31,
2016.
Startup Costs
The
Company expensed startup costs related to the development of its
business including approximately $24,600 incurred prior to legal
formation. Patent legal costs incurred are expensed as research and
development costs until evidence of patentability is
confirmed.
Research and Development Costs
Research
and development costs consist primarily of contract development
costs and experimental work materials and certain startup patent
costs. Research and development costs with no alternative use are
expensed as incurred.
Income Taxes
The
Company is treated as a partnership for federal and state income
tax purposes and generally does not incur income taxes. Instead,
its income or losses are included in the income tax returns of the
member partners. Accordingly, no provision or liability for federal
or state income taxes has been included in these financial
statements.
The
Company recognizes and measures tax benefits when realization of
the benefits is uncertain under a two-step approach. The first step
is to determine whether the benefit meets the more-likely-than-not
condition for recognition and the second step is to determine the
amount to be recognized based on the cumulative probability that
exceeds 50%. The Company has not recognized any liability for
unrecognized tax benefits and has not identified any uncertain tax
positions.
Wrap Technologies, LLC
Notes to Financial Statements
1.
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES
(continued)
The
Company files income tax returns in the U.S. federal jurisdictions
and being domiciled in Nevada currently files no state income tax
returns.
Recent Accounting Pronouncements
In May
2014, the Financial Accounting Standards Board (“
FASB
”) issued Accounting
Standards Update (“
ASU
”) No.
2014-09,
Revenue from
Contracts with Customers
. This new standard will
replace most of the existing revenue recognition guidance in U.S.
GAAP when it becomes effective and permits the use of either the
retrospective or cumulative effect transition method. The new
standard, as amended, becomes effective for the Company in the
first quarter of 2018, but allows the Company to adopt the standard
one year earlier if it so chooses. Should the Company enter into
any applicable customer contracts in 2017 it plans to apply the
provisions of this standard.
In
August 2014, FASB issued Accounting Standards Update (ASU) No.
2014-15,
Preparation of Financial
Statements – Going Concern (Subtopic 205-40), Disclosure of
Uncertainties about an Entity’s Ability to Continue as a
Going Concern.
The new standard provides guidance around
management's responsibility to evaluate whether there is
substantial doubt about an entity's ability to continue as a going
concern and to provide related footnote disclosures. The Company
adopted this standard during the year ended December 31,
2016.
In
February 2016, the FASB issued ASU 2016-02,
“Leases (Topic 842).”
The
new guidance will replace the current lease guidance. The new
guidance requires that entities recognize the assets and
liabilities associated with leases on the balance sheet and to
disclose key information about leasing arrangements. The new
guidance is effective in fiscal years beginning after December 15,
2018, including interim periods within those fiscal years.
Therefore, the Company is required to adopt the guidance on January
1, 2019. Early adoption is permitted. The Company is currently
evaluating the possible impact of ASU 2016-02, but does not
anticipate that it will have a material impact on the Company's
results of operations, financial position or cash
flows.
In August
2016, the FASB issued ASU 2016-15,
Statement of Cash Flows (Topic 230):
Classification of Certain Cash Receipt and Cash Payments
.
The new guidance addresses certain classification issues related to
the statement of cash flows which will eliminate the diversity of
practice in how certain cash receipts and cash payments are
presented and classified in the statement of cash flows. The
guidance is effective for fiscal years beginning after December
2017. Early adoption is permitted. The Company is currently
evaluating the possible impact of ASU 2016-15, but does not
anticipate that it will have a material impact on the Company's
results of operations, financial position or cash
flows.
The
Company has reviewed other recently issued, but not yet effective,
accounting pronouncements and does not believe the future adoptions
of any such pronouncements will be expected to cause a material
impact on its financial condition or the results of
operations.
Wrap Technologies, LLC
Notes to Financial Statements
2.
PROPERTY AND EQUIPMENT, NET
Property
and equipment consist of the following at December 31,
2016:
Equipment
|
$
7,342
|
Furniture
|
2,196
|
|
9,538
|
Accumulated
depreciation
|
(1,312
)
|
|
$
8,226
|
Depreciation
expense was $1,312 for the period ended December 31,
2016.
Effective March 2016 the Company began accruing
monthly compensation for the services of two officers in the
aggregate amount of $7,000 per month payable to Syzygy Licensing,
LLC (“
Syzygy
”). The balance as of December 31, 2016 was
$70,000 and accrues without interest. No repayment terms or
schedule has been established.
The
Company has one class of membership units which include certain
transfer restrictions as specified in the operating agreement and
pursuant to applicable tax and securities law, with each unit
representing a pro rata ownership in the Company’s capital,
profits, losses and distributions. Losses are allocated to members
in accordance with their capital balances until zero and thereafter
based upon their respective percentage of units held. Income is
allocated first to the extent of previous losses and thereafter
allocated to members based upon their respective percentage of
units held.
During
2016 the Company obtained cash capital contributions of $442,500
from the issuance of 729 membership units.
5.
COMMITMENTS AND CONTINGENCIES
Facility Lease
Commencing December
1, 2016 the Company leased 1,890 square feet of improved office,
assembly and warehouse space in Las Vegas, Nevada for a period of
37 months terminating December 31, 2019. The gross monthly base
rent is $1,512 increasing approximately 3.5% per year, subject to
certain future adjustments. The Company may receive an aggregate of
three months of base rent concessions over the term of the lease
subject to timely rent payments.
Rent
expense for the period ended December 31, 2016 was $1,510. The
remaining future annual minimum lease obligations under the
foregoing facility lease are $15,158, $17,123 and $19,051 for 2017,
2018 and 2019, respectively.
Related Party Technology License Agreement
The
Company is obligated to pay royalties and pay development and
patent costs pursuant to an exclusive Amended and Restated
Intellectual Property License Agreement dated as of September 30,
2016 with Syzygy, a company owned and controlled by member/officers
Mr. Norris and Mr. Barnes (also a Manager of the Company). The
agreement provides for royalties of 4% of revenues from products
employing the licensed ensnarement device technology up to an
aggregate of $1,000,000 of royalties or until September 30, 2026,
whichever is earlier. The license reverted to Syzygy unless the
Company obtained aggregated capitalization of at least $300,000 by
December 31, 2016 (subject to a 6-month extension). As the
requirement was met, Syzygy has assigned patent applications and
the technology to the Company subject to the royalty
obligation.
Wrap Technologies, LLC
Notes to Financial Statements
5. COMMITMENTS AND CONTINGENCIES (continued)
Indemnifications and Guarantees
Our
officers and managers are indemnified as to personal liability as
provided by the Delaware law and the Company’s operating
agreement. The Company may also undertake indemnification
obligations in the ordinary course of business related to its
operations. The Company is unable to estimate with any reasonable
accuracy the liability that may be incurred pursuant to any such
indemnification obligations now or in the future. Because of the
uncertainty surrounding these circumstances, the Company’s
current or future indemnification obligations could range from
immaterial to having a material adverse impact on its financial
position and its ability to continue in the ordinary course of
business. The Company has no liabilities recorded for such
indemnities.
Regulatory Agencies
The
Company may be subject to oversight from regulatory agencies
regarding firearms that arise in the ordinary course of its
business.
6.
RELATED PARTY TRANSACTIONS
During
the period ended December 31, 2016 the Company paid $25,409 of
patent legal costs incurred by Syzygy for the ensnarement device
technology pursuant to the license agreement (see Note 6) with such
technology subsequently assigned to the Company. See Notes 3, 5 and
7 for additional related party transactions and
information.
In
January 2017 the Company obtained additional cash capital
contributions of $225,000 from the issuance of 90 membership
units.
On
March 22, 2017 the Company issued 16.75 membership units to Petro
River Oil Corp. (“
Petro
”) to acquire 100% ownership
of its non-operating subsidiary Megawest Energy Montana Corp.
(“
Megawest
”).
Megawest had no assets or liabilities as of the acquisition date.
Scot Cohen, who is a member and manager of the Company,
beneficially owns 14% of Petro. The Company intends to merge into
Megawest and as part of the purchase of Megawest agreed to file a
registration statement with respect to its shares within 60
days.
8.
UNAUDITED PRO FORMA FINANCIAL INFORMATION
On
March 31, 2017 Wrap Technologies, LLC merged with and into its
wholly-owned subsidiary MegaWest (see Note 7). Wrap Technologies,
LLC ceased separate existence with Megawest continuing as the
surviving entity. MegaWest changed its name to Wrap Technologies,
Inc. and amended and restated new articles of incorporation
authorizing 150,000,000 shares of Common Stock, par value $0.0001,
and 5,000,000 shares of preferred stock, par value $0.0001. All
outstanding 835.75 membership units of Wrap LLC were exchanged for
20,000,000 shares of Common Stock of the Company.
The
Company’s subsequent merger with and into the MegaWest
wholly-owned subsidiary and exchange of membership units for Common
Stock will be accounted for as a reverse recapitalization of the
Company. Wrap Technologies, Inc. financial statements are in
substance those of Wrap Technologies, LLC and deemed to be a
continuation of the Company’s business from its inception
date of March 2, 2016. The balance sheet of the Company continues
at historical cost as the accounting acquiree (“
Megawest
”) had no operating
business, no assets or liabilities and no goodwill or intangible
assets was recorded as part of the recapitalization of the
Company.
Wrap Technologies, LLC
Notes to Financial Statements
8.
UNAUDITED PRO FORMA FINANCIAL INFORMATION (continued)
The
following illustrates the pro forma adjustments to
stockholders’ equity related to the reverse recapitalization
and the pro forma net loss and net loss per share as though the
transaction occurred at the inception of Wrap Technologies,
LLC:
|
|
MegaWest Energy Montana Corp.
|
|
Pro Forma Recapitalization
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders’ equity:
|
|
|
|
|
Preferred
stock - 5,000,000 authorized; par value $0.0001 per share; none
issued and outstanding
|
-
|
-
|
-
|
-
|
Common stock -
1,000 authorized; par value $0.01 per share; 1,000 shares issued
and outstanding
|
-
|
10
|
(10
)
|
-
|
Common stock -
150,000,000 authorized; par value $0.0001 per share; 17,846,246
shares issued and outstanding
|
-
|
-
|
1,785
|
1,785
|
Additional
paid-in capital
|
-
|
1,784,759
|
(1,344,044
)
|
440,715
|
Members'
equity
|
442,500
|
-
|
(442,500
)
|
-
|
Accumulated
deficit
|
(234,356
)
|
(1,786,269
)
|
1,786,269
|
(234,356
)
|
Total stockholders' equity
|
208,144
|
(1,500
)
|
1,500
|
208,144
|
Total liabilities and stockholders' equity
|
$
293,109
|
$
-
|
$
-
|
$
293,109
|
|
|
|
|
|
Pro
forma net loss
|
$
(234,356
)
|
|
|
$
(234,356
)
|
Net
loss per common share
|
|
|
|
$
(0.03
)
|
Weighted
average common shares outstanding
|
|
|
|
8,366,286
|
Wrap Technologies, Inc.
Condensed Balance Sheets
|
|
|
|
|
|
ASSETS
|
|
|
Current
assets:
|
|
|
Cash
|
$
344,629
|
$
255,072
|
Prepaid expenses
and other assets
|
28,771
|
28,299
|
Total
current assets
|
373,400
|
283,371
|
Property
and equipment, net
|
11,527
|
8,226
|
Other
assets, net
|
1,512
|
1,512
|
Total
assets
|
$
386,439
|
$
293,109
|
|
|
|
LIABILITIES
AND STOCKHOLDERS' EQUITY
|
|
|
Current
liabilities:
|
|
|
Accounts
payable
|
$
35,255
|
$
12,065
|
Deferred and
accrued officer compensation
|
96,000
|
70,000
|
Accrued
liabilities
|
23,795
|
2,900
|
Total
current liabilities
|
155,050
|
84,965
|
|
|
|
Commitments
and contingencies (Note 6)
|
|
|
|
|
|
Stockholders'
equity:
|
|
|
Preferred
stock - 5,000,000 authorized; par value $0.0001 per share; none
issued and outstanding
|
-
|
-
|
Common stock -
150,000,000 authorized; par value $0.0001 per share; 20,000,000 and
17,445,408 shares issued and outstanding, respectively
|
2,000
|
1,745
|
Additional
paid-in capital
|
665,500
|
440,755
|
Accumulated
deficit
|
(436,111
)
|
(234,356
)
|
Total
stockholders' equity
|
231,389
|
208,144
|
Total
liabilities and stockholders' equity
|
$
386,439
|
$
293,109
|
See
accompanying notes to condensed interim financial
statements.
Wrap Technologies, Inc.
Condensed Statements of Operations
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
expenses:
|
|
|
Selling,
general and administrative
|
75,792
|
3,690
|
Research
and development
|
125,963
|
27,909
|
Total operating
expenses
|
201,755
|
31,599
|
Loss from
operations
|
(201,755
)
|
(31,599
)
|
|
|
|
Net
loss
|
$
(201,755
)
|
$
(31,599
)
|
|
|
|
Net loss per basic
common share
|
$
(0.01
)
|
$
(0.01
)
|
Weighted average
common shares used to compute net loss per basic common
share
|
19,134,044
|
4,307,509
|
|
See
accompanying notes to condensed interim financial
statements.
Wrap
Technologies, Inc.
Condensed
Statement of Stockholders' Equity
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
Balance
at Inception (March 2, 2016)
|
-
|
$
-
|
$
-
|
$
-
|
$
-
|
Sale of common
stock in March 2016 at $0.00836 per share
|
4,786,121
|
479
|
39,521
|
-
|
40,000
|
Sale of common
stock in September 2016 at $0.00836 per share
|
4,786,120
|
479
|
39,521
|
-
|
40,000
|
Sale of common
stock in October 2016 at $0.00836 per share
|
4,786,120
|
479
|
39,521
|
-
|
40,000
|
Sale of common
stock in December 2016 at $0.10447 per share
|
3,087,047
|
308
|
322,192
|
-
|
322,500
|
Net loss for the
period
|
-
|
-
|
-
|
(234,356
)
|
(234,356
)
|
Balance
at December 31, 2016
|
17,445,408
|
$
1,745
|
$
440,755
|
$
(234,356
)
|
$
208,144
|
Sale of common
stock in January 2017 at $0.10447 per share
|
2,153,754
|
215
|
224,785
|
-
|
225,000
|
Shares issued to
acquire merger subsidiary to effect reverse
recapitalization
|
400,838
|
40
|
(40
)
|
-
|
-
|
Net loss for the
period
|
-
|
-
|
-
|
(201,755
)
|
(201,755
)
|
Balance
at March 31, 2017
|
20,000,000
|
$
2,000
|
$
665,500
|
$
(436,111
)
|
$
231,389
|
See accompanying
notes to condensed interim financial
statements.
Wrap Technologies, Inc.
Condensed Statements of Cash Flows
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
Flows From Operating Activities:
|
|
|
Net
loss
|
$
(201,755
)
|
$
(31,599
)
|
Adjustments to
reconcile net loss to net cash
used in
operating activities:
|
|
|
Depreciation
|
795
|
-
|
Changes in assets
and liabilities:
|
|
|
Prepaid expenses
and other assets
|
(472
)
|
-
|
Accounts
payable
|
23,190
|
12,390
|
Deferred and
accrued officer compensation
|
26,000
|
7,000
|
Accrued
liabilities
|
20,895
|
-
|
Net cash used in
operating activities
|
(131,347
)
|
(12,209
)
|
|
|
|
Cash
Flows From Investing Activities:
|
|
|
Capital
expenditures for property and equipment
|
(4,096
)
|
-
|
Net cash used in
investing activities
|
(4,096
)
|
-
|
|
|
|
Cash
Flows From Financing Activities:
|
|
|
Sale of common
stock
|
225,000
|
40,000
|
Net cash provided
by financing activities
|
225,000
|
40,000
|
|
|
|
Net
increase in cash and cash equivalents
|
89,557
|
27,791
|
Cash,
beginning of period
|
255,072
|
-
|
Cash,
end of period
|
$
344,629
|
$
27,791
|
See
accompanying notes to condensed interim financial
statements.
Wrap Technologies, LLC
Notes to Unaudited Condensed Interim Financial
Statements
1.
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES
Organization and Business Description
Wrap Technologies, Inc. (the
“
Company
”)
is a developer of security
products designed for use by law enforcement and security
personnel. The Company plans to introduce its first product, the
BolaWrap™ 100 remote restraint device, during
2017.
The
Company resulted from the March 31, 2017 merger of Wrap
Technologies, LLC (“
Wrap
LLC
”) with and into its wholly-owned subsidiary
MegaWest Energy Montana Corp. (“
MegaWest
”). Wrap LLC ceased
separate existence with MegaWest continuing as the surviving
entity. MegaWest changed its name to Wrap Technologies, Inc. and
amended and restated new articles of incorporation authorizing
150,000,000 shares of Common Stock, par value $0.0001, and
5,000,000 shares of preferred stock, par value $0.0001. All
outstanding 835.75 membership units of Wrap LLC were exchanged for
20,000,000 shares of Common Stock of the Company.
Wrap
LLC acquired privately held MegaWest from Petro River Oil Corp.
(“
Petro River
”)
on March 22, 2017 through the issuance of 16.75 membership units
representing a 2% ownership interest in Wrap LLC. Petro River is
owned 11% by Scot Cohen its Executive Chairman who also was a
Manager and 26% owner of Wrap LLC and a director and officer of the
Company. MegaWest had no assets or liabilities at the date of
acquisition nor at December 31, 2016 and is not considered an
operating business.
Wrap
LLC’s acquisition of MegaWest and its subsequent merger with
and into the MegaWest wholly-owned subsidiary and exchange of
membership units for Common Stock has been accounted for as a
reverse recapitalization of Wrap LLC. Wrap LLC, now the Company, is
deemed the accounting acquirer with MegaWest the accounting
acquiree. The Company’s financial statements are in substance
those of Wrap LLC and deemed to be a continuation of its business
from its inception date of March 2, 2016. The balance sheet of the
Company continues at historical cost as the accounting acquiree had
no assets or liabilities and no goodwill or intangible assets was
recorded as part of the recapitalization of the
Company.
To
reflect the recapitalization historical common shares and
additional paid-in capital have been retroactively adjusted using
the exchange ratio of approximately 23,930.60 shares for each
membership unit of Wrap LLC.
Basis of Presentation and Use of Estimates
The
Company’s unaudited interim financial statements
included herein have been prepared in accordance with Article 8 of
Regulation S-X and the rules and regulations of the Securities
and Exchange Commission (“
SEC
”). Certain information and
footnote disclosures normally included in financial statements
prepared in accordance with U.S. generally accepted accounting
principles have been condensed or omitted pursuant to such rules
and regulations. In management’s opinion, the accompanying
statements reflect adjustments necessary to present fairly the
financial position, results of operations, and cash flows for the
periods indicated, and contain adequate disclosure to make the
information presented not misleading. Adjustments included herein
are of a normal, recurring nature unless otherwise disclosed in the
footnotes. The interim financial statements and notes thereto
should be read in conjunction with the Company’s audited
financial statements and notes thereto for the year ended December
31, 2016. Results of operations for interim periods are not
necessarily indicative of the results of operations for a full
year.
The
preparation of financial statements in conformity with accounting
principles generally accepted in the United States of America
requires management to make estimates and assumptions (e.g.,
recognition and measurement of contingencies and accrued costs)
that affect the reported amounts of assets and liabilities, and
disclosure of contingent assets and liabilities at the date of the
financial statements and affect the reported amounts of revenues
and expenses during the reporting period. Actual results could
materially differ from those estimates.
Wrap Technologies, LLC
Notes to Unaudited Condensed Interim Financial
Statements
1.
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(continued)
Going Concern
Since
inception in March 2016, the Company has generated significant
losses from operations and anticipates that it will continue to
generate significant losses from operations for the foreseeable
future, and that in order to continue as a going concern, the
business will require substantial additional investment that has
not yet been secured. The Company’s loss from
operations was $234,356 for the period ended December 31, 2016 and
$201,755 for the three months ended March 31, 2017. The net cash
used from operations and investing was $187,428 for the period
ended December 31, 2016 and $131,347 for the three months ended
March 31, 2017. On March 31, 2017 the Company had $344,629 in
cash. As of March 31, 2017, the Company’s obligations
included $155,050 of current liabilities and lease commitments of
approximately $48,300.
Management has
concluded that due to the conditions described above, there is
substantial doubt about the Company’s ability to continue as
a going concern through April 17, 2018.
Management has
evaluated the significance of the conditions in relation to the
Company’s ability to meet its obligations and believes that
the current cash balance will provide sufficient capital to
continue operations through approximately June 2017. While the
Company plans to raise capital to address its capital deficiencies
and meet its operating cash requirements, there is no assurance
that its plans will be successful. Management cannot assure you
that financing will be available on favorable terms or at all.
Additionally, if additional capital is raised through the sale of
equity or convertible debt securities, the issuance of such
securities would result in dilution to the Company’s existing
shareholders. Furthermore, despite management’s optimism
regarding the Company’s technology and planned products, even
in the event that the Company is adequately funded, there is no
guarantee that any products or product candidates will perform as
hoped or that such products can be successfully
commercialized.
Net Loss per Share
Basic
loss per common share is computed by dividing net loss for the
period by the weighted-average number of shares of Common Stock
outstanding during the period. Diluted loss per common share is
computed by dividing net loss by the weighted-average number of
shares of Common Stock outstanding during the period increased to
include the number of additional shares of Common Stock that would
have been outstanding if the potentially dilutive securities had
been issued. There were no Common Stock equivalents outstanding
during the periods presented; accordingly, the Company’s
basic and diluted net loss per share are the same.
Income Taxes
Until
its reverse recapitalization on March 31, 2017, the Company was
treated as a partnership for federal and state income tax purposes
and did not incur income taxes. Instead, its losses were included
in the income tax returns of the member partners. Accordingly, no
provision or liability for federal or state income taxes has been
included in these financial statements.
Recent Accounting Pronouncements
The
Company has reviewed recently issued, but not yet effective,
accounting pronouncements and does not believe the future adoptions
of any such pronouncements will be expected to cause a material
impact on its financial condition or the results of
operations.
Wrap Technologies, LLC
Notes to Unaudited Condensed Interim Financial
Statements
2.
PROPERTY AND EQUIPMENT, NET
Property
and equipment consisted of the following:
|
|
|
|
|
|
Laboratory
equipment
|
$
11,222
|
$
7,342
|
Computer
equipment
|
216
|
-
|
Furniture and
fixtures
|
2,196
|
2,196
|
|
13,634
|
9,538
|
Accumulated
depreciation
|
(2,107
)
|
(1,312
)
|
|
$
11,527
|
$
8,226
|
Depreciation
expense was $795 for the three months ended March 31,
2017.
3.
DEFERRED AND ACCRUED COMPENSATION
Effective
March 2016 the Company began accruing monthly compensation for the
services of two officers in the aggregate amount of $7,000 per
month payable to Syzygy Licensing, LLC (“Syzygy”).
Beginning in March 2017 the Company began accruing $6,000 per month
compensation to each of the two officers. The balance payable to
Syzygy as of March 31, 2017 was $84,000 and the accrued
compensation aggregated $12,000. These balances accrue without
interest. No repayment terms or schedule has been
established.
4.
STOCKHOLDERS’ EQUITY AND SHARE-BASED
COMPENSATION
The
Company’s authorized capital consists of 150,000,000 shares
of Common Stock, par value $0.0001, and 5,000,000 shares of
preferred stock, par value $0.0001.
To
reflect the recapitalization (see Note 1) historical shares of
Common Stock and additional paid-in capital have been retroactively
adjusted using the exchange ratio of approximately 23,930.60 shares
of Common Stock for each membership unit of Wrap
LLC.
Effective
with the merger, the Company adopted and the shareholders approved
on March 31, 2017 the 2017 Equity Compensation Plan authorizing
2,000,000 shares of Common Stock for issuance as stock options and
restricted stock units to employees, directors or consultants. At
March 31, 2017, there had been no option grants or restricted stock
awards made and none were outstanding.
5.
COMMITMENTS AND CONTINGENCIES
Facility Lease
Commencing December
1, 2016 the Company leased 1,890 square feet of improved office,
assembly and warehouse space in Las Vegas, Nevada for a period of
37 months terminating December 31, 2019. The gross monthly base
rent is $1,512 increasing approximately 3.5% per year, subject to
certain future adjustments. The Company may receive an aggregate of
three months of base rent concessions over the term of the lease
subject to timely rent payments.
Rent
expense for the period ended March 31, 2017 was $4,530. The
remaining future annual minimum lease obligations under the
foregoing facility lease are $12,134, $17,123 and $19,051 for the
balance of 2017, 2018 and 2019, respectively.
Wrap Technologies, LLC
Notes to Unaudited Condensed Interim Financial
Statements
5.
COMMITMENTS AND CONTINGENCIES (continued)
Related Party Technology License Agreement
The
Company is obligated to pay royalties and pay development and
patent costs pursuant to an exclusive Amended and Restated
Intellectual Property License Agreement dated as of September 30,
2016 with Syzygy, a company owned and controlled by
stockholder/officers Mr. Norris and Mr. Barnes. The agreement
provides for royalties of 4% of revenues from products employing
the licensed ensnarement device technology up to an aggregate of
$1,000,000 of royalties or until September 30, 2026, whichever is
earlier.
Regulatory Agencies
The
Company may be subject to oversight from regulatory agencies
regarding firearms that arise in the ordinary course of its
business.
6.
RELATED PARTY TRANSACTIONS
See
Notes 1, 3 and 5 for information on related party transactions and
information.
Shares
of Common Stock
Prospectus
All dealers that buy, sell or trade the Common Stock
identified herein may be required to deliver a prospectus,
regardless of whether they are participating in this offering. This
is in addition to the dealers’ obligation to deliver a
prospectus when acting as underwriters and with respect to their
unsold allotments or subscriptions.
[Alternate Page for Resale Prospectus]
The information in this preliminary prospectus is not complete and
may be changed. These securities may not be sold until the
registration statement filed with Securities and Exchange
Commission is effective. This prospectus is not an offer to sell
these securities and is not soliciting an offer to buy these
securities in any state or other jurisdiction where the offer or
sale is not permitted.
Prospectus
|
|
____________, 2017
|
400,838
Shares of Common
Stock
OF WRAP TECHNOLOGIES, INC.
BEING DISTRIBUTED BY
PETRO RIVER OIL CORP.
This
prospectus is being furnished in connection with the distribution
to holders of common stock, par value $0.0001 per share, of Petro
River Oil Corp. (“
Petro
River
”), of all of the outstanding shares of common
stock, par value $0.0001 per share (“
Common Stock
”), of Wrap
Technologies, Inc. (the “
Company
”) owned by Petro River
(the “
Distribution
”). Petro River is
effecting the Distribution pursuant to the terms of a resolution
approved by the Board of Directors of the Company on March 28,
2017. Petro River currently owns 2% of the
Company’s Common Stock issued and outstanding. On the
date of the distribution (the “
Distribution Date
”), all Petro
River’s common shareholders will receive one share of Common
Stock of the Company for every ___________shares (or their
equivalent) of Petro River held. Since there are
15,827,998
shares of Petro
River common stock outstanding, 1/ _________th, or
_____________shares of Common Stock of the Company will be issued
to Petro River’s common shareholders.
Reason for Furnishing this Prospectus
We are
furnishing this prospectus to provide information to holders of
Petro River who will be issued shares of Common Stock of the
Company in the Distribution. It is not, and is not to be construed
as, an inducement or encouragement to buy or sell any of the
Company’s securities or those of Petro River. The information
contained in this prospectus is believed by us to be accurate as of
the date set forth on its cover. Changes may occur after that date,
and neither the Company nor Petro River are required to update the
information except in the normal course of our public disclosure
obligations and practices.
No stockholder approval of the Distribution is required, and none
is being sought. Neither Petro River nor the Company are
asking you for a proxy.
No
public market currently exists for the Company’s Common
Stock. Following the Distribution, we currently anticipate that
quotations for our Common Stock will be available on the OTCBB
quotation and trading system, and that a ticker symbol for our
Common Stock will be assigned for our Common Stock shortly before
quotations for our Common Stock first become available. It is
possible that a limited trading market, known as a
“when-issued” trading market, may develop on or shortly
before the record date for the distribution and that regular
trading, to the extent available on the OTCBB quotation and trading
system, will begin on the first trading day after the effective
date of the Distribution. Petro River will continue to list its
common stock on the OTCBB under the symbol “PTRC”
following the Distribution.
The
Company has also filed for an direct public offering of up to $4.0
million (“
DPO
”). Any such DPO
would include the materials constituting this registered
filing.
IN REVIEWING THIS PROSPECTUS, YOU SHOULD CAREFULLY CONSIDER THE
MATTERS DESCRIBED UNDER THE CAPTION “RISK FACTORS”
BEGINNING ON
PAGE
5.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE
SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED THESE SECURITIES
OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR
COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A
CRIMINAL OFFENSE.
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE
SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES
COMMISSION NOR HAS THE SECURITIES AND EXCHANGE COMMISSION OR ANY
STATE SECURITIES COMMISSION PASSED UPON THE ACCURACY OR ADEQUACY OF
THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL
OFFENSE.
NO PERSON IS AUTHORIZED TO GIVE ANY INFORMATION NOT CONTAINED IN
THE PROSPECTUS IN CONNECTION WITH THIS OFFERING AND, IF GIVEN OR
MADE, SUCH INFORMATION OR REPRESENTATION MUST NOT BE RELIED UPON AS
HAVING BEEN AUTHORIZED.
UNTIL ____________, 2017 (90 DAYS AFTER THE DATE HEREOF), ANY
BROKER-DEALER EFFECTING TRANSACTIONS IN THE SHARES, WHETHER OR NOT
PARTICIPATING IN THIS DISTRIBUTION, MAY BE REQUIRED TO DELIVER A
CURRENT COPY OF THIS PROSPECTUS. THIS IS IN ADDITION TO
THE OBLIGATION OF DEALERS TO DELIVER A COPY OF THIS PROSPECTUS WHEN
ACTING AS UNDERWRITERS AND WITH RESPECT TO ANY UNSOLD ALLOTMENTS OR
SUBSCRIPTIONS.
[Alternate Page for Resale Prospectus]
ABOUT THIS PROSPECTUS
You
should rely only on the information contained in this prospectus or
in any free writing prospectus we or Petro River may authorize to
be delivered or made available to you. Neither we, nor Petro River
have authorized anyone to provide you with different information.
We and Petro River are distributing the shares of Common Stock only
in jurisdictions where offers and sales are permitted. The
information in this prospectus is accurate only as of the date of
this prospectus, regardless of the time of delivery of this
prospectus or of any sale of shares of our Common Stock. Our
business, financial condition, operating results and prospects may
have changed since that date.
Unless the context
otherwise requires, the words “
Wrap
Technologies, Inc.,
”
“
Wrap
Technologies
,”
“
Wrap
Tech
,”
“
we
,”
“
the
Company
,”
“
us
”
and “
our
”
refer to Wrap Technologies, Inc., a Delaware
corporation.
[Alternate Page for Resale Prospectus]
The Offering
Common Stock offered by Petro River
|
400,838
shares as of the date of this prospectus.
|
|
|
Common Stock outstanding
|
___________
shares of Common Stock.
|
|
|
Use of proceeds
|
We will
not receive any proceeds from the distribution of the Common Stock
by Petro River.
|
|
|
Risk factors
|
You
should read the “
Risk
Factors
” section of this prospectus and the other
information in this prospectus for a discussion of factors to
consider carefully before deciding to invest in shares of our
Common Stock.
|
|
|
Summary of the
Distribution
The
following is a summary of the terms of the distribution. Please see
“
The
Distribution
” beginning on page __ for a more detailed
description of the matters described below.
The Distribution
Distributing company
|
|
Petro
River Oil Corp. (“
Petro
River
”), a Delaware corporation.
|
|
|
|
Distributed company
|
|
Wrap
Technologies, Inc., a Delaware corporation (the “
Company
”). The Company’s
principal executive offices are located at 4620 Arville Street,
Suite E, Las Vegas, Nevada 89103.
|
|
|
|
Distribution ratio
|
|
Each
holder of Petro River common stock will receive a dividend of ___
share of Company Common Stock for every ___ shares of Petro River
common stock held on the record date. Any fractional shares will be
rounded down to the next whole share.
|
|
|
|
Securities to be distributed
|
|
Approximately
400,838 shares of Company Common Stock, which will constitute all
of the outstanding shares of the Company’s Common Stock
beneficially owned by Petro River.
|
|
|
|
Record date
|
|
The
record date is the close of business, _______, 2017. To receive
shares of Common Stock of the Company in the Distribution, holders
of Petro River common stock must be shareholders as of the close of
business on the record date.
|
|
|
|
Distribution date
|
|
The
distribution date will be on or about ________, 2017
(“
Distribution
Date
”).
|
|
|
|
As a
result of the distribution, we will be a publicly-traded company.
The Distribution involves the following steps:
●
Approval of the
distribution by the Board of Directors of Petro River at a special
meeting held on March 15, 2017; and
●
Following the
Distribution, the application for listing and quotation of the
Company’s Common Stock on the OTCBB.
For a
further explanation of the distribution, see “
The Distribution
” beginning on
page __.
[Alternate Page for Resale Prospectus]
Risk Factors Relating to the Distribution
If the distribution, together with certain related transactions,
fails to qualify for tax-free treatment for U.S. federal income tax
purposes, then our shareholders, we and/or Petro River might be
subject to significant tax liability.
If the Distribution fails to qualify for tax-free treatment, Petro
River would be treated as if it had sold the Common Stock of the
Company for its fair market value, resulting in a taxable gain to
the extent of the excess of such fair market value over its tax
basis in our stock. In general, our initial Petro River public
shareholders would be treated as if they had received a taxable
distribution equal to the fair market value of our Common Stock
that was distributed to them. For additional information, see
“
Material U.S. Federal Income
Tax Consequences of the Distribution
” beginning on page __.
[Alternate Page for Resale Prospectus]
PETRO RIVER OIL CORP.
In addition to the shares of Common Stock offered
by the Company herein, this prospectus also relates to the
distribution by Petro River Oil Corp. (“
Petro River
”) of shares of our Common Stock which were
issued to Petro River in connection with the merger of the Company
with and into MegaWest Energy Montana Corp., a wholly-owned
subsidiary of the Company (“
MegaWest
”) on March 31, 2017 (the
“
MegaWest
Merger
”), as further
described below.
The MegaWest Merger
On March 22, 2017, Wrap Technologies, LLC
(“
Wrap LLC
”) and Petro River entered into a Stock
Purchase Agreement, pursuant to which the Company acquired from
Petro River all the capital stock of MegaWest, in consideration for
the issuance to Petro River of 2% of the issued and outstanding
membership interests in Wrap LLC. As a result, MegaWest became a
wholly-owned subsidiary of Wrap LLC. On March 31, 2017, Wrap LLC
and MegaWest entered into a Merger Agreement, pursuant to which
Wrap LLC was merged with and into MegaWest, and MegaWest changed
it’s name to Wrap Technologies, Inc., a Delaware corporation.
In connection with the MegaWest Merger, all of the membership
interests in Wrap LLC prior to March 31, 2017 were converted into
and exchanged for 20.0 million shares of Common Stock of the
Company.
As
a result of the MegaWest Merger, Petro River received an aggregate
total of 400,838 shares of Common Stock, representing approximately
2% of the issued and outstanding Common Stock of the Company upon
consummation of the MegaWest Merger. The remaining 19,599,162
shares of Common Stock of the Company was issued to the the members
of Wrap LLC immediately prior to the consummation of the MegaWest
Merger. As a part of the MegaWest Merger, the Company agreed to
register all shares of the Company’s Common Stock held by
Petro River for distribution to Petro River’s shareholders as
a dividend.
The
total number of shares registered for resale in the offering does
not include 19,599,162 shares issued in connection with the
MegaWest Merger that are not being registered, which shares are
held by former members of Wrap LLC.
[Alternate Page for Resale Prospectus]
USE OF PROCEEDS
We
will not receive any of the proceeds from the distribution of the
Common Stock by Petro River.
[Alternate Page for Resale Prospectus]
400,838 Shares of Common
Stock
Prospectus
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
The following table presents the costs and
expenses in connection with the issuance and distribution of the
securities to be registered, other than the placement agent fees
payable by us in connection with the sale of Common Stock being
registered. Except as otherwise noted, we will pay all of these
amounts. All amounts are estimates except the Securities and
Exchange Commission (“
SEC
”) registration fee and the Financial
Industry Regulatory Authority (“
FINRA
”) registration fee.
SEC registration
fee
|
$
464
|
Accounting fees and
expenses
|
$
7,500
|
Legal fees and
expenses
|
$
35,000
|
Blue Sky filing
fees
|
$
5,000
|
Miscellaneous fees
and expenses
|
$
2,036
|
Total
|
$
50,000
|
Item 14. Indemnification of Directors and
Officers
Our
Certificate of Incorporation and Bylaws contain provisions relating
to the limitation of liability and indemnification of directors and
officers. Our certificate of incorporation provides that a director
will not be personally liable to us or our shareholders for
monetary damages for breach of fiduciary duty as a director, except
for liability:
●
for
any breach of the director’s duty of loyalty to us or our
shareholders;
●
for
acts or omissions not in good faith or that involve intentional
misconduct or a knowing violation of law;
●
under Section 174 of the Delaware General
Corporation Law (the “
DGCL
”); or
●
for
any transaction from which the director derived any improper
personal benefit.
Our
Certificate of Incorporation also provides that if the DGCL is
amended to authorize corporate action further eliminating or
limiting the personal liability of directors, then the liability of
our directors will be eliminated or limited to the fullest extent
permitted by the DGCL.
Our
Bylaws provide that we will indemnify our directors and officers to
the fullest extent not prohibited by the DGCL; provided, however,
that we may limit the extent of such indemnification by individual
contracts with our directors and executive officers; and provided,
further, that we are not required to indemnify any director or
executive officer in connection with any proceeding (or part
thereof) initiated by such person or any proceeding by such person
against us or our directors, officers, employees or other agents
unless:
●
such
indemnification is expressly required to be made by
law;
●
the
proceeding was authorized by the board of directors;
or
●
such
indemnification is provided by us, in our sole discretion, pursuant
to the powers vested in us under the DGCL.
Our
Bylaws provide that we shall advance, prior to the final
disposition of any proceeding, promptly following request therefor,
all expenses by any director or executive officer in connection
with any such proceeding upon receipt of any undertaking by or on
behalf of such person to repay said amounts if it should be
determined ultimately that such person is not entitled to e
indemnified under Article XI of our bylaws or otherwise.
Notwithstanding the foregoing, unless otherwise determined, no
advance shall be made by us if a determination is reasonably and
promptly made by the board of directors by a majority vote of a
quorum of directors who were not parties to the proceeding, or if
such a quorum is not obtainable, or even if obtainable, a quorum of
disinterested directors so directs, by independent legal counsel in
a written opinion, that the facts known to the decision-making
party at the time such determination is made demonstrate clearly
and convincingly that such person acted in bad faith or in a manner
that such person did not believe to be in or not opposed to our
best interests.
Our
bylaws also authorize us to purchase insurance on behalf of any
person required or permitted to be indemnified pursuant to our
Bylaws.
Section
145(a) of the DGCL authorizes a corporation to indemnify any person
who was or is a party, or is threatened to be made a party, to a
threatened, pending or completed action, suit or proceeding,
whether civil, criminal, administrative or investigative (other
than an action by or in the right of the corporation), by reason of
the fact that the person is or was a director, officer, employee or
agent of the corporation, or is or was serving at the request of
the corporation as a director, officer, employee or agent of
another corporation, partnership, joint venture, trust or other
enterprise, against expenses (including attorneys’ fees),
judgments, fines and amounts paid in settlement actually and
reasonably incurred by the person in connection with such action,
suit or proceeding, if the person acted in good faith and in a
manner the person reasonably believed to be in, or not opposed to,
the best interests of the corporation and, with respect to any
criminal action or proceeding, had no reasonable cause to believe
the person’s conduct was unlawful.
Section
145(b) of the DGCL provides in relevant part that a corporation may
indemnify any person who was or is a party or is threatened to be
made a party to any threatened, pending or completed action or suit
by or in the right of the corporation to procure a judgment in its
favor by reason of the fact that the person is or was a director,
officer, employee or agent of the corporation, or is or was serving
at the request of the corporation as a director, officer, employee
or agent of another corporation, partnership, joint venture, trust
or other enterprise against expenses (including attorneys’
fees) actually and reasonably incurred by the person in connection
with the defense or settlement of such action or suit if the person
acted in good faith and in a manner the person reasonably believed
to be in or not opposed to the best interests of the corporation
and except that no indemnification shall be made in respect of any
claim, issue or matter as to which such person shall have been
adjudged to be liable to the corporation unless and only to the
extent that the Court of Chancery or the court in which such action
or suit was brought shall determine upon application that, despite
the adjudication of liability but in view of all the circumstances
of the case, such person is fairly and reasonably entitled to
indemnity for such expenses which the Court of Chancery or such
other court shall deem proper.
The
DGCL also provides that indemnification under Section 145(d) can
only be made upon a determination that indemnification of the
present or former director, officer or employee or agent is proper
in the circumstances because such person has met the applicable
standard of conduct set forth in Section 145(a) and
(b).
Section
145(g) of the DGCL also empowers a corporation to purchase and
maintain insurance on behalf of any person who is or was a
director, officer, employee or agent of the corporation, or is or
was serving at the request of the corporation as a director,
officer, employee or agent of another corporation, partnership,
joint venture, trust or other enterprise against any liability
asserted against such person and incurred by such person in any
such capacity, or arising out of such person’s status as
such, whether or not the corporation would have the power to
indemnify such person against such liability under Section 145 of
the DGCL.
Section
102(b)(7) of the DGCL permits a corporation to provide for
eliminating or limiting the personal liability of one of its
directors for any monetary damages related to a breach of fiduciary
duty as a director, as long as the corporation does not eliminate
or limit the liability of a director for acts or omissions which
(1) which breached the director’s duty of loyalty to the
corporation or its shareholders, (2) which were not in good faith
or which involve intentional misconduct or knowing violation of
law, (3) under Section 174 of the DGCL; or (4) from which the
director derived an improper personal benefit.
We
have obtained directors’ and officers’ insurance to
cover our directors and officers for certain
liabilities.
Item 15. Recent Sales of Unregistered
Securities
The
following sets forth information regarding all unregistered
securities issued and sold by the Registrant since April 17,
2015:
(1) In March,
September, and October 2016, the Registrant issued and sold to
three officers/directors and two investors an aggregate of
14,358,361 shares of its Common Stock, at a purchase price of
$0.00836 per share, for aggregate gross consideration of
$120,000;
(2) In
December 2016 and January 2017, the Registrant issued and sold to
three officers/directors and five investors an aggregate of
5,240,801 shares of its Common Stock, at a purchase price of
$0.10477 per share, for aggregate gross consideration of $547,500;
and
(3) In March
2017, the Registrant issued and sold to Petro River Oil Corp.
(“
Petro River
”)
an aggregate of 400,838 shares of its Common Stock, for and in
consideration for 100% of the equity of MegaWest Energy Montana
Corp.
The
offers, sales and issuances of the securities described in
paragraphs (1) and (2) above were deemed to be exempt from
registration under the Securities Act in reliance on
Section 4(a)(2) of the Securities Act and Rule 506
promulgated under Regulation D promulgated thereunder as
transactions by an issuer not involving a public offering. The
recipients of securities in each of these transactions acquired the
securities for investment only and not with a view to or for sale
in connection with any distribution thereof and appropriate legends
were affixed to the securities issued in these transactions. Each
of the recipients of securities in these transactions was an
accredited investor within the meaning of Rule 501 of
Regulation D under the Securities Act and had adequate access,
through employment, business or other relationships, to information
about the Registrant. No underwriters were involved in these
transactions.
The
offer, sale and issuance of the securities described in paragraph
(3) above were deemed to be exempt from registration under the
Securities Act in reliance on Section 4(2) of the Securities Act,
as a transaction by an issue not involving a public offering.
Petro River acquired the shares of Common Stock with the
intent to distribute the shares of Common Stock acquired by it to
its shareholders, and therefore may be construed to be an
underwriter under the Securities Act; however, such shares are
proposed to be registered on this Registration Statement prior to
such distribution.
Item 16. Exhibits and Financial Statement
Schedules
(a)
Exhibits
.
The following
exhibits are filed as part of this Registration
Statement:
2.1
|
Stock
Purchase Agreement, dated March 22, 2017, by and between Wrap
Technologies, LLC, Petro River Oil Corp., and Megawest Energy
Montana Corp.
|
|
|
|
Merger
Agreement between Wrap Technologies, LLC and Megawest Energy
Montana Corp., dated March 30, 2017.
|
|
|
|
Amended
and Restated Certificate of Incorporation of the
Registrant
|
|
|
|
Bylaws
of the Registrant
|
|
|
4.1
|
Form of
Common Stock Certificate*
|
|
|
5.1
|
Opinion
of Disclosure Law Group, a Professional Corporation, regarding
legality*
|
|
|
|
Amended
and Restated Intellectual Property License Agreement, dated
September 30, 2016, by and between Wrap Technologies, LLC and
Syzygy Licensing LLC.
|
|
|
|
2017
Equity Compensation Plan
|
|
|
|
Code of
Ethics of the Registrant Applicable to Directors, Officers And
Employees
|
|
|
|
Consent
of
Rosenberg Rich Baker Berman &
Company
, independent registered public accounting
firm
|
|
|
23.2
|
Consent
of Disclosure Law Group, a Professional Corporation (to be included
in Exhibit 5.1)*
|
|
|
24.1
|
Power
of Attorney (included on signature page)
|
|
|
* To be filed by
amendment.
|
(b)
Financial
Statements.
See page
F-1 for an index of the financial statements included in the
Registration Statement.
Item 17. Undertakings
The undersigned registrant hereby undertakes:
|
1.
|
To
file, during any period in which offers or sales are being made, a
post-effective amendment to this registration
statement:
|
|
(i)
|
To
include any prospectus required by section 10(a)(3) of the
Securities Act of 1933;
|
|
(ii)
|
To
reflect in the prospectus any facts or events arising after the
effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the
aggregate, represent a fundamental change in the information set
forth in the registration statement. Notwithstanding the foregoing,
any increase or decrease in volume of securities offered (if the
total dollar value of securities offered would not exceed that
which was registered) and any deviation from the low or high end of
the estimated maximum offering range may be reflected in the form
of prospectus filed with the Commission pursuant to Rule 424(b)
(§230.424(b) of this chapter) if, in the aggregate, the
changes in volume and price represent no more than a 20% change in
the maximum aggregate offering price set forth in the "Calculation
of Registration Fee" table in the effective registration statement;
and
|
|
(iii)
|
To
include any material information with respect to the plan of
distribution not previously disclosed in the registration statement
or any material change to such information in the registration
statement.
|
|
2.
|
That,
for the purpose of determining any liability under the Securities
Act of 1933, each such post-effective amendment shall be deemed to
be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be
deemed to be the initial bona fide offering thereof.
|
|
3.
|
To
remove from registration by means of a post-effective amendment any
of the securities being registered which remain unsold at the
termination of the offering.
|
|
4.
|
That,
for the purpose of determining liability under the Securities Act
of 1933 to any purchaser, each prospectus filed pursuant to Rule
424(b) as part of a registration statement relating to an offering,
other than registration statements relying on Rule 430B or other
than prospectuses filed in reliance on Rule 430A, shall be deemed
to be part of and included in the registration statement as of the
date it is first used after effectiveness.
Provided, however
, that no statement
made in a registration statement or prospectus that is part of the
registration statement or made in a document incorporated or deemed
incorporated by reference into the registration statement or
prospectus that is part of the registration statement will, as to a
purchaser with a time of contract of sale prior to such first use,
supersede or modify any statement that was made in the registration
statement or prospectus that was part of the registration statement
or made in any such document immediately prior to such date of
first use.
|
|
5.
|
That,
for the purpose of determining liability of the registrant under
the Securities Act of 1933 to any purchaser in the initial
distribution of the securities:
|
|
The undersigned registrant undertakes that in a primary offering of
securities of the undersigned registrant pursuant to this
registration statement, regardless of the underwriting method used
to sell the securities to the purchaser, if the securities are
offered or sold to such purchaser by means of any of the following
communications, the undersigned registrant will be a seller to the
purchaser and will be considered to offer or sell such securities
to such purchaser:
|
|
(i)
|
Any preliminary prospectus or prospectus of the undersigned
registrant relating to the offering required to be filed pursuant
to Rule 424;
|
|
(ii)
|
Any free writing prospectus relating to the offering prepared by or
on behalf of the undersigned registrant or used or referred to by
the undersigned registrant;
|
|
(iii)
|
The portion of any other free writing prospectus relating to the
offering containing material information about the undersigned
registrant or its securities provided by or on behalf of the
undersigned registrant; and
|
|
(iv)
|
Any other communication that is an offer in the offering made by
the undersigned registrant to the purchaser.
|
|
Insofar as indemnification for liabilities arising under the
Securities Act of 1933 may be permitted to directors, officers, and
controlling persons of the registrant pursuant to the foregoing
provisions, or otherwise, the registrant has been advised that in
the opinion of the Securities and Exchange Commission such
indemnification is against public policy as expressed in the Act
and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by
the registrant of expenses incurred or paid by a director, officer
or controlling person of the registrant in the successful defense
of any action, suit or proceeding) is asserted by such director,
officer or controlling person in connection with the securities
being registered, the registrant will, unless in the opinion of its
counsel the matter has been settled by controlling precedent,
submit to a court of appropriate jurisdiction the question whether
such indemnification by it is against public policy as expressed in
the Act and will be governed by the final adjudication of such
issue.
|
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, the registrant
has duly caused this registration statement to be signed on its
behalf by the undersigned, thereunto duly authorized, in Las Vegas,
Nevada, on April 17, 2017.
|
WRAP
TECHNOLOGIES, INC.
|
|
|
|
|
|
|
By:
|
/s/ James A. Barnes
|
|
|
|
James
A. Barnes, Chief Executive Officer
|
|
POWER
OF ATTORNEY
KNOW ALL MEN BY THESE
PRESENTS
, that each person
whose signature appears below hereby constitutes and appoints James
A. Barnes his true and lawful attorney-in-fact and agent, with full
power of substitution and re-substitution, for him and in his name,
place and stead, in any and all capacities, to sign any and all
amendments to this Registration Statement, and any additional
related registration statement filed pursuant to Rule 462(b) under
the Securities Act of 1933, as amended (including post-effective
amendments to the registration statement and any such related
registration statements), and to file the same, with all exhibits
thereto, and any other documents in connection therewith, granting
unto said attorney-in-fact and agent full power and authority to do
and perform each and every act and thing requisite and necessary to
be done in and about the premises, as fully to all intents and
purposes as he might or could do in person, hereby ratifying and
confirming all that said attorney-in-fact and agent, or his
substitute or substitutes, may lawfully do or cause to be done by
virtue hereof.
Pursuant
to the requirement of the Securities Act of 1933, this registration
statement has been signed by the following persons in the
capacities and on the dates indicated.
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
|
|
/s/ James A.
Barnes
|
|
President, Chief
Financial Officer and Director
|
|
April
17, 2017
|
|
|
|
(Principal
Executive Officer and Principal Accounting Officer)
|
|
|
|
|
|
|
|
|
|
/s/ Scot
Cohen
|
|
Director
|
|
April
17, 2017
|
|
Scot
Cohen
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Elwood G.
Norris
|
|
Director and Chief
Technology Officer
|
|
April
17, 2017
|
|
Elwood
G. Norris
|
|
|
|
|
Exhibit 2.1
EXECUTION COPY
STOCK PURCHASE AGREEMENT
This Stock Purchase Agreement (this
“
Agreement
”)
is made as of this 22nd day of March, 2017, among Wrap
Technologies, LLC, a Delaware limited liability company
(“
Buyer
”),
Petro River Oil Corp., a Delaware corporation (the
“
Shareholder
”),
and Megawest Energy Montana Corp., a Delaware corporation (the
“
Company
”).
RECITALS
A.
The Shareholder owns all of the presently issued
and outstanding shares of capital stock of the Company (the
“
Shares
”)
and desires and intends to sell the Shares to Buyer at the price
and on the terms and subject to the conditions set forth below;
and
B.
The
Buyer desires and intends to acquire the Shares from the
Shareholder at the price and on the terms and subject to the
conditions set forth below.
AGREEMENT
NOW
THEREFORE, in consideration of the covenants and conditions set
forth herein, the parties agree as follows:
1.
|
Purchase and Sale of Shares
|
Subject
to the terms and conditions of this Agreement, at the Closing (as
defined in Section 3 of this Agreement), the Shareholder shall
sell, convey, transfer, and assign, upon the terms and conditions
hereinafter set forth, to Buyer, free and clear of all liens,
pledges, claims, and encumbrances of every kind, nature and
description, and Buyer shall purchase and accept from the
Shareholder the Shares, which comprise all of the outstanding
capital stock of the Company.
Buyer shall purchase the Shares for and in
consideration for the issuance to Shareholder at the Closing of
16.75 membership units of Buyer (the “
Membership
Interest
”) (the
“
Purchase
Price
”), which Membership
Interest shall represent 2% of the issued and outstanding
membership interests of the Buyer.
The Shareholder shall not retain any right, title
and interest in any assets of the Company (the
“
Excluded
Assets
”) following
consummation of the Closing.
The consummation of the purchase and sale of the
Shares contemplated herein (the “
Closing
”)
shall take place at the offices of the Company at 55
5
th
Avenue, New York, New York 10003 at
such other time and place as the Buyer, the Shareholder and the
Company agree upon orally or in writing. The date upon which the
Closing occurs is referred to herein as the
“
Closing
Date
”.
5.
|
Representations and Warranties of the Company and the
Shareholder
|
The
Company and the Shareholder, jointly and severally, represent and
warrant to the Buyer as of the date hereof (which representations
and warranties shall survive the Closing as provided in Section
13.1 of this Agreement) as follows:
The Shareholder owns one thousand (1,000) shares
of the Company’s common stock, $0.01 par value, (the
“
Common
Stock
”), which represents
all of the issued and outstanding capital stock of the
Company.
Such Shares are owned free and clear of any lien,
encumbrance, adverse claim, restriction on sale, transfer or voting
(other than restrictions imposed by applicable securities laws),
preemptive right, option or other right to purchase, and upon the
consummation of the sale of such Shares as contemplated hereby, the
Buyer will have good title to such Shares, free and clear of any
lien, encumbrance, adverse claim, restriction on sale, transfer or
voting (other than restrictions imposed by applicable securities
laws), preemptive right, option or other right to
purchase.
The Shareholder has all requisite power, right and
authority to enter into this Agreement and the documents
contemplated hereby (the “
Transaction
Documents
”) to which they
are a party, to consummate the transactions contemplated hereby and
thereby, and to sell and transfer the Shares without the consent or
approval of any other person, corporation, partnership, joint
venture, organization, other entity or governmental or regulatory
authority (“
Person
”).
The Shareholder has taken, or will take prior to the Closing, all
actions necessary for the authorization, execution, delivery and
performance of this Agreement and the other Transaction
Documents.
This
Agreement has been, and the other Transaction Documents to which
the Shareholder is a party on the Closing Date, will be, duly
executed and delivered by the Shareholder, and this Agreement is,
and each of the other Transaction Documents to which they are a
party on the Closing will be, the legal, valid and binding
obligation of the Shareholder, enforceable against the Shareholder
in accordance with their terms.
|
5.1.4
|
No Approvals or Notices Required; No Conflicts
|
The
execution, delivery and performance of this Agreement and the other
Transaction Documents by the Shareholder, and the consummation of
the transactions contemplated hereby and thereby, will not (a)
constitute a violation (with or without the giving of notice or
lapse of time, or both) of any provision of any law, judgment,
decree, order, regulation or rule of any court, agency or other
governmental authority applicable to the Shareholder, (b) require
any consent, approval or authorization of, or declaration, filing
or registration with, any Person, (c) result in a default (with or
without the giving of notice or lapse of time, or both) under,
acceleration or termination of, or the creation in any party of the
right to accelerate, terminate, modify or cancel, any agreement,
lease, note or other restriction, encumbrance, obligation or
liability to which the Company is a party or by which it is bound
or to which any assets of the Company are subject, or (d) result in
the creation of any lien or encumbrance upon the assets of the
Shareholder, or upon the Shares or other securities of the
Company.
|
5.1.5
|
Securities Law Representations and Warranties
|
The Shareholder has been advised that the
Membership Interest is not registered under the Securities Act of
1933, as amended (the “
Act
”),
or applicable state securities laws, but is being issued pursuant
to exemptions from such laws, and that the Buyer’s reliance
upon such exemptions is predicated in part on the
Shareholder’s representations contained herein. The
Shareholder acknowledges that the Buyer is relying in part upon the
Shareholder’s representations and warranties contained herein
for the purpose of qualifying the issuance of the Membership
Interest for applicable exemptions from registration or
qualification pursuant to federal or state securities laws, rules
and regulations.
|
(a)
|
Acquired Entirely for Own Account
|
The Membership Interest will be acquired for the
Shareholder’s own account, not as a nominee or agent, and not
with a view to distributing all or any part thereof, except in
compliance with the Act;
provided,
however
, it is currently
intended that the Membership Interest may be distributed to
stockholders of Shareholder as a dividend at such time as the
Membership Interest, or such securities issuable upon conversion or
exchange of such Membership Interest, is registered under the Act.
Other than as set forth above, the Shareholder has no present
intention of selling, granting any participation in or otherwise
distributing any of the Membership Interest in a manner contrary to
the Act or any applicable state securities law. The Shareholder
does not have any contract, undertaking, agreement or arrangement
with any person to sell, transfer or grant participation to such
person or to any third person with respect to any of the Membership
Interest.
The
Shareholder has been solely responsible for their own due diligence
investigation of the Buyer and its business, and their analysis of
the merits and risks of the investment made pursuant to this
Agreement, and are not relying on anyone else’s analysis or
investigation of the Buyer, its business or the merits and risks of
the Membership Interest other than professional advisors employed
specifically by the Shareholder to assist the
Shareholder.
|
(c)
|
Access to Information
|
The
Shareholder believes they have been given access to full and
complete information regarding the Buyer, including, in particular,
the current financial condition and lack of tangible assets of the
Buyer and the risks associated therewith, and has utilized such
access to its satisfaction for the purpose of obtaining information
about the Buyer; particularly, the Shareholder has either attended
or been given reasonable opportunity to attend a meeting with the
senior executives of the Buyer, for the purpose of asking questions
of, and receiving answers from, such persons concerning the terms
and conditions of the issuance of the Membership
Interest and to obtain any additional information, to the extent
reasonably available, necessary to verify the accuracy of
information provided to the Shareholder about the Buyer. No such
investigation, however, shall qualify in any respect the
representations and warranties of the Buyer in this
Agreement.
The
Shareholder, either alone or with the assistance of their
professional advisor, are sophisticated investors, are able to fend
for themselves in the transactions contemplated by this Agreement,
and have such knowledge and experience in financial and business
matters that they are capable of evaluating the merits and risks of
the prospective investment in the Membership Interest.
The
investment in the Membership Interest is suitable for the
Shareholder based upon its investment objectives and financial
needs, and the Shareholder has adequate net worth and means for
providing for their current financial needs and contingencies and
has no need for liquidity of investment with respect to the
Membership Interest. The Shareholder’s overall commitment to
investments that are illiquid or not readily marketable is not
disproportionate to its net worth, and investment in the Membership
Interest will not cause such overall commitment to become
excessive.
The
Shareholder has obtained, to the extent it deems necessary, its own
professional advice with respect to the risks inherent in the
investment in the Membership Interest, the condition of the Buyer
and the suitability of the investment in the Membership Interest in
light of the Shareholder’s financial condition and investment
needs.
The
Shareholder is in a financial position to purchase and hold the
Membership Interest and is able to bear the economic risk and
withstand a complete loss of its investment in the Membership
Interest.
|
(h)
|
Restricted Securities
|
The Shareholder realizes that (a) the Membership
Interests have not been registered under the Act, is characterized
under the Act as “
restricted
securities
” and,
therefore, cannot be sold or transferred unless subsequently
registered under the Act or an exemption from such registration is
available, and (b) there is presently no public market for the
Membership Interest and the Shareholder would most likely not be
able to liquidate its investment in the event of an emergency or to
pledge the Membership Interest as collateral security for loans.
The Shareholder’s financial condition is such that it is
unlikely that the Shareholder would need to dispose of any of the
Membership Interest in the foreseeable future. In this connection,
the Shareholder represents that it is familiar with Rule 144 of the
Securities and Exchange Commission (the “
SEC
”),
as presently in effect, and understand the resale limitations
imposed thereby and by the Act.
|
5.2
|
Company Organization, Good Standing; Corporate Authority;
Enforceability
|
|
5.2.1
|
Organization, Good Standing, etc.
|
The
Company is a corporation duly organized, validly existing and in
good standing under the laws of the State of Delaware. The Company
is duly qualified to do business and is in good standing in the
states where qualification is required due to (a) the
Company’s ownership or lease of real or personal property for
use in the operation of the Company’s business or (b) the
nature of the business conducted by the Company. The Company has
not at any time owned nor leased any real or personal property, or
had any business, operations, obligations or liabilities under any
assumed or fictitious names. The Company has all requisite power,
right and authority to own, operate and lease its properties and
assets, and to carry on its business as now conducted.
|
5.2.2
|
Corporate Authority
|
The
Company has full corporate power and authority to execute and
deliver this Agreement and the documents contemplated hereby to
which it is a party and to perform its obligations hereunder and
thereunder. The execution and delivery by the Company of this
Agreement and the Transaction Documents to which it is a party, the
performance by the Company of its obligations hereunder and
thereunder and the consummation by the Company of the transactions
contemplated hereby and thereby have been duly authorized by all
necessary corporate action. This Agreement constitutes a valid and
binding obligation of the Company, enforceable against the Company
in accordance with its terms, and the Transaction Documents to
which the Company is a party, when executed and delivered by the
Company, will constitute valid and binding obligations of the
Company, enforceable against the Company in accordance with their
respective terms.
(a) The authorized capital stock of the Company
consists of one thousand (1,000) shares of common stock, without
par value (the “
Common
Stock
”).
(b)
The issued and outstanding capital stock of the Company consists
and as of the Closing will consist solely of one thousand (1,000)
shares of Common Stock, all of which are, and as of the Closing
Date will be, held of record by the Shareholder. All shares of
Common Stock, that are issued and outstanding are, and as of the
Closing Date will be, duly authorized, validly issued, fully paid
and nonassessable, and issued in compliance with all applicable
federal, state and foreign securities laws. Except for the
Shareholder, no Person holds any interest in any
Shares.
(c)
There are no outstanding rights of first refusal, preemptive
rights, options, warrants, conversion rights or other agreements,
either directly or indirectly, for the purchase or acquisition from
the Company of the Common Stock or other securities of the
Company.
(d)
The Company is not a party or subject to any agreement or
understanding, and there is no agreement or understanding between
any Persons, that affects or relates to the voting or giving of
written consents with respect to any securities of the Company or
the voting by any director of the Company.
|
5.4
|
Subsidiaries and Affiliates
|
The
Company does not have, and has never had, any Subsidiaries. The
Company does not own, directly or indirectly, any ownership,
equity, profits or voting interest in, or otherwise control, any
corporation, partnership, joint venture or other entity, and has no
agreement or commitment to purchase any such interest.
The
execution, delivery and performance of this Agreement and/or the
Transaction Documents by the Company and the consummation of the
transactions contemplated hereby and thereby will not: (a) violate,
conflict with, or result in any breach of, or constitute a default
under, any provision of the Company’s articles of
incorporation or by-laws; (b) violate, conflict with, result in any
breach of, or constitute a default (or an event that, with notice
or lapse of time or both, would constitute a default) under, any
contract or judgment to which the Company is a party or by which it
is bound or which relates to the Company’s business or
assets; (c) result in the creation of any encumbrance, security
interest, mortgage, lien, charge, option, license, adverse claim or
restriction of any kind on any of the assets of the Company or upon
any Shares or other securities of the Company; (d) violate any
applicable law, statute, rule, ordinance or regulation of any
governmental body; (e) give any party with rights under any
contract, judgment or other restriction to which the Company is a
party or by which it is bound, the right to terminate, modify or
accelerate any rights, obligations or performance under such
contract, judgment or restriction; (f) result in the creation of
any lien or encumbrance upon the assets of the Company, or upon any
Shares or other securities of the Company; or (g) invalidate or
adversely affect any permit, license, authorization or status used
in the conduct of the business of the Company.
|
5.6
|
Consents and Approvals
|
(a)
No consent, approval or authorization of, or declaration, filing or
registration with, any governmental body is required for the
execution, delivery and performance by the Company of this
Agreement and the Transaction Documents to which it is a party or
for the consummation by the Company of the transactions
contemplated hereby and thereby and (b) no consent, approval or
authorization of any third party is required for the execution,
delivery and performance by the Company of this Agreement and the
Transaction Documents to which it is a party and the consummation
by the Company of the transactions contemplated hereby and
thereby.
|
5.7
|
Corporate Books and Records
|
The
Company has furnished to Buyer true and complete copies of (a) the
articles of incorporation and bylaws of the Company as currently in
effect, including all amendments thereto, (b) the minute books of
the Company and (c) the stock transfer books of the Company. Such
minutes reflect all meetings of the Company’s shareholders,
Board of Directors and any committees thereof since the
Company’s inception, and such minutes accurately reflect the
events of and actions taken at such meetings. Such stock transfer
books accurately reflect all issuances and transfers of shares of
capital stock of the Company since its inception.
The
Company is and has been in compliance with all laws, statutes,
rules, ordinances and regulations promulgated by any governmental
body and all judgments applicable to the operation of its business,
to its employees or to its property. The Company has not received
notice of any alleged violation (whether past or present and
whether remedied or not), nor is the Company aware of any basis for
any claim of any such violation, of any such law, statute, rule,
ordinance, regulation or judgment.
No
broker, finder or other financial consultant has acted on behalf of
the Company or the Shareholder in connection with this
Agreement.
|
5.10
|
Financial
Statements
|
The Company has provided to the Buyer an unaudited
balance sheet, dated December 31, 2016 and an unuadited operating
statement for the 12 month periods ended December 31, 2016
(collectively, the “
Financial
Statements
”). The
Financial Statements were prepared from the books and records kept
by the Company and fairly present the financial position, results
of operations and changes in financial position of the Company, as
of their respective dates and for the periods indicated, in
accordance with generally accepted accounting principles
consistently applied. The Company has no liabilities or obligations
of any nature (absolute, accrued or contingent) that are not fully
reflected or reserved against in the balance sheet dated December
31, 2016 (the “
Most Recent
Balance Sheet
”), as
prescribed by generally accepted accounting principles, except
liabilities or obligations incurred since the date of the Most
Recent Balance Sheet in the ordinary course of business and
consistent with past practice. The Company is not a guarantor,
indemnitor, surety or other obligor of any indebtedness of any
other Person.
|
5.11
|
Absence of Undisclosed Liabilities
|
The
Company has no liabilities or obligations, secured or unsecured,
whether accrued, absolute, contingent, unasserted or otherwise,
except for liabilities (a) reflected or reserved against in the
Most Recent Balance Sheet or (b) incurred in the ordinary course of
business after the date of the Most Recent Balance Sheet and not
material in amount, either individually or in the aggregate. The
Company has not entered into or agreed to enter into any
transaction, agreement or commitment, suffered the occurrence of
any event or events or experienced any change in financial
condition, business, results of operations or otherwise that, in
the aggregate, has (i) interfered with the normal and usual
operations of the business or business prospects of the Company or
(ii) resulted, or could reasonably be expected to result, in a
material adverse change in the business, assets, operations,
prospects or condition (financial or otherwise) of the
Company.
|
5.12
|
E
nvironmental
Matters.
|
The
Company is, and at all times has been, in full compliance with, and
has not been and is not in violation of or liable under, any
federal, state and municipal environmental laws
(“
Environmental
Laws
”). There are no pending or, to the knowledge of
Company, threatened claims, encumbrances, or other restrictions of
any nature, resulting from any environmental, health, and safety
liabilities or arising under or pursuant to any Environmental Law,
with respect to or affecting any of the assets of the
Company.
6.
|
Representations and Warranties of Buyer
|
The
Buyer represents and warrants to the Company and the Shareholder as
follows:
|
6.1
|
Organization, Good Standing, etc.
|
The
Buyer is a corporation, duly organized, validly existing and in
good standing under the laws of the State of Delaware. Buyer has
all requisite power and authority to own, operate and lease its
assets and to carry on its business as it is now
conducted.
The
Buyer has full power and authority to execute and deliver this
Agreement and the Transaction Documents to which it is a party and
to perform its obligations hereunder and thereunder. The execution
and delivery by the Buyer of this Agreement and Transaction
Documents to which it is a party, the performance by the Buyer of
its obligations hereunder and thereunder and the consummation by
the Buyer of the transactions contemplated hereby and thereby have
been duly authorized. This Agreement constitutes a valid and
binding obligation of the Buyer, enforceable against the Buyer in
accordance with its terms, and the Transaction Documents to which
the Buyer is a party, when executed and delivered by the Buyer,
will constitute valid and binding obligations of the Buyer,
enforceable against the Buyer in accordance with their respective
terms.
The
execution, delivery and performance of this Agreement and/or the
Transaction Documents by the Buyer and the consummation of the
transactions contemplated hereby or thereby by the Buyer will not
(a) violate, conflict with, or result in any breach of, any
provision of the Buyer’s articles of incorporation or bylaws;
(b) violate, conflict with, result in any breach of, or constitute
a default (or an event that, with notice or lapse of time or both,
would constitute a default) under any contract or judgment to which
the Buyer is a party or by which it is bound or (c) violate any
applicable law, statute, rule, ordinance or regulation of any
governmental body.
7.
|
Conditions Precedent to Buyer’s Obligations
|
The
Buyer’s obligations under this Agreement are subject to the
satisfaction of each of the following conditions, each of which is
material, for the sole benefit of the Buyer and may be waived only
in writing by the Buyer:
|
7.1
|
Representations and Warranties
|
The
representations of the Company and the Shareholder contained in
Section 5 of this Agreement shall be true on and as of the Closing
Date with the same effect as though such representations and
warranties had been made on and as of the Closing
Date.
|
7.2
|
Performance of Agreements
|
The
Company and the Shareholder shall have duly performed and complied
with all covenants and obligations contained in this Agreement or
any other Transaction Document that are required to be performed or
complied with by them on or before the Closing Date.
|
7.3
|
Officer’s Certificate
|
The
Buyer shall have received a certificate of an officer of the
Company, in a form reasonably acceptable to Buyer, dated the
Closing Date, certifying that the conditions set forth in Sections
7.1, 7.2, 7.4, 7.6, 7.7, 7.9, 7.11, 7.12, 7.13, and 7.15 have been
fulfilled.
|
7.4
|
Shareholder’s Certificate
|
The
Buyer shall have received a certificate of the Shareholder, in a
form reasonably acceptable to the Buyer, dated the Closing Date,
certifying that the conditions set forth in Sections 7.1, 7.2, 7.5,
7.6, 7.7, 7.8, 7.9, 7.10, 7.11, 7.12, 7.13 and 7.15 have been
fulfilled.
The
Buyer shall have received the resignations from all officers and
directors of the Company, effective as of the Closing.
|
7.8
|
Delivery of Certificates
|
The
Shareholder shall have delivered to the Buyer certificates
representing the Shares, duly endorsed for transfer on the
Company’s books.
Authority
to act on behalf of the Company shall be transferred solely to the
Buyer, in connection with all banks, trust companies, savings and
loan associations and other financial institutions at which the
Company maintains safe deposit boxes or accounts.
|
7.10
|
Termination of Options and Warrants
|
All
options, warrants and other contractual rights to purchase capital
stock of the Company shall have expired or been
terminated.
The
results of the Buyer’s due diligence investigation of the
Company and the Shareholder as it relates to the Shares shall be
satisfactory in all respects to the Buyer.
From
the date of this Agreement to the Closing Date, there shall not
have been any material adverse change in (a) the business,
operations, assets, liabilities, earnings, condition (financial or
otherwise) or prospects of the Company or (b) with respect to the
Shareholder and the Shares, and no material adverse change shall
have occurred (or be threatened) in any domestic or foreign laws
affecting the Company or in any third party contractual or other
business relationships of the Company.
8.
|
Conditions to the Company’s and Shareholder’s
Obligations
|
The
Company’s and Shareholder’s obligations under this
Agreement are subject to the satisfaction of the following
conditions:
|
8.1
|
Representations and Warranties
|
The
representations of the Buyer contained in Section 6 of this
Agreement shall be true on and as of the Closing Date with the same
effect as though such representations and warranties had been made
on and as of the Closing Date.
|
8.2
|
R
egistration
Agreement
|
The
Buyer shall agree to file a registration statement with the SEC
withing sixty (60) daysfrom the Closing Date, which registration
statement registers the Shares under the Act.
|
8.3
|
Performance of Agreements
|
Buyer
shall have duly performed and complied with all covenants and
obligations contained in this Agreement or any other Transaction
Document that are required to be performed or complied with by it
on or before the Closing Date.
From
the date of this Agreement through the Closing Date, the Company
shall conduct its business in the ordinary course consistent with
the Company’s past practice and shall not engage in any
extraordinary transaction without the Buyer’s prior written
Consent.
Upon
the terms and subject to the conditions hereof, each of the parties
shall (a) make promptly its respective filings, and thereafter make
any other required submissions, under applicable laws with respect
to the transactions contemplated hereby and shall cooperate with
the Buyer with respect to such filings and submissions and (b)
use
under
this Agreement, the substantially prevailing party shall be
entitled to recover its attorneys’ its best efforts to take,
or cause to be taken, all appropriate action, and to do, or cause
to be done, all things necessary, proper or advisable under
applicable laws and regulations to consummate and make effective
the transactions contemplated hereby, including, without
limitation, using its best efforts to obtain all waivers, licenses,
permits, consents, approvals, authorizations, qualifications and
orders of governmental authorities and parties to contracts as are
necessary for the consummation of the transactions contemplated
hereby and to fulfill the conditions to the closing of the sale of
the Shares to the Buyer. In case at any time after the Closing Date
any further action is necessary or desirable to carry out the
purposes of this Agreement, each party to this Agreement shall use
its best efforts to take all such action. None of the Buyer, the
Company or the Shareholder will undertake any course of action
inconsistent with this Agreement or that would make any
representations, warranties or agreements made by such party in
this Agreement untrue or any conditions precedent to this Agreement
unable to be satisfied at or prior to the Closing.
Buyer
shall prepare, or cause to be prepared, and file, or cause to be
filed, all tax returns of the Company for all periods ending on or
prior to the Closing Date (which are filed after the Closing Date)
and for all periods that began before the Closing Date and end
after the Closing Date.
Each
party shall be responsible for its own costs and expenses incurred
in connection with the preparation, negotiation and delivery of
this Agreement and the Transaction Documents, including but not
limited to attorneys’ and accountants’ fees and
expenses; except that in no event shall any of such costs or
expenses be borne by or charged to the Company.
12.
|
Attorneys’ Fees and Costs
|
In
the event that a party commences a legal proceeding (including
arbitration pursuant to Section 14.2 of this Agreement) to enforce
its rights fees and costs from the non-prevailing party or parties,
including those incurred in any arbitration, bankruptcy or appeal
procedure.
13.
|
Survival and Indemnification
|
All
representations and warranties of the Company and the Shareholder
contained in this Agreement or in the Transaction Documents or in
any certificate delivered pursuant hereto or thereto shall survive
the Closing for a period of twenty-four (24) months after the
Closing Date. The covenants and agreements of the Company, the
Shareholder and the Buyer contained in this Agreement or in the
Transaction Documents shall survive the Closing and shall continue
until all obligations with respect thereto shall have been
performed or satisfied or shall have been terminated in accordance
with their terms.
(a) The Shareholder shall indemnify, defend and
hold harmless Buyer and the Company from and against all claims,
damages, losses, liabilities, costs, expenses (including, without
limitation, settlement costs and any legal, accounting or other
expenses for investigating or defending any actions or threatened
actions and any damages or additional tax costs attributable to any
reductions in any tax attributes of the Company for taxable periods
after the Closing Date) (“
Damages
”)
incurred by the Company prior to the Closing Date or resulting
from:
(i)
any breach by the Company or the Shareholder of any representation
or warranty in this Agreement or any Transaction
Document;
(ii)
any breach of any covenant, agreement or obligation of the Company
or the Shareholder contained in this Agreement or any Transaction
Document;
(iii)
any misrepresentation contained in any statement, certificate or
schedule furnished by or on behalf of the Company or the
Shareholder pursuant to this Agreement, the Transaction Documents
or in connection with the transactions contemplated
thereby;
(iv)
any federal, state and local income, sales, business and
occupation, franchise, or other activity-based tax liabilities
incurred by the Company on or prior to the Closing Date, and any
taxes arising out of or resulting from the payment of the Purchase
Price; or
(v)
any claims or legal proceedings against the Company arising prior
to the Closing Date.
(b)
The Buyer shall indemnify and hold the Shareholder harmless from
any and all Damages resulting from (i) any breach of any
representation or warranty made by the Buyer in this Agreement or
in any Transaction Document and (ii) any breach by the Buyer of any
covenant, agreement or obligation of the Buyer contained in this
Agreement or any Transaction Document.
|
13.3
|
Claims for Indemnification
|
Whenever any claim shall arise for indemnification
under Section 13 of this Agreement, the party seeking
indemnification (the “
Indemnified
Party
”) shall promptly
notify the party from whom indemnification is sought (the
“
Indemnifying
Party
”) of the existence
of the claim and, when known, the facts constituting the basis for
such claim. In the event any such claim for indemnification is made
resulting from or in connection with any claim or legal proceedings
by a third party, the notice to the Indemnifying Party shall
specify, if known, the amount or an estimate of the amount of the
liability arising from such claim. The Indemnified Party shall not
settle or compromise any claim by a third party for which it is
entitled to indemnification without the prior written consent of
the Indemnifying Party, which consent shall not unreasonably be
withheld, unless suit shall have been instituted against it and the
Indemnifying Party shall not have taken control of such suit after
notification as provided in Section 14.4 of this
Agreement.
|
13.4
|
Defense by Indemnifying Party
|
In
connection with any claim giving rise to indemnity resulting from
or arising out of any claim or legal proceeding by a person or
entity who is not a party to this Agreement, the Indemnifying Party
at its sole cost and expense may, upon written notice to the
Indemnified Party, assume the defense of any such claim or legal
proceeding if it acknowledges to the Indemnified Party in writing
its obligations to indemnify the Indemnified Party with respect to
all elements of such claim. The Indemnified Party shall be entitled
to participate in (but not control) the defense of any such action,
with its counsel and at its own expense. If the Indemnifying Party
does not assume the defense of any such claim or resulting
litigation within thirty (30) days after the date that notice of
such claim is received from the Indemnified Party, (a) the
Indemnified Party may defend against such claim or litigation, in
such manner as it may deem appropriate, including, but not limited
to, settling such claim or litigation, after giving notice of the
same to the Indemnifying Party, on such terms as the Indemnified
Party may deem appropriate, and (b) the Indemnifying Party shall be
entitled to participate in (but not control) the defense of such
action, with its counsel and at its own expense. If the
Indemnifying Party thereafter seeks to question the manner in which
the Indemnified Party defended such third party claim or the amount
or nature of any such settlement, the Indemnifying Party shall have
the burden to prove by a preponderance of the evidence that the
Indemnified Party did not defend or settle such third party claim
in a reasonably prudent manner.
No
party may assign any of its rights or obligations hereunder without
the prior written consent of the other party. This Agreement shall
be binding upon and inure to the benefit of the parties and their
respective heirs, legal representatives, successors and
assigns.
Any claims or disputes arising out of this
Agreement which cannot be resolved amicably between the parties
shall be settled by submission to the American Arbitration
Association (the “
AAA
”)
for binding arbitration to be conducted in New York, New York. The
arbitration shall be conducted by one arbitrator mutually agreed
upon by the parties, or, if the parties cannot agree, chosen in
accordance with the AAA rules, and resolution of the dispute by
such arbitrator shall be binding and conclusive upon the parties.
On prior leave of the arbitrator, the parties may engage in limited
discovery, including limited depositions. Any award made pursuant
to this Section 15.2 may be entered in and enforced by any court
having jurisdiction, and the parties consent and commit themselves
to the jurisdiction of the courts of the State of New York for the
purpose of the enforcement of any such award. The arbitrator shall
award attorneys’ fees and costs to the substantially
prevailing party in accordance with Section 13 of this Agreement.
The fees of the arbitrator shall be borne equally by the parties
except that, in the discretion of the arbitrator, any award may
include a party’s share of such fees.
This
Agreement embodies and constitutes the entire understanding among
the parties with respect to the transactions contemplated by this
Agreement, and all prior or contemporaneous agreements,
understandings, representations and statements between the parties,
oral or written, are merged into and superseded by this
Agreement.
|
14.4
|
Modification and Waiver
|
Neither
this Agreement nor any of its provisions may be modified, amended,
discharged or terminated except in writing signed by the party
against which the enforcement of such modification, amendment,
discharge or termination is sought, and then only to the extent set
forth in such writing. No failure of a party to insist upon strict
performance by the other party of any of the terms and conditions
of this Agreement shall constitute or be deemed to be a waiver of
any such term or condition, or constitute an amendment or waiver of
any such term or provision by course of performance, and each
party, notwithstanding any failure to insist upon strict
performance, shall have the right thereafter to insist upon strict
performance by the other party of any and all of the terms and
conditions of this Agreement. Any party may, in its sole and
absolute discretion, waive, only in writing, any condition set
forth in this Agreement to such party’s obligations under
this Agreement which is for the sole benefit of the waiving party,
in which event the non-waiving party or parties shall be obligated
to close the transaction upon all of the remaining terms and
conditions of this Agreement.
Any
notice required or permitted under this Agreement shall be in
writing, and shall be delivered personally or sent by first class
certified mail, or by air courier, postage or other charges
prepaid, to the parties at the following addresses:
|
|
|
to the Company:
|
|
Megawest
Energy Montana Corp
55
5
th
Avenue, Suite 1702
New
York, NY 10003
|
|
|
to the Shareholder:
|
|
Petro
River Oil Corp
55
5
th
Avenue, Suite 1702
New
York, NY 10003
|
|
|
to
Buyer:
|
|
Wrap
Technologies, LLC
4620
Arville Street, Ste ELas Vegas, NV 89103
|
or to such other address or addresses as the parties may from time
to time specify in writing. Notice shall be provided by air courier
and shall be deemed effective upon the earlier of actual delivery
to the recipient or six days after the date on which such notice
was delivered to the courier service. If notice is sent in any
manner other than as provided by this Section 15.5, notice shall be
deemed received when actually received by the party to whom the
notice was delivered.
|
14.6
|
Governing Law; Severability
|
This
Agreement shall be governed for all purposes by the laws of the
State of New York applicable to agreements executed and to be
wholly performed in New York. Nothing contained in this Agreement
shall be construed so as to require the commission of any act
contrary to law, and whenever there is any conflict between any
provision contained in this Agreement and any present or future
statute or law, ordinance or regulation or judicial ruling or
governmental decision with the force of law contrary to which the
parties have no legal right to contract, the latter shall prevail,
but the provision of the Agreement which is affected shall be
limited only to the extent necessary to bring it within the
requirements of such law, ruling or decision without invalidating
or affecting the remaining provisions of the
Agreement.
This
Agreement may be executed in counterparts, each of which shall be
an original, but such documents shall constitute one and the same
document.
|
14.8
|
Contract Interpretation
|
The
parties acknowledge that they have caused this Agreement to be
reviewed and approved by legal counsel of their own choice. This
Agreement has been specifically negotiated, and any presumption
that an ambiguity contained in this Agreement shall be construed
against the party that caused this Agreement to be drafted shall
not apply to the interpretation of this Agreement.
Nothing
contained in this Agreement shall be construed as giving any
person, firm, corporation or other entity, other than the parties
to this Agreement and their successors and permitted assigns, any
right, remedy or claim under or in respect of this Agreement or any
term or condition contained in this Agreement.
|
14.10
|
Incorporation by Reference
|
All
attached exhibits and schedules are incorporated as terms of this
Agreement by this reference.
[Signature page follows]
IN WITNESS
WHEREOF, the parties have caused this Agreement to
be duly executed by their respective representatives hereunto
authorized as of the day and year first above
written.
|
THE
COMPANY:
|
|
MEGAWEST ENERGY MONTANA CORP
|
|
|
|
|
|
|
By:
|
|
/s/
Stephen Brunner
|
|
|
Stephen
Brunner
Its
Authorized Officer
|
|
|
|
|
THE
SHAREHOLDER:
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Stephen
Brunner
|
|
|
Stephen
Brunner
Its
President
|
|
|
|
|
BUYER:
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ James A.
Barnes
|
|
|
James
A. Barnes
|
|
|
Its:
Manager
|
Exhibit 2.2
MERGER AGREEMENT
This Merger Agreement, dated as of March 30,
2017 (this “
Agreement
”),
is entered into by and between Wrap Technologies, LLC, a Delaware
limited liability company (“
Wrap
LLC
”), and Megawest
Energy Montana Corp., a Delaware corporation (the
“
Company
”).
RECITALS
A. The Company has an authorized capital of 1000
shares of common stock, par value $0.01 per share
(“
Old Common
Stock
”), of which 1000
shares are issued and outstanding;
B.
At the Effective Time (defined below), all of the shares of Old
Common Stock are owned by Wrap LLC, its sole
stockholder;
C. Each of the members listed on Schedule A
(“
Wrap
Members
”), collectively
own 100% of the limited liability company interests in Wrap LLC
(each, a “
Membership
Interest
” and,
collectively, the “
Membership
Interests
”);
D. The parties desire to merge Wrap LLC with and
into the Company, pursuant to which the Company will continuing as
the surviving corporation and the separate existence of Wrap LLC
will cease, upon the terms and subject to the conditions set forth
in this Agreement (the “
Merger
”);
E.
The board of directors of the Company and the managers of Wrap LLC
have each determined that the Merger is advisable and in the best
interest of the Company and Wrap LLC and have each approved and
adopted this Agreement and recommended that the respective equity
holders of the Company and Wrap LLC approve and adopt this
Agreement and approve the Merger; and
F.
The holders of the voting equity of each of the Company and Wrap
LLC have unanimously approved and adopted this Agreement and the
Merger.
NOW,
THEREFORE
, in consideration of
the premises and the respective representations, warranties,
covenants and agreements set forth in this Agreement, Wrap LLC and
the Company agree as follows:
I. THE MERGER
1.1
Merger
. In accordance with the provisions of this
Agreement and the Delaware General Corporation Law (the
“
DGCL
”),
at the Effective Time (as defined below), Wrap LLC will be merged
with and into the Company, Wrap LLC’s separate existence will
cease and the Company will be the surviving corporation in the
Merger and shall succeed to and assume all the rights and
obligations of Wrap LLC. The Company, as the surviving corporation
after the Merger, is herein sometimes referred to as the
“
Surviving
Corporation
.”
1.2
Filing and
Effectiveness
. The parties will
cause a Certificate of Merger (the “
Certificate
of Merger
”) in
substantially the form of
Exhibit
A
hereto, meeting the
requirements of the DGCL, to be executed and filed with the
Secretary of State of the State of Delaware. The Merger will become
effective at the time when the Certificate of Merger has been duly
filed with the Secretary of State of the State of Delaware (the
“
Effective
Time
”).
1.3
Effects of the
Merger
.
(a)
General
.
The Merger will have the effects specified in Section 259 of
the DGCL.
(b)
Certificate of
Incorporation and Bylaws
. At
the Effective Time, the Company’s certificate of
incorporation shall be amended and restated as set forth
in
Exhibit
B
attached hereto (the
“
Certificate
of Incorporation
”) and
shall continue to be the certificate of incorporation of the
Surviving Corporation until thereafter amended in accordance with
the provisions thereof and applicable law. The Company’s
bylaws as in effect immediately prior to the Effective Time (the
“
Bylaws
”)
will be the Surviving Corporation’s bylaws until thereafter
amended in accordance with the provisions thereof and applicable
law.
(c)
Directors and
Officers
. Following the
Effective Time, the directors of the Company immediately prior to
the Effective Time shall be the directors of the Surviving
Corporation, and the officers of the Company immediately prior to
the Effective Time shall be the officers of the Surviving
Corporation, in each case until their respective successors are
duly elected or appointed and qualified or until their earlier
death, resignation, retirement, disqualification or removal in
accordance with applicable law and the Certificate of Incorporation
and Bylaws.
(d)
Effect on Capital
Stock
. At and as of the
Effective Time, without any action on the part of Wrap LLC or the
Company, as the case may be, or of any holder of any Membership
Interests, shares of capital stock of or other equity interest in
Wrap LLC or the Company, the Membership Interests, shares of
capital stock and other securities of Wrap LLC and the Company will
be treated as follows:
(i)
Cancellation of Old
Common Stock
. Each share of Old
Common Stock outstanding immediately prior to the Effective Time
will be canceled without payment of any consideration therefor and
shall cease to exist.
(ii)
Conversion of the
Membership Interests
. All the
Membership Interests issued and outstanding immediately prior to
the Effective Time will be converted into and exchanged
for
20,000,000
validly
issued, fully paid and nonassessable shares of the common stock of
the Surviving Corporation, par value $0.0001 per share
(“
Surviving
Common Stock
”).
(iii)
Surrender of Old
Common Stock
. At or before the
Effective Time, Wrap LLC shall surrender any and all outstanding
certificates representing shares of Old Common Stock to the
Surviving Corporation.
1.4
Taking of Necessary Action;
Further Action
. Prior to the
Effective Time, the Company and Wrap LLC shall take all such action
as shall be necessary or appropriate to effectuate the Merger. If,
at any time after the Effective Time, any such further action is
necessary or desirable to carry out the purposes of this Agreement
and to vest the Surviving Corporation with full right, title and
possession to all assets, property, rights, privileges, powers, and
franchises of the Company and Wrap LLC, the officers and directors
of the Surviving Corporation are fully authorized, in the name of
and on behalf of the Company and Wrap LLC, to take, and the Company
will cause them to take, all such lawful and necessary
action.
II. GENERAL
2.1
Termination
. Wrap LLC and the Company, by written agreement,
may terminate this Agreement as to all parties and the Merger may
be abandoned for any reason whatsoever, at any time prior to the
Effective Time.
2.2
No Third Party
Beneficiaries
. There are no
third party beneficiaries having rights under or with respect to
this Agreement.
2.3
Governing
Law
. This Agreement will be
governed by and construed in accordance with the laws of the State
of Delaware, without giving effect to any choice of law
principles.
2.4
Amendments
. This Agreement may not be amended or modified
except by a writing signed by all of the
parties.
2.5
Entire
Agreement
. This Agreement,
together with the Exhibits hereto, constitutes the entire agreement
and understanding of the parties in respect of its subject matter
and supersedes all prior understandings, agreements or
representations by or among the parties, written or oral, to the
extent they relate in any way to the subject matter
hereof.
2.6
Counterparts
. This Agreement may be executed in two or more
counterparts, each of which will be deemed to be an original and
all of which together will constitute one and the same
instrument.
[SIGNATURE PAGE FOLLOWS]
IN
WITNESS WHEREOF, the parties have caused this Agreement to be
executed by their authorized representative as of the date stated
in the introductory paragraph of this Agreement.
|
|
WRAP
TECHNOLOGIES, LLC
|
|
|
By
:
|
/s/
James A. Barnes
|
|
|
Name:
|
James
A. Barnes
|
|
|
Title:
|
Managing
Member
|
|
|
MEGAWEST ENERGY MONTANA CORP.
|
|
|
|
|
|
|
By:
|
/s/ Stephen
Brunner
|
|
|
|
Name:
|
Stephen
Brunner
|
|
|
|
Title:
|
President
|
|
Merger Agreement
Signature Page
EXHIBIT A
CERTIFICATE OF MERGER
OF
WRAP TECHNOLOGIES, LLC
WITH AND INTO
MEGAWEST ENERGY MONTANA CORP.
Pursuant
to Title 8, Section 264(c) of the Delaware General Corporation
Law and Title 6, Section 18-209 of the Delaware Limited
Liability Company Act, the undersigned corporation, hereby
certifies that:
FIRST:
The name of the surviving corporation is
Megawest Energy Montana Corp., a Delaware corporation, and the name
of the limited liability company being merged into this surviving
corporation is Wrap Technologies, LLC.
SECOND:
An agreement of merger has been approved,
adopted, certified, executed and acknowledged by the surviving
corporation and the merging limited liability company in accordance
with the requirements of Delaware law.
THIRD:
The name of the surviving corporation
following the consummation of the Merger shall be Wrap
Technologies, Inc., a Delaware corporation.
FOURTH:
The merger is to become effective upon the
filing of this certificate of merger.
FIFTH:
The Company’s certificate of
incorporation shall be amended and restated in the merger, and the
certificate of incorporation of the surviving corporation shall be
as set forth in
Exhibit
A
attached
hereto.
SIXTH
: The executed agreement of merger is on file at
4620 Arville Street, Ste E, Las Vegas, NV 89103, the address of the
principal place of business of the surviving
corporation.
SEVENTH:
A copy of the agreement of merger will be
furnished by the surviving corporation, on request and without
cost, to any stockholder of any constituent corporation or member
of any constituent limited liability company.
IN WITNESS
WHEREOF
, Megawest Energy
Montana Corp. has caused this certificate to be signed by an
authorized officer on this 30th day of March,
2017.
|
MEGAWEST ENERGY MONTANA CORP.
|
|
|
|
By:
|
|
|
Name:
|
|
|
Title:
|
|
EXHIBIT B
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
OF
MEGAWEST ENERGY MONTANA, INC.
ARTICLE ONE
The
name of this Corporation is Wrap Technologies, Inc.
ARTICLE TWO
The
address of the Corporation’s registered office in the State
of Delaware is to be located at 160 Greentree Drive, Ste 101,
Dover, DE 19904. The registered agent in charge thereof is National
Registered Agents, Inc.
ARTICLE THREE
The
purpose of the Corporation is to engage in any lawful act or
activity for which corporations may be organized under the General
Corporation Law of Delaware.
ARTICLE FOUR
The
Corporation is authorized to issue two classes of stock to be
designated, respectively, “Common Stock” and
“Preferred Stock”.
The
total number of shares this Corporation shall have authority to
issue is 155,000,000. 150,000,000 shares shall be designated Common
Stock and shall have a par value of $0.0001 per share. 5,000,000
shares shall be designated Preferred Stock and shall have a par
value of $0.0001 per share.
The
Preferred Stock may be issued from time to time in one or more
series. The Board of Directors is hereby authorized, subject to
limitations prescribed by law, to fix by resolution or resolutions
the designations, powers, preferences, and rights and the
qualifications, limitations, or restrictions thereof, of each such
series of Preferred Stock, including without limitation, authority
to fix by resolution or resolutions the dividend rights, dividend
rate, conversion rights, voting rights, rights and terms of
redemption (including sinking fund provisions), redemption price or
prices, and liquidation preferences of any wholly unissued series
of Preferred Stock, and the number of shares constituting such
series and the designation thereof, or any of the foregoing. The
Board of Directors is further authorized to increase (but not above
the total number of authorized shares of the class) or decrease
(but not below the number of shares of any such series then
outstanding) the number of shares of any series, the number of
which was fixed by it, subsequent to the issue of shares of such
series then outstanding, subject to the powers, preferences, and
rights and the qualifications, limitations, and restrictions
thereof stated in the resolution of the Board of Directors
originally fixing the number of shares of such series. If the
number of shares of any series is so decreased, then the shares
constituting such decrease shall resume the status which they had
prior to the adoption of the resolution originally fixing the
number of shares of such series.
ARTICLE FIVE
The
Corporation is to have perpetual existence.
ARTICLE SIX
The
number of Directors which constitutes the whole Board of Directors
of the Corporation and the manner of their election shall be
designated in the Bylaws of the Corporation.
ARTICLE SEVEN
(a) The
business and affairs of the Corporation shall be managed by or
under the direction of the Board of Directors. In addition to the
powers and authority expressly conferred upon them by statute or by
this Amended and Restated Certificate of Incorporation or the
Bylaws of the Corporation, the directors are hereby empowered to
exercise all such powers and do all such acts and things as may be
exercised or done by the Corporation.
(b)
In furtherance and not in limitation of the powers conferred by
statute, the Board of Directors is expressly authorized to adopt,
amend, alter or repeal the Bylaws of the Corporation. The
affirmative vote of at least a majority of the Board of Directors
then in office shall be required in order for the Board of
Directors to adopt, amend, alter or repeal the Corporation’s
Bylaws. The Corporation’s Bylaws may also be adopted,
amended, altered or repealed by the stockholders of the Corporation
in accordance with the Bylaws. No Bylaw hereafter legally amended,
altered or repealed shall invalidate any prior act of the directors
or officers of the Corporation that would have been valid if such
Bylaw had not been amended, altered or repealed.
(c)
Elections of directors need not be by written ballot unless the
Bylaws of the Corporation shall so provide.
(d)
Subject to the rights of any holders of any series of Preferred
Stock to act by written consent as specified in any duly authorized
certificate of designation of any series of Preferred Stock, any
action required or permitted to be taken by the stockholders of the
Corporation must be effected at a duly called annual or special
meeting of stockholders of the Corporation and may not be effected
by any action by written consent by such stockholders.
(e)
Subject to the rights of holders of any series of Preferred Stock
then outstanding to elect additional directors under specified
circumstances, the number of directors that constitute the whole
Board of Directors shall be fixed exclusively in the manner
designated in the Bylaws of the Corporation.
ARTICLE EIGHT
(a)
To the fullest extent permitted by the
Delaware General Corporation Law as the same exists or as may
hereafter be amended, a Director of the Corporation shall not be
personally liable to the Corporation or its stockholders for
monetary damages for breach of fiduciary duty as a Director;
provided, however, that this provision shall not eliminate or limit
the liability of a Director: (i) for any breach of the
Director’s duty of loyalty to the Corporation or its
stockholders; (ii) for acts or omissions not in good faith or which
involve material misconduct or a knowing violation of law; (iii)
under the Delaware General Corporation Law; or (iv) for any
transaction from which the Director derived an improper personal
benefit
(b)
The Corporation may indemnify to the
fullest extent permitted by law any person made or threatened to be
made a party to an action or proceeding, whether criminal, civil,
administrative, or investigative, by reason of the fact that he or
his testator or testate is or was a director, officer, employee, or
agent of the Corporation or any predecessor of the Corporation or
serves or served at any other enterprise as a director, officer,
employee, or agent at the request of the Corporation or any
predecessor to the Corporation.
(c)
Neither any amendment nor repeal of
this Article Eight, nor the adoption of any provision of this
Corporation’s Certificate of Incorporation inconsistent with
this Article Eight, shall eliminate or reduce the effect of this
Article Eight in respect of any matter occurring, or any action or
proceeding accruing or arising or that, but for this Article Eight,
would accrue or arise, prior to such amendment, repeal, or adoption
of an inconsistent provision.
ARTICLE NINE
(a)
Any
director may be removed from the Board of Directors by the
stockholders of the Corporation only for cause, and in such case
only by the affirmative vote of the holders of at least a majority
of the voting power of the issued and outstanding shares of capital
stock of the Corporation then entitled to vote in the election of
directors. Vacancies occurring on the Board of Directors for any
reason and newly created directorships resulting from an increase
in the authorized number of directors may be filled solely by a
vote of a majority of the remaining members of the Board of
Directors, although less than a quorum, or by a sole remaining
director, at any meeting of the Board of Directors. A person so
elected by the Board of Directors to fill a vacancy or newly
created directorship shall hold office until the next election of
the Board of Directors and until his or her successor shall be duly
elected and qualified. No decrease in the number of directors
constituting the Board of Directors shall shorten the term of any
incumbent director.
(b)
At each meeting of stockholders of the Corporation at which
directors are to be elected, directors shall be elected by a
plurality of the votes of the issued and outstanding shares of
captital stock of the Corporation present in person or represented
by proxy at the meeting and entitled to vote on the election of
directors.
Cummulative voting for the
election of directors shall not be permitted.
ARTICLE TEN
Advance
notice of new business and stockholder nominations for the election
of Directors shall be given in the manner and to the extent
provided in this Bylaws of the Corporation.
ARTICLE ELEVEN
The
Corporation reserves the right to amend or repeal any provision
contained in this Amended and Restated Certificate of Incorporation
in the manner prescribed by the laws of Delaware and all rights
conferred upon stockholders are granted subject to this
reservation.
IN
WITNESS WHEREOF, the Corporation has caused this Amended and
Restated Certificate of Incorporation to be signed by the
undersigned, a duly authorized officer of the Corporation, on March
31, 2017
|
By:
/s/ James A. Barnes
Name:
James A. Barnes
Title:
President & Chief Executive Officer
|
|
|
Exhibit 3.1
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
OF
MEGAWEST ENERGY MONTANA INC.
ARTICLE ONE
The
name of this Corporation is Wrap Technologies, Inc.
ARTICLE TWO
The
address of the Corporation’s registered office in the State
of Delaware is to be located at 160 Greentree Drive, Ste 101,
Dover, DE 19904. The registered agent in charge thereof is National
Registered Agents, Inc.
ARTICLE THREE
The
purpose of the Corporation is to engage in any lawful act or
activity for which corporations may be organized under the General
Corporation Law of Delaware.
ARTICLE FOUR
The
Corporation is authorized to issue two classes of stock to be
designated, respectively, “Common Stock” and
“Preferred Stock”.
The
total number of shares this Corporation shall have authority to
issue is 155,000,000. 150,000,000 shares shall be designated Common
Stock and shall have a par value of $0.0001 per share. 5,000,000
shares shall be designated Preferred Stock and shall have a par
value of $0.0001 per share.
The
Preferred Stock may be issued from time to time in one or more
series. The Board of Directors is hereby authorized, subject to
limitations prescribed by law, to fix by resolution or resolutions
the designations, powers, preferences, and rights and the
qualifications, limitations, or restrictions thereof, of each such
series of Preferred Stock, including without limitation, authority
to fix by resolution or resolutions the dividend rights, dividend
rate, conversion rights, voting rights, rights and terms of
redemption (including sinking fund provisions), redemption price or
prices, and liquidation preferences of any wholly unissued series
of Preferred Stock, and the number of shares constituting such
series and the designation thereof, or any of the foregoing. The
Board of Directors is further authorized to increase (but not above
the total number of authorized shares of the class) or decrease
(but not below the number of shares of any such series then
outstanding) the number of shares of any series, the number of
which was fixed by it, subsequent to the issue of shares of such
series then outstanding, subject to the powers, preferences, and
rights and the qualifications, limitations, and restrictions
thereof stated in the resolution of the Board of Directors
originally fixing the number of shares of such series. If the
number of shares of any series is so decreased, then the shares
constituting such decrease shall resume the status which they had
prior to the adoption of the resolution originally fixing the
number of shares of such series.
ARTICLE FIVE
The
Corporation is to have perpetual existence.
ARTICLE SIX
The
number of Directors which constitutes the whole Board of Directors
of the Corporation and the manner of their election shall be
designated in the Bylaws of the Corporation.
ARTICLE SEVEN
(a)
The business and
affairs of the Corporation shall be managed by or under the
direction of the Board of Directors. In addition to the powers and
authority expressly conferred upon them by statute or by this
Amended and Restated Certificate of Incorporation or the Bylaws of
the Corporation, the directors are hereby empowered to exercise all
such powers and do all such acts and things as may be exercised or
done by the Corporation.
(b)
In furtherance and
not in limitation of the powers conferred by statute, the Board of
Directors is expressly authorized to adopt, amend, alter or repeal
the Bylaws of the Corporation. The affirmative vote of at least a
majority of the Board of Directors then in office shall be required
in order for the Board of Directors to adopt, amend, alter or
repeal the Corporation’s Bylaws. The Corporation’s
Bylaws may also be adopted, amended, altered or repealed by the
stockholders of the Corporation in accordance with the Bylaws. No
Bylaw hereafter legally amended, altered or repealed shall
invalidate any prior act of the directors or officers of the
Corporation that would have been valid if such Bylaw had not been
amended, altered or repealed.
(c)
Elections of
directors need not be by written ballot unless the Bylaws of the
Corporation shall so provide.
(d)
Subject to the
rights of any holders of any series of Preferred Stock to act by
written consent as specified in any duly authorized certificate of
designation of any series of Preferred Stock, any action required
or permitted to be taken by the stockholders of the Corporation
must be effected at a duly called annual or special meeting of
stockholders of the Corporation and may not be effected by any
action by written consent by such stockholders.
(e)
Subject to the
rights of holders of any series of Preferred Stock then outstanding
to elect additional directors under specified circumstances, the
number of directors that constitute the whole Board of Directors
shall be fixed exclusively in the manner designated in the Bylaws
of the Corporation.
ARTICLE EIGHT
(a
)
To
the fullest extent permitted by the Delaware General Corporation
Law as the same exists or as may hereafter be amended, a Director
of the Corporation shall not be personally liable to the
Corporation or its stockholders for monetary damages for breach of
fiduciary duty as a Director; provided, however, that this
provision shall not eliminate or limit the liability of a Director:
(i) for any breach of the Director’s duty of loyalty to the
Corporation or its stockholders; (ii) for acts or omissions not in
good faith or which involve material misconduct or a knowing
violation of law; (iii) under the Delaware General Corporation Law;
or (iv) for any transaction from which the Director derived an
improper personal benefit
(b
)
The
Corporation may indemnify to the fullest extent permitted by law
any person made or threatened to be made a party to an action or
proceeding, whether criminal, civil, administrative, or
investigative, by reason of the fact that he or his testator or
testate is or was a director, officer, employee, or agent of the
Corporation or any predecessor of the Corporation or serves or
served at any other enterprise as a director, officer, employee, or
agent at the request of the Corporation or any predecessor to the
Corporation.
(c
)
Neither
any amendment nor repeal of this Article Eight, nor the adoption of
any provision of this Corporation’s Certificate of
Incorporation inconsistent with this Article Eight, shall eliminate
or reduce the effect of this Article Eight in respect of any matter
occurring, or any action or proceeding accruing or arising or that,
but for this Article Eight, would accrue or arise, prior to such
amendment, repeal, or adoption of an inconsistent
provision.
ARTICLE NINE
(a
)
Any director may be
removed from the Board of Directors by the stockholders of the
Corporation only for cause, and in such case only by the
affirmative vote of the holders of at least a majority of the
voting power of the issued and outstanding shares of capital stock
of the Corporation then entitled to vote in the election of
directors. Vacancies occurring on the Board of Directors for any
reason and newly created directorships resulting from an increase
in the authorized number of directors may be filled solely by a
vote of a majority of the remaining members of the Board of
Directors, although less than a quorum, or by a sole remaining
director, at any meeting of the Board of Directors. A person so
elected by the Board of Directors to fill a vacancy or newly
created directorship shall hold office until the next election of
the Board of Directors and until his or her successor shall be duly
elected and qualified. No decrease in the number of directors
constituting the Board of Directors shall shorten the term of any
incumbent director.
(b
)
At each meeting of
stockholders of the Corporation at which directors are to be
elected, directors shall be elected by a plurality of the votes of
the issued and outstanding shares of captital stock of the
Corporation present in person or represented by proxy at the
meeting and entitled to vote on the election of directors.
Cummulative voting for the election of
directors shall not be permitted.
ARTICLE TEN
Advance
notice of new business and stockholder nominations for the election
of Directors shall be given in the manner and to the extent
provided in this Bylaws of the Corporation.
ARTICLE ELEVEN
The
Corporation reserves the right to amend or repeal any provision
contained in this Amended and Restated Certificate of Incorporation
in the manner prescribed by the laws of Delaware and all rights
conferred upon stockholders are granted subject to this
reservation.
IN
WITNESS WHEREOF, the Corporation has caused this Amended and
Restated Certificate of Incorporation to be signed by the
undersigned, a duly authorized officer of the Corporation, on March
31, 2017
|
By:
/s/ James A.
Barnes
Name:
James A. Barnes
Title:
President & Chief Executive Officer
|
Exhibit 3.2
BYLAWS
OF
WRAP
TECHNOLOGIES, INC.
ARTICLE
I
OFFICES
The registered office of the Corporation in the State of Delaware,
shall be
160 Greentree Drive,
Ste 101, Dover, DE 19904
. The
registered agent in charge thereof shall be National Registered
Agents, Inc. The Corporation may have such other offices, either
within or without the State of Delaware, as the Board of Directors
may designate or as the business of the Corporation may require
from time to time.
ARTICLE II
SHAREHOLDERS
SECTION 1. ANNUAL MEETING.
The annual meeting of the shareholders
shall be held on such
date and at such time as may be designated from time to time by the
Board of Directors
for the purpose of
electing Directors and for the transaction of such other business
as may come before the meeting. If the election of Directors shall
not be held on the day designated herein for any annual meeting of
the shareholders, or at any adjournment thereof, the Board of
Directors shall cause the election to be held at a special meeting
of the shareholders as soon thereafter as conveniently may
be.
SECTION 2. SPECIAL MEETINGS
.
Special meetings of the shareholders, for any purpose or purposes,
unless otherwise prescribed by statute, may be called by the
President or by the Board of Directors, and shall be called by the
President at the request of the holders of not less than 51%
percent of all the outstanding shares of the Corporation entitled
to vote at the meeting.
SECTION
3. PLACE OF MEETING
.
Meetings of the shareholders of the Corporation
may be held at such place, either within or without the State of
Delaware, as may be determined from time to time by the Board of
Directors, or, if not so designated, then at the principal
executive offices of the Corporation required to be maintained
pursuant to Section 1 of these Bylaws. The Board of Directors may,
in its sole discretion, determine that the meeting shall not be
held at any place, but may instead be held solely by means of
remote communication as provided under the Delaware General
Corporation Law (the “
DGCL
”).
SECTION 4. NOTICE OF
MEETING.
Written notice stating the place, day and hour of
the meeting and, in the case of a special meeting, the purpose or
purposes for which the meeting is called, shall unless otherwise
prescribed by statute, be delivered not less than 20 nor more than
60 days before the date of the meeting, to each shareholder of
record entitled to vote at such meeting. If mailed, such notice
shall be deemed to be delivered when deposited in the United States
Mail, addressed to the shareholder at his address as it appears on
the stock transfer books of the Corporation, with postage thereon
prepaid.
SECTION 5. CLOSING OF TRANSFER
BOOKS OF EXISTING RECORD
. The purpose of determining
shareholders entitled to notice of or to vote at any meeting of
shareholders or any adjournment thereof, or shareholders entitled
to receive payment of any dividend, or in order to make a
determination of shareholders for any other proper purpose, the
Board of Directors of the Corporation may provide that the stock
transfer books shall be closed for a stated period, but not to
exceed in any case fifty (50) days. If the stock transfer books
shall be closed for the purpose of determining shareholders
entitled to notice of or to vote at a meeting of shareholders, such
books shall be closed for at least 30 days immediately preceding
such meeting. In lieu of closing the stock transfer books, the
Board of Directors may fix in advance a date as the record date for
any such determination of shareholders, such date in any case to be
not more than sixty (60) days and, in case of a meeting of
shareholders, not less than twenty (20) days, prior to the date on
which the particular action requiring such determination of
shareholders is to be taken. If the stock transfer books are not
closed and no record date is fixed for the determination of
shareholders entitled to notice of or to vote at a meeting of
shareholders, or shareholders entitled to receive payment of a
dividend, the date on which the notice of the meeting is mailed or
the date on which the resolution of the Board of Directors
declaring such dividend is adopted, as the case may be, shall be
the record date for such determination of shareholders. When a
determination of shareholders entitled to vote at any meeting of
shareholders has been made as provided in this section, such
determination shall apply to any adjournment thereof.
SECTION 6. VOTING LISTS
. The
officer or agent having charge of the stock transfer books for
shares of the Corporation shall make a complete list of the
shareholders entitled to vote at each meeting of shareholders or
any adjournment thereof, arranged in alphabetical order, with the
address of and the number of shares held by each. Such list shall
be produced and kept open at the time and place of the meeting and
shall be subject to the inspection of any shareholder during the
whole time of the meeting for the purposes thereof.
SECTION 7. QUORUM
. A
majority of the outstanding shares of the Corporation entitled to
vote, represented in person or by proxy, shall constitute a quorum
at a meeting of shareholders. If less than a majority of the
outstanding shares are represented at a meeting, a majority of the
shares so represented may adjourn the meeting from time to time
without further notice. At such adjourned meeting at which a quorum
shall be present or represented, any business may be transacted
which might have been transacted at the meeting as originally
noticed. The shareholders present at a duly organized meeting may
continue to transact business until adjournment, notwithstanding
the withdrawal of enough shareholders to leave less than a
quorum.
SECTION 8. PROXIES
. At all
meetings of shareholders, a shareholder may vote in person or by
proxy executed in writing by the shareholder or by his duly
authorized attorney-in-fact. Such proxy shall be filed with the
secretary of the Corporation before or at the time of the meeting.
A meeting of the Board of Directors may be had by means of a
telephone conference or similar communications equipment by which
all persons participating in the meeting can hear each other, and
participation in a meeting under such circumstances shall
constitute presence at the meeting.
SECTION 9. VOTING OF SHARES
.
Each outstanding share entitled to vote shall be entitled to one
vote upon each matter submitted to a vote at a meeting of
shareholders.
SECTION 10. VOTING OF SHARES BY
CERTAIN HOLDERS
. Shares standing in the name of another
Corporation may be voted by such officer, agent or proxy as the
Bylaws of such Corporation may prescribe or, in the absence of such
provision, as the Board of Directors of such Corporation may
determine. Shares held by an administrator, executor, guardian or
conservator may be voted by him, either in person or by proxy,
without a transfer of such shares into his name. Shares standing in
the name of a trustee may be voted by him, either in person or by
proxy, but no trustee shall be entitled to vote shares held by him
without a transfer of such shares into his name. Shares standing in
the name of a receiver may be voted by such receiver, and shares
held by or under the control of a receiver may be voted by such
receiver without the transfer thereof into his name, if authority
so to do be contained in an appropriate order of the court by which
such receiver was appointed. A shareholder whose shares are pledged
shall be entitled to vote such shares until the shares have been
transferred into the name of the pledgee, and thereafter the
pledgee shall be entitled to vote the shares so transferred. Shares
of its own stock belonging to the Corporation shall not be voted,
directly or indirectly, at any meeting, and shall not be counted in
determining the total number of outstanding shares at any given
time.
SECTION 11. INFORMAL ACTION BY
SHAREHOLDERS
.
Unless otherwise provided in the
Certificate of Incorporation or these Bylaws, any action required
or permitted to be taken at a meeting of the shareholders may be
taken without a meeting if, before or after the action, a written
consent thereto is signed by shareholders holding at least a
majority of the voting power, except that if a different proportion
of voting power is required for such an action at a meeting, then
that proportion of written consents is required.
ARTICLE III
BOARD
OF DIRECTORS
SECTION 1. GENERAL POWERS.
The business and affairs of the Corporation shall be managed by its
Board of Directors.
SECTION 2. NUMBER. TENURE AND
QUALIFICATIONS.
The number of directors of the Corporation
shall be fixed by the Board of Directors, but in no event shall be
less than three.
Directors, who shall be elected at the
annual meeting of stockholders for a term of one (l) year and shall
hold office until their successors are elected and qualified.
Directors need not be shareholders. The Corporation may provide in
any designation of a class of preferred stock or otherwise by
amendment to the Corporation’s Certificate of Incorporation,
for the designation of a director nominee required to be appointed
by the Board to fill a vacancy.
SECTION 3. REGULAR MEETINGS.
A regular meeting of the Board of Directors shall be held without
other notice than this Bylaw immediately after, and at the same
place as, the annual meeting of shareholders. The Board of
Directors may provide, by resolution, the time and place for the
holding of additional regular meetings without notice other than
such resolution.
SECTION 4. SPECIAL MEETINGS.
Special meetings of the Board of Directors may be called by or at
the request of the President or any two directors. The person or
persons authorized to call special meetings of the Board of
Directors may fix the place for holding any special meeting of the
Board of Directors called by them.
SECTION 5. NOTICE
. Notice of
any special meeting shall be given at least one (1) day previous
thereto by written notice delivered personally, mailed to each
director at his business address, or by electronic communication.
If mailed, such notice shall be deemed to be delivered when
deposited in the United States Mail so addressed, with postage
thereon prepaid. If notice be given by electronic communication,
such notice shall be deemed to be delivered when the electronic
communication is transmitted to the Director. Any directors may
waive notice of any meeting. The attendance of a director at a
meeting shall constitute a waiver of notice of such meeting, except
where a director attends a meeting for the express purpose of
objecting to the transaction of any business because the meeting is
not lawfully called or convened.
SECTION 6. QUORUM.
A
majority of the number of directors fixed by Section 2 of this
Article III shall constitute a quorum for the transaction of
business at any meeting of the Board of Directors, but if less than
such majority is present at a meeting, a majority of the directors
present may adjourn the meeting from time to time without further
notice.
SECTION 7. MANNER OF ACTING
.
The act of the majority of the directors present at a meeting at
which a quorum is present shall be the act of the Board of
Directors.
SECTION 8. ACTION WITHOUT A
MEETING.
Any action that may be taken by the Board of
Directors at a meeting may be taken without a meeting if a consent
in writing, setting forth the action so to be taken, shall be
signed before such action by all of the directors.
SECTION 9. VACANCIES
. Any
vacancy occurring in the Board of Directors may be filled by the
affirmative vote of a majority of the remaining directors though
less than a quorum of the Board of Directors, unless otherwise
provided by law. A director elected to fill a vacancy shall be
elected for the unexpired term of his predecessor in office. Any
directorship to be filled by reason of an increase in the number of
directors may be filled by election by the Board of Directors for a
term of office continuing only until the next election of directors
by the shareholders.
SECTION 10. COMPENSATION
. By
resolution of the Board of Directors, each director may be paid his
expenses, if any, of attendance at each meeting of the Board of
Directors, and may be paid a stated salary as director or a fixed
sum for attendance at each meeting of the Board of Directors or
both. No such payment shall preclude any director from serving the
Corporation in any other capacity and receiving compensation
therefor.
SECTION 11. PRESUMPTION OF
ASSENT
. A director of the Corporation who is present at a
meeting of the Board of Directors at which action on any corporate
matter is taken shall be presumed to have assented to the action
taken unless his dissent shall be entered in the minutes of the
meeting or unless he shall file his written dissent to such action
with the person acting as the Secretary of the meeting before the
adjournment thereof, or shall forward such dissent by registered
mail to the Secretary of the Corporation immediately after the
adjournment of the meeting. Such right to dissent shall not apply
to director who voted in favor of such action.
ARTICLE IV
OFFICERS
SECTION 1. NUMBER
. The
officers of the Corporation shall be a President, one or more Vice
Presidents, a Secretary, and a Treasurer, each of whom shall be
elected by the Board of Directors. Such other officers and
assistant officers as may be deemed necessary may be elected or
appointed by the Board of Directors, including a Chairman of the
Board. In its discretion, the Board of Directors may leave unfilled
for any such period as it may determine any office except those of
President and Secretary. Any two or more offices may be held by the
same person, except for the offices of President and Secretary
which may not be held by the same person. Officers may be directors
or shareholders of the Corporation.
SECTION 2. ELECTION AND TERM OF
OFFICE.
The officers of the Corporation to be elected by the
Board of Directors shall be elected annually by the Board of
Directors at the first meeting of the Board of Directors held after
each annual meeting of the shareholders. If the election of
officers shall not be held at such meeting, such election shall be
held as soon thereafter as conveniently may be. Each officer shall
hold office until his successor shall have been duly elected and
shall have qualified, or until his death, or until he shall resign
or shall have been removed in the manner hereinafter
provided.
SECTION 3. REMOVAL
. Any
officer or agent may be removed by the Board of Directors whenever,
in its judgment, the best interests of the Corporation will be
served thereby, but such removal shall be without prejudice to the
contract rights, if any, of the person so removed. Election or
appointment of an officer or agent shall not of itself create
contract rights, and such appointment shall be terminable at
will.
SECTION 4. VACANCIES
. A
vacancy in any office because of death, resignation, removal,
disqualification or otherwise, may be filled by the Board of
Directors for the unexpired portion of the term.
SECTION 5. PRESIDENT.
The
President shall be the principal executive officer of the
Corporation and, subject to the control of the Board of Directors,
shall in general supervise and control all of the business and
affairs of the Corporation. He shall, when present, preside at all
meetings of the shareholders and of the Board of Directors, unless
there is a Chairman of the Board in which case the Chairman shall
preside. He may sign, with the Secretary or any other proper
officer of the Corporation thereunto authorized by the Board of
Directors, certificates for shares of the Corporation, any deeds,
mortgages, bonds, contracts, or other instruments which the Board
of Directors has authorized to be executed, except in cases where
the signing and execution thereof shall be expressly delegated by
the Board of Directors or by these Bylaws to some other officer or
agent of the Corporation, or shall be required by law to be
otherwise signed or executed; and in general shall perform all
duties incident to the office of President and such other duties as
may be prescribed by the Board of Directors from time to
time.
SECTION 6. VICE PRESIDENT.
In the absence of the President or in event of his death, inability
or refusal to act, the Vice President shall perform the duties of
the President, and when so acting, shall have all the powers of and
be subject to all the restrictions upon the President. The Vice
President shall perform such other duties as from time to time may
be assigned to him by the President or by the Board of Directors.
If there is more than one Vice President, each Vice President shall
succeed to the duties of the President in order of rank as
determined by the Board of Directors. If no such rank has been
determined, then each Vice President shall succeed to the duties of
the President in order of date of election, the earliest date
having the first rank.
SECTION 7. SECRETARY.
The
Secretary shall:
(i) Keep the minutes of the proceedings of the shareholders and of
the Board of Directors in one or more minute books provided for
that purpose; (ii) see that all notices are duly given in
accordance with the provisions of these Bylaws or as required by
law; (iii) be custodian of the corporate records and of the seal of
the Corporation and see that the seal of the Corporation is affixed
to all documents, the execution of which on behalf of the
Corporation under its seal is duly authorized; (iv) keep a register
of the post office address of each shareholder which shall be
furnished to the Secretary by such shareholder; (v) sign with the
President certificates for shares of the Corporation, the issuance
of which shall have been authorized by resolution of the Board of
Directors; (vi) have general charge of the stock transfer books of
the Corporation; and (vii) in general perform all duties incident
to the office of the Secretary and such other duties as from time
to time may be assigned to him by the President or by the Board of
Directors.
SECTION 8. TREASURER.
The
Treasurer shall: (i) have charge and custody of and be responsible
for all funds and securities of the Corporation; (ii) receive and
give receipts for moneys due and payable to the Corporation from
any source whatsoever, and deposit all such moneys in the name of
the Corporation in such banks, trust companies or other
depositories as shall be selected in accordance with the provisions
of Article VI of these Bylaws; and (iii) in general perform all of
the duties incident to the office of Treasurer and such other
duties as from time to time may be assigned to him by the President
or by the Board of Directors. If required by the Board of
Directors, the Treasurer shall give a bond for the faithful
discharge of his duties in such sum and with such sureties as the
Board of Directors shall determine.
SECTION 9. SALARIES
. The
salaries of the officers shall be fixed from time to time by the
Board of Directors, and no officer shall be prevented from
receiving such salary by reason of the fact that he is also a
director of the Corporation.
ARTICLE
V
INDEMNIFICATION
OF OFFICERS, DIRECTORS, EMPLOYEES AND AGENTS
SECTION 1. RIGHT TO
INDEMNIFICATION
. Each person who was or is a party or is
threatened to be made a party to or is involved (as a party,
witness, or otherwise), in any threatened, pending, or completed
action, suit, or proceeding, whether civil, criminal,
administrative, or investigative (a “
Proceeding
”), by reason of the fact that he, or a
person of whom he is the legal representative, is or was a
director, officer, employee, or agent of the Corporation or is or
was serving at the request of the Corporation as a director,
officer, employee, or agent of another corporation or of a
partnership, joint venture, trust, or other enterprise, including
service with respect to employee benefit plans, whether the basis
of the Proceeding is alleged action in an official capacity as a
director, officer, employee, or agent or in any other capacity
while serving as a director, officer, employee, or agent (an
“
Agent
”), shall be indemnified and held harmless
by the Corporation to the fullest extent authorized by the DGCL, as
the same exists or may hereafter be amended or interpreted (but, in
the case of any such amendment or interpretation, only to the
extent that such amendment or interpretation permits the
Corporation to provide broader indemnification rights than were
permitted prior thereto) against all expenses, liability, and loss
(including attorneys’ fees, judgments, fines, ERISA excise
taxes or penalties, and amounts paid or to be paid in settlement,
and any interest, assessments, or other charges imposed thereon,
and any federal, state, local, or foreign taxes imposed on any
Agent as a result of the actual or deemed receipt of any payments
under this Article) reasonably incurred or suffered by such person
in connection with investigating, defending, being a witness in, or
participating in (including on appeal), or preparing for any of the
foregoing in, any Proceeding (“
Expenses
”);
provided,
however
, that except as to
actions to enforce indemnification rights pursuant to
Section 3 of this Article, the Corporation shall indemnify any
Agent seeking indemnification in connection with a Proceeding (or
part thereof) initiated by such person only if the Proceeding (or
part thereof) was authorized by the Board of Directors of the
Corporation. The right to indemnification conferred in this
Article shall be a contract right.
SECTION 2. AUTHORITY TO ADVANCE
EXPENSES
. Expenses incurred by an officer or director
(acting in his capacity as such) in defending a Proceeding shall be
paid by the Corporation in advance of the final disposition of such
Proceeding,
provided,
however
, that if required by
the DGCL, such Expenses shall be advanced only upon delivery to the
Corporation of an undertaking by or on behalf of such director or
officer to repay such amount if it shall ultimately be determined
that he is not entitled to be indemnified by the Corporation as
authorized in this Article or otherwise. Expenses incurred by
other Agents of the Corporation (or by the directors or officers
not acting in their capacity as such, including service with
respect to employee benefit plans) may be advanced upon such terms
and conditions as the Board of Directors deems appropriate.
Any obligation to reimburse the Corporation for Expense advances
shall be unsecured and no interest shall be charged
thereon.
SECTION 3. RIGHT OF CLAIMANT TO
BRING SUIT.
If a claim under Section 1 or 2 of this
Article is not paid in full by the Corporation within 90 days
after a written claim has been received by the Corporation, the
claimant may at any time thereafter bring suit against the
Corporation to recover the unpaid amount of the claim and, if
successful in whole or in part, the claimant shall be entitled to
be paid also the expense (including attorneys’ fees) of
prosecuting such claim. It shall be a defense to any such
action (other than an action brought to enforce a claim for
expenses incurred in defending a Proceeding in advance of its final
disposition where the required undertaking has been tendered to the
Corporation) that the claimant has not met the standards of conduct
that make it permissible under the DGCL for the Corporation to
indemnify the claimant for the amount claimed. The burden of
proving such a defense shall be on the Corporation. Neither
the failure of the Corporation (including its Board of Directors,
independent legal counsel, or its stockholders) to have made a
determination prior to the commencement of such action that
indemnification of the claimant is proper under the circumstances
because he has met the applicable standard of conduct set forth in
the DGCL, nor an actual determination by the Corporation (including
its Board of Directors, independent legal counsel, or its
stockholders) that the claimant had not met such applicable
standard of conduct, shall be a defense to the action or create a
presumption that claimant has not met the applicable standard of
conduct.
SECTION 4. PROVISIONS
NONEXCLUSIVE
. The rights conferred on any person by this
Article shall not be exclusive of any other rights that such person
may have or hereafter acquire under any statute, provision of the
Certificate of Incorporation, agreement, vote of stockholders or
disinterested directors, or otherwise, both as to action in an
official capacity and as to action in another capacity while
holding such office. To the extent that any provision of the
Certificate, agreement, or vote of the stockholders or
disinterested directors is inconsistent with these bylaws, the
provision, agreement, or vote shall take precedence.
SECTION 5. AUTHORITY TO
INSURE
. The Corporation may purchase and maintain insurance
to protect itself and any Agent against any Expense, whether or not
the Corporation would have the power to indemnify the Agent against
such Expense under applicable law or the provisions of this
Article.
SECTION 6. SURVIVAL OF
RIGHTS.
The rights provided by this Article shall continue
as to a person who has ceased to be an Agent and shall inure to the
benefit of the heirs, executors, and administrators of such a
person.
SECTION 7. SETTLEMENT
OF
CLAIMS. The Corporation shall not be liable to indemnify
any Agent under this Article (i) for any amounts paid in
settlement of any action or claim effected without the
Corporation’s written consent, which consent shall not be
unreasonably withheld; or (ii) for any judicial award if the
Corporation was not given a reasonable and timely opportunity, at
its expense, to participate in the defense of such
action.
SECTION 8. EFFECT OF AMENDMENT
.
Any amendment,
repeal, or modification of this Article shall not adversely affect
any right or protection of any Agent existing at the time of such
amendment, repeal, or modification.
SECTION 9. SUBROGATION
. In
the event of payment under this Article, the Corporation shall be
subrogated to the extent of such payment to all of the rights of
recovery of the Agent, who shall execute all papers required and
shall do everything that may be necessary to secure such rights,
including the execution of such documents necessary to enable the
Corporation effectively to bring suit to enforce such
rights.
SECTION 10. NO DUPLICATION OF
PAYMENTS
. The Corporation shall not be liable under this
Article to make any payment in connection with any claim made
against the Agent to the extent the Agent has otherwise actually
received payment (under any insurance policy, agreement, vote, or
otherwise) of the amounts otherwise indemnifiable
hereunder.
ARTICLE VI
CHECKS,
DEPOSITS CONTRACTS, AND LOANS
SECTION 1. CHECKS
. All
checks, drafts or other orders for the payment of money, notes or
other evidences of indebtedness issued in the name of the
Corporation, shall be signed by such officer or officers, agent or
agents of the Corporation and in such manner as shall from time to
time be determined by resolution of the Board of
Directors.
SECTION 2. DEPOSITS.
All
funds of the Corporation not otherwise employed shall be deposited
from time to time to the credit of the Corporation in such banks,
trust companies or other depositories as the Board of Directors may
select.
SECTION 3. CONTRACTS.
The
Board of Directors may authorize any officer or officers, agent or
agents, to enter into any contract or execute and deliver any
instrument in the name of and on behalf of the Corporation, and
such authority may be general or confined to specific
instances.
SECTION 4. LOANS.
No loans
shall be contracted on behalf of the Corporation and no evidences
of indebtedness shall be issued in its name unless authorized by a
resolution of the Board of Directors. Such authority may be general
or confined to specific instances.
ARTICLE
VII
CERTIFICATES
FOR SHARES AND THEIR TRANSFER
SECTION 1. CERTIFICATES FOR
SHARES
. Certificates representing shares of the Corporation
shall be in such form as shall be determined by the Board of
Directors. Such certificates shall be signed by the President and
by the Secretary or by such other officers authorized by law and by
the Board of Directors so to do, and sealed with the corporate
seal. All certificates for shares shall be consecutively numbered
or otherwise identified. The name and address of the person to whom
the shares represented thereby are issued, with the number of
shares and date of issue, shall be entered on the stock transfer
books of the Corporation. All certificates surrendered to the
Corporation for transfer shall be canceled and no new certificate
shall be issued until the former certificate for a like number of
shares shall have been surrendered and canceled, except that in
case of a lost, destroyed or mutilated certificate, a new one may
be issued upon such terms and indemnity to the Corporation as the
Board of Directors may prescribe.
SECTION 2. TRANSFER OF
SHARES.
Transfer of shares of the Corporation shall be made
only on the stock transfer books of the Corporation by the holder
of record thereof or by his legal representative, who shall furnish
proper evidence of authority to transfer, or by his attorney
thereunto authorized by power of attorney duly executed and filed
with the Secretary of the Corporation, and on surrender for
cancellation of the certificate for such shares. The person in
whose name shares stand on the books of the Corporation shall be
deemed by the Corporation to be the owner thereof for all
purposes;
provided,
however
, that upon any action
undertaken by the shareholders to elect S Corporation status
pursuant to Section 1362 of the Internal Revenue Code and upon any
shareholders agreement thereto restricting the transfer of such
shares so as to disqualify such S Corporation status, such
restriction on transfer shall be made a part of the these Bylaws so
long as such agreement is in force and effect.
ARTICLE
VIII
FISCAL
YEAR
The
fiscal year of the Corporation shall be fixed by resolution of the
Board Directors.
ARTICLE
IX
DIVIDENDS
The Board of Directors may from time to time declare, and the
Corporation may pay, dividends on its outstanding shares in the
manner and upon the terms and conditions provided by law and its
Certificate of Incorporation.
ARTICLE
X
CORPORATE
SEAL
At the discretion of the Board of Directors, the Corporation may
adopt a corporate seal, circular in form and shall have inscribed
thereon the name of the Corporation and the State of incorporation
and the words, "Corporate Seal". No seal shall be necessary to make
any contract or undertaking valid.
ARTICLE
XI
WAIVER
OF NOTICE
Unless otherwise provided by law, whenever any notice is required
to be given to any shareholder or director of the Corporation under
the provisions of these Bylaws or under the provisions of the
Certificate of Incorporation or under the provisions of the DGCL, a
waiver thereof in writing, signed by the person or persons entitled
to such notice, whether before or after the time stated therein,
shall be deemed equivalent to the giving of such
notice.
ARTICLE
XII
EXCLUSIVE
FORUM FOR LITIGATION
Unless
the Corporation consents in writing to the selection of an
alternative forum, the Court of Chancery of the State of Delaware
shall be the sole and exclusive forum for (i) any derivative action
or proceeding brought on behalf of the Corporation, (ii) any action
asserting a claim of breach of a fiduciary duty owed by, or other
wrongdoing by, any director, officer, or other employee of the
Corporation to the Corporation or the Corporation’s
stockholders, (iii) any action asserting a claim against the
Corporation arising pursuant to any provision of the DGCL, the
Corporation’s Certificate of Incorporation or these Bylaws,
or (iv) any action to interpret, apply, enforce or determine the
validity of the Corporation’s Certificate of Incorporation or
these Bylaws, or (v) any action asserting a claim against the
Corporation governed by the internal affairs doctrine. Any person
or entity purchasing or otherwise acquiring any interest in shares
of stock of the Corporation shall be deemed to have notice of and
consented to the provisions of this Article XII.
ARTICLE
XIII
AMENDMENTS
These Bylaws may be altered, amended or repealed and new Bylaws may
be adopted by the Board of Directors at any regular or special
meeting of the Board of Directors.
CERTIFICATE
OF SECRETARY
The
undersigned, Secretary of Wrap Technologies, Inc., a Delaware
corporation, hereby certifies that the foregoing is a full, true
and correct copy of the Bylaws of the Corporation, with all
amendments to date of this Certificate.
WITNESS
the signature of the undersigned this 31st day of March
2017.
|
/s/ Scot
Cohen
Scot
Cohen, Corporate Secretary
|
Exhibit 10.1
AMENDED AND RESTATED
INTELLECTUAL PROPERTY LICENSE AGREEMENT
This Amended and Restated Intellectual Property
License Agreement (this "
Agreement
")
is made and entered into as of the 30
th
day of September, 2016
("
Effective
Date
"), by and between Wrap
Technologies, LLC, a Delaware limited liability company (the
"
Company
")
and Syzygy Licensing LLC, a Nevada limited liability company
("
Licensing
Member
"). Licensing Member and
Company may each individually be referred to as a
"
Party
"
and collectively as the "
Parties
."
Recitals
WHEREAS
, Licensing Member and Scot Cohen have formed the
Company to jointly develop certain technology, devices and products
relating to non-lethal weapons as described on
Exhibit A
hereto (the “
Business
”);
WHEREAS
, the Parties entered into the Intellectual
Property License Agreement dated as of March 10, 2016 (the
“Prior Licensing Agreement”) pursuant to which certain
Intellectual Property owned by Licensing Member shall be licensed
to the Company; and
WHEREAS
, each Party is willing amend and restate the
Prior Licensing Agreement in its entirety with this Agreement and
grant the licenses contemplated hereby on the terms and conditions
set forth herein.
NOW,
THEREFORE
, for and in
consideration of the mutual promises and covenants hereinafter
contained, the Parties hereto agree as follows:
Agreement
"
Intellectual
Property
" means all worldwide
intellectual property rights, including (a) inventions,
patents and patent applications; (b) Trademarks, service
marks, trade names, trade dress, Internet domain names and other
source indicators, together with the goodwill associated
exclusively therewith; (c) copyrights, Software, websites;
(d) registrations and applications for registration of any of
the foregoing in (a) – (c); and (e) trade secrets,
know-how and proprietary or confidential
information.
"
Improvement
"
means any improvement, modification, translation, update, upgrade,
new version, enhancement or other derivative
work.
"
Licensed Intellectual
Property
" means any
Intellectual Property developed and owned by the Licensing Member
that is used in the Business, including without limitation the
Patents and any Improvements thereto created by the Licensing
Member or the Company.
“
Licensed Product(s)
”
shall include any
product that is covered by the Intellectual Property.
"
Patents
" means any patent applications,
patents and trade secrets related to products developed by the
Licensing Member for the Business.
"
Software
"
means any and all computer programs, software (in object and source
code), firmware, middleware, applications, APIs, web widgets, code
and related algorithms, models and methodologies, files,
documentation and all other tangible embodiments
thereof.
"
Trademarks
"
means trademarks, service marks, domain names, trade dress, trade
names, corporate names, logos, designs, symbol, slogan, social
media identifiers and other identifiers of source or
goodwill.
2.
Grant, Scope of
License and Costs.
2.1
Subject to the terms and conditions herein, Licensing Member hereby
grants to the Company a worldwide, exclusive license relating to
the Licensed Intellectual Property and any Licensed Product, to
use, reproduce, modify, prepare derivative works of, perform,
display, or otherwise exploit. Licensing Members agrees that,
during the term of this Agreement, it will not, directly or
indirectly, use or allow third parties to use the Licensed
Intellectual Property without the written consent of the
Company.
2.1.1
Royalty
. In consideration of the rights conveyed by this
Agreement
the Company shall pay Licensing Member a royalty
of four percent (4.0%)
of the Net Sales of Licensed
Products until the earlier of (1) payment of aggregate royalties of
$1,000,000 or (2) ten years from the date of this Agreement (the
“Royalty”). “Net Sales” shall
be defined as the Company’s
gross receipts or revenue, computed on a cash basis, for each
Licensed Product that is sold, distributed, leased, or otherwise
transferred for monetary payment to any third party, less the
following:
2.1.1.1
The actual cost of freight charges or of freight absorption, if
any, separately stated in such invoice;
2.1.1.2
Any trade, quantity or standard trade cash discounts, if any,
allowed;
2.1.1.3
Any tax, duties, imposts or other government charge on the sale,
transportation, or delivery which is separately stated on the
invoice (unless in the nature of a value added tax, which need not
be separately stated);
2.1.1.4
Any credit and cash refunds for returned goods; and
2.1.1.5
Any allowances for damaged, obsolete, and defective
goods.
2.1.2
Quarterly Payments
. The
Royalties set forth in this Section shall accrue on the Net Sales
made day-to-day, on a cash receipts basis, in each calendar
quarter. On or before the thirtieth day following the end of a
calendar quarter (i.e. April 30
th
, July
30
th
,
October 30
th
, and January
30
th
),
Company shall submit payment of all accrued royalties on the Net
Sales made in that calendar quarter.
2.1.3
Late Payments
. In the event
that any payment due hereunder is not received by Licensing Member
within 10 days of the due date for said payment, then Licensing
Member shall be entitled to charge Company interest at the rate of
five percent (5%) per annum on said payments accrued from the date
such payment was due.
2.1.4
Quarterly Reports.
Company
shall provide Licensing Member with a quarterly report on or before
the thirtieth day following the end of a calendar quarter (i.e.
April 30
th
, July
30
th
,
October 30
th
, and January
30
th
)
detailing the Net Sales made in that calendar quarter. This
quarterly report shall include at least an accounting of the Net
Sales made, with any deductions therefore, and of all payments
due.
2.1.5
Records.
Company shall keep records for a
reasonable period of time of the Licensed Products manufactured,
sold and distributed in sufficient detail to enable the Royalty
Payment and any other payments due to Licensing Member to be
determined. In the event that Licensing Member disagrees with any
such accounting, Licensing Member or its designated representative
shall have the right, upon reasonable notice to Company, at
Licensing Member’s expense and no more often than
semi-annually to review and inspect the books and records of
Company relating to the sale and distribution of the Licensed
Products during normal business hours of Company at the location
where such books and records are maintained, but for no more than
the preceding two (2) years. In the event that any inspection by
Licensing Member discloses any deficiencies in payments made to
Licensing Member, then Company shall pay such additional amounts to
Licensing Member within twenty (20) days following receipt of
written notice thereof, together with all documentation necessary
to support such additional payment by Company. In the event that
any such inspection discloses an overpayment by Company, then
Company shall be entitled to deduct and offset any such overpayment
from the subsequent amounts that become due. In the event that
there are no such subsequent payments to become due, then Licensing
Member agrees to pay Company the full amount of any such
overpayment within twenty (20) days following receipt of written
notice thereof from Company.
2.1.6
Payment in U.S. Dollars.
All payments due hereunder shall be made in U.S.
Dollars.
2.1.7
Taxes.
Licensee will pay
any taxes incurred by it due to the use, manufacture, sale,
distribution, or importation or exportation by Licensee of the
Licensed Products.
2.1.8
Sublicenses by Company
.
Company may not sublicense its rights under this Agreement unless
it obtains Licensing Member’s written permission to do so.
Any Licensed Products sold under such a sublicense shall be subject
to the provisions of this Section; however the royalty rates of any
such sublicense may differ from those delineated in this Section.
The parties agree to negotiate royalty rates of any sublicense in
good faith with the intent to provide for gross margins to Company
and Licensing Member comparable to those delineated in and/or being
the consequence of this Section.
2.2
The Company may sublicense the licenses received herein solely
(a) to its vendors, consultants, contractors and suppliers,
solely in connection with their providing services to the Company;
and (b) to its distributors, customers and end-users, solely
in connection with the distribution, licensing, offering and sale
of their current and future products related to its
businesses.
2.3
The Company shall be obligated for the costs of development of the
Licensed Intellectual Property and for Patent costs during the term
of this Agreement. While it is contemplated the Company shall pay
directly such costs, the Company shall reimburse Licensing Member
for any reasonable Patent and development costs paid or incurred
through the date of assignment (Section 4.3) or through the date of
termination (Section 4.1).
3.
Confidential
Information.
Each
Party hereto shall maintain the confidentiality of confidential
information in accordance with procedures adopted by such Party in
good faith to protect confidential information of third parties
delivered to such Party, provided that such Party may deliver or
disclose confidential information to (a) such Party's
officers, directors, employees, investors, agents, representatives,
accountants and counsel who agree to hold confidential the
confidential information; (b) any governmental authority
having jurisdiction over such Party to the extent required by law;
or (c) any other person to which such delivery or disclosure
may be necessary or appropriate (i) to effect compliance with
any law applicable to such party, (ii) in response to any
subpoena or other legal process, or (iii) in connection with
any litigation to which such Party is a Party; provided further
that, in the cases of clauses (b) or (c), such Party shall
provide each other Party hereto with prompt written notice thereof
so that the appropriate Party may seek (with the cooperation and
reasonable efforts of each other Party) a protective order,
confidential treatment or other appropriate remedy.
4.1
Subject to Section 4.2, this Agreement shall commence as of the
date first above written and shall continue in effect until
December 31, 2016. Thereafter, or after the extension in Section
4.4, should the requirement of Section 4.2 not be satisfied, all
Intellectual Property (including the Patents) shall be the sole
property of the Licensing Member without obligation to the Company
for any royalties or reimbursements of any costs or expenses
incurred by the Company related thereto.
4.2
At any time following an aggregate capitalization of $300,000 in
the Company (the “Trigger Amount”), the term of this
Agreement shall be perpetual and the license granted in Section 2
above shall not be terminable by the Licensing Member, but subject
to the Royalty set forth in Section 2.1.1.
4.3.
Within 30 days of the satisfying the Trigger Amount, both Parties
covenant and hereby agree that the Licensing Member shall assign,
transfer and sell the Licensed Intellectual Property including
Patents to the Company for $10, but subject to the Royalty set
forth in Section 2.1.1.
4.4
The Company shall have a right to an automatic 6 month extension to
the termination date set forth in Section 4.1 if the Company is in
the process of funding the Trigger Amount in good
faith.
EXCEPT
AS PROVIDED IN THIS AGREEMENT, (I) THE INTELLECTUAL PROPERTY
LICENSED HEREUNDER IS PROVIDED "AS IS," (II) NEITHER PARTY PROVIDES
ANY WARRANTIES, EITHER EXPRESS, IMPLIED, STATUTORY, OR OTHERWISE,
WITH RESPECT TO ANY SUCH INTELLECTUAL PROPERTY, AND (III) THE
PARTIES SPECIFICALLY DISCLAIM ALL IMPLIED WARRANTIES, INCLUDING THE
IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT AND FITNESS
FOR A PARTICULAR PURPOSE OR ANY WARRANTIES THAT MAY BE OTHERWISE
IMPLIED FROM ANY COURSE OF DEALING OR COURSE OF PERFORMANCE OR
USAGE.
6.
Limitation of
Liability.
EXCEPT
FOR ANY BREACH OF SECTION 2 OF THIS AGREEMENT, IN NO EVENT SHALL
EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY LOST PROFITS OR
CONSEQUENTIAL, INDIRECT, PUNITIVE, EXEMPLARY, SPECIAL, OR
INCIDENTAL DAMAGES ARISING FROM OR RELATING TO THIS AGREEMENT,
WHETHER IN CONTRACT OR TORT OR OTHERWISE, EVEN IF SUCH PARTY KNEW
OR SHOULD HAVE KNOWN OF THE POSSIBILITY OF SUCH
DAMAGES.
7.1
All notices, requests, claims, demands, and other communications
under this Agreement shall be in writing and shall be given or made
(and shall be deemed to have been duly given or made upon receipt)
by delivery in person, by an internationally recognized overnight
courier service, or by facsimile to the respective parties hereto
at the following addresses (or at such other address for a party as
shall be specified in a notice given in accordance with this
Section 9.1):
(a)
if to
Licensing Member:
Syzygy
Licensing LLC
8617
Canyon View Drive
Las
Vegas, Nevada 89117
email:
jimbarnes@cox.net
Attention:
Jim Barnes
(b)
if to
the Company:
Wrap
Technologies, LLC
55 5
th
Avenue, Suite 1702
New
York, NY 10003
Facsimile:
212-504-0863
Attention:
Scot Cohen
7.2
This Agreement shall be governed by, and construed in accordance
with, the laws of New York without regard to the conflict of laws
rules stated therein. Both Parties hereby submit to jurisdiction of
the state and federal courts located in the State of New York,
County of New York.
7.3
This Agreement may not be amended or modified except (a) by an
instrument in writing signed by, or on behalf of, both Parties that
expressly references the section of this Agreement to be amended;
or (b) by a waiver in accordance with
Section 7.4.
7.4
Any Party to this Agreement may (a) extend the time for the
performance of any of the obligations or other acts of the other
Party; (b) waive any inaccuracies in the representations and
warranties of the other Party contained herein or in any document
delivered by the other Party pursuant to this Agreement; or
(c) waive compliance with any of the agreements of the other
Party or conditions to such obligations contained herein. Any such
extension or waiver shall be valid only if set forth in an
instrument in writing signed by the Parties to be bound thereby.
Notwithstanding the foregoing, no failure or delay by any Party
hereto in exercising any right hereunder shall operate as a waiver
thereof nor shall any single or partial exercise thereof preclude
any other or future exercise of any other right hereunder. The
failure of any Party hereto to assert any of its rights hereunder
shall not constitute a waiver of any of such rights.
7.5
If any term or other provision of this Agreement is invalid,
illegal or incapable of being enforced by any Law or public policy,
all other terms and provisions of this Agreement shall nevertheless
remain in full force and effect for so long as the economic or
legal substance of the transactions contemplated by this Agreement
is not affected in any manner materially adverse to any Party
hereto. Upon such determination that any term or other provision is
invalid, illegal or incapable of being enforced, the Parties hereto
shall negotiate in good faith to modify this Agreement so as to
effect the original intent of the Parties hereto as closely as
possible in a mutually acceptable manner in order that the
transactions contemplated by this Agreement are consummated as
originally contemplated to the greatest extent
possible.
7.6
The headings in this Agreement are for purposes of reference only
and shall not in any way limit or affect the meaning or
interpretation of any of the terms hereof.
7.7
The Parties hereto acknowledge and agree that the Parties hereto
may be irreparably damaged if any of the provisions of this
Agreement are not performed in accordance with their specific terms
or are otherwise breached and that any non-performance or breach of
this Agreement by any Party hereto may not be adequately
compensated by monetary damages alone and that the Parties hereto
may not have any adequate remedy at law. Accordingly, in addition
to any other right or remedy to which any Party hereto may be
entitled, at law or in equity (including monetary damages), such
Party shall be entitled to enforce any provision of this Agreement
(including Sections 2.1 and 2.2) by a decree of specific
performance and to temporary, preliminary and permanent injunctive
relief to prevent breaches or threatened breaches of any of the
provisions of this Agreement without posting any bond or other
undertaking.
7.8
This Agreement, together with all the Schedules and other
attachments hereto, constitutes the entire agreement of the Parties
hereto as of the date hereof with respect to the subject matter
hereof and thereof and supersedes all prior agreements, including
the Prior Licensing Agreement, and undertakings, both written and
oral, among the Parties hereto with respect to the subject matter
hereof and thereof.
[Signature Page to Follow]
IN
WITNESS WHEREOF, the Parties hereto, each acting under due and
proper authority, have executed this Agreement as of the day, month
and year first written above.
|
WRAP TECHNOLOGIES, LLC
By:
/s/ Scot
Cohen________________________
Name:
Scot Cohen
Title:
Manager
SYZYGY LICENSING LLC
By:
/s/ James A.
Barnes___________________
Name:
James A. Barnes
Title:
Manager
|
|
|
Schedule A
Licensed Intellectual Property
A non-lethal ensnarement device technology utilizing a bola
mechanism for capturing or slowing fleeing persons primarily
targeting use by law enforcement and military. The word
“bola” generally describes a weapon consisting of a
number of balls connected by strong cord, which when thrown
entangles the limbs of the quarry. The subject technology being
developed employs the use of a firearm (or firearm type) device as
a housing for launching a bola and incorporates a number of
improvements (believed to be patentable) over prior attempts to
employ a bola mechanism for such purpose.
Exhibit 10.2
WRAP
TECHNOLOGIES, INC.
2017 Equity Compensation
Plan
1. Purposes.
(a) Eligible Stock Award
Recipients
. The persons eligible to receive Stock
Awards are the Employees, Directors and Consultants of the Company
and its Affiliates.
(b
)
Available Stock
Awards
. The purpose of the Plan is to provide a
means by which eligible recipients of Stock Awards may be given an
opportunity to benefit from increases in value of the Common Stock
through the granting of the following Stock Awards: (i) Stock
Options, (iii) Common Stock, (iv) Restricted Stock, and
(v) Restricted Stock Units.
(c
)
General
Purpose
. The Company, by means of the Plan, seeks
to retain the services of the group of persons eligible to receive
Stock Awards, to secure and retain the services of new members of
this group and to provide incentives for such persons to exert
maximum efforts for the success of the Company and its
Affiliates.
2. Definitions.
(a
)
“
Affiliate
”
means any parent corporation or subsidiary corporation of the
Company, whether now or hereafter existing, as those terms are
defined in Sections 424(e) and (f), respectively, of the
Code.
(b
)
“
Board
”
means the Board of Directors of the Company.
(c
)
“Cause”
for termination of Continuous Service means there exists (i) a
reasonable and good faith finding by the Company as determined by
it in its sole discretion, of a material and repeated failure of
the Participant to provide his or her full business time and
attention to his reasonably assigned duties for the Company
(including, without limitation, unexcused failure to report for
work) for reasons other than the Participant’s death or
disability, or the Participant's gross negligence or willful
misconduct; which failure or deficiency remains uncured (if
curable) for a period of thirty (30) days following written notice
by the Company to the Participant which specifies the reasons for
the potential cause determination; (ii) the material breach by the
Participant of any of the provisions of his or her employment
agreement (if the Participant has an employment agreement with the
Company) for reasons other than the Participant’s death or
disability, which breach remains uncured (if curable) for a period
of thirty (30) days following written notice by the Company to the
Participant which specifies the reasons for the potential cause
determination; (iii) the conviction of the Participant of, or the
entry of a pleading of guilty or
nolo
contendere
by the Participant
to, any felony; (iv) the Participant having committed any theft,
embezzlement, fraud or other intentional act of dishonesty
involving the business of the Company; or (v) any adjudication in
any civil suit, or written acknowledgment by the Participant in any
agreement or stipulation of the commission of any theft,
embezzlement, fraud or other intentional act of dishonesty
involving any other person.
(d
)
Intentionally Left Blank.
(e
)
“
Code
” means
the Internal Revenue Code of 1986, as amended. Reference
to a specific section of the Code or regulation thereunder shall
include such section or regulation, any valid regulation
promulgated under such section, and any comparable provision of any
future legislation or regulation amending, supplementing or
superseding such section or regulation.
(f
)
“
Committee
”
means a committee of one or more members of the Board appointed by
the Board in accordance with subsection 3(c).
(g
)
“
Common Stock
”
means the common stock of the Company.
(h
)
“
Company
”
means Wrap Technologies, Inc., a Delaware corporation.
(i
)
“
Consultant
”
means any person, including an advisor, (i) engaged by the
Company or an Affiliate to render consulting or advisory services
and who is compensated for such services or (ii) who is a
member of the Board of Directors of an
Affiliate. However, the term “Consultant”
shall not include either Directors who are not compensated by the
Company for their services as Directors or Directors who are merely
paid a director’s fee by the Company for their services as
Directors.
(j
)
“
Continuous
Service
” means that the Participant’s service
with the Company or an Affiliate, whether as an Employee, Director
or Consultant, is not interrupted or terminated. The
Participant’s Continuous Service shall not be deemed to have
terminated merely because of a change in the capacity in which the
Participant renders service to the Company or an Affiliate as an
Employee, Consultant or Director or a change in the entity for
which the Participant renders such service, provided that there is
no interruption or termination of the Participant’s
Continuous Service. For example, a change in status from
an Employee of the Company to a Consultant of an Affiliate or a
Director will not constitute an interruption of Continuous
Service. The Board or the chief executive officer of the
Company, in that party’s sole discretion, may determine
whether Continuous Service shall be considered interrupted in the
case of any leave of absence approved by that party, including sick
leave, military leave or any other personal leave.
(k
)
“
Covered
Employee
” means the chief executive officer and the
four (4) other highest compensated officers of the Company for whom
total compensation is required to be reported to stockholders under
the Exchange Act, as determined for purposes of Section 162(m)
of the Code.
(l
)
“
Director
”
means a member of the Board of Directors of the
Company.
(m
)
“
Disability
”
means the permanent and total disability of a person within the
meaning of Section 22(e)(3) of the Code.
(n
)
“
Employee
”
means any person employed by the Company or an
Affiliate. Mere service as a Director or payment of a
director’s fee by the Company or an Affiliate shall not be
sufficient to constitute “employment” by the Company or
an Affiliate.
(o
)
“
Exchange
Act
” means the Securities Exchange Act of 1934, as
amended.
(p
)
“
Fair
Market Value
” means, as of any date, the value of the
Common Stock determined as follows:
(i
)
If the Common
Stock is listed on any established stock exchange or traded on a
NASDAQ Capital Market or quoted on the Over the Counter Bulletin
Board, the Fair Market Value of a share of Common Stock shall be
the closing sales price (last trade) for such stock as quoted on
such exchange or market (or the exchange or market with the
greatest volume of trading in the Common Stock) on the last market
trading day prior to the day of determination, as reported in
The Wall Street Journal
or
such other source as the Board deems reliable.
(ii
)
In the absence of
such markets for the Common Stock, the Fair Market Value shall be
determined in good faith by the Board.
(q
)
“Good
Reason”
means, without the written consent
of the Participant, (i) a material reduction by the Company in the
Participant's duties or position, (ii) a reduction of the
Participant's compensation or benefits as set forth in the
Company’s benefits policies as of the date hereof or in
Participant’s employment agreement, (iii) the relocation of
the Participant’s principal place of employment by more than
50 miles, or (iv) any material breach by the Company of the
Participant’s employment agreement, if any. Prior to a
termination of Continuous Service with good reason, the Company
shall have thirty (30) days to cure the deficiency or deficiencies
related to the potential good reason determination.
(r
)
“ Incentive Stock
Option
”
means
a Stock Option meeting the requirements of Section 421(b) of the
Code
.
(s
)
“
Non-Employee
Director
” means a Director who either (i) is not
a current Employee or Officer of the Company or its parent or a
subsidiary, does not receive compensation (directly or indirectly)
from the Company or its parent or a subsidiary for services
rendered as a consultant or in any capacity other than as a
Director (except for an amount as to which disclosure would not be
required under Item 404(a) of Regulation S-K promulgated
pursuant to the Securities Act
(“Regulation S-K”)), does not possess an interest
in any other transaction as to which disclosure would be required
under Item 404(a) of Regulation S-K and is not engaged in a
business relationship as to which disclosure would be required
under Item 404(b) of Regulation S-K; or (ii) is otherwise
considered a “non-employee director” for purposes of
Rule 16b-3.
(t
)
“
Non-statutory
Stock Option
” means an Option not intended to qualify
as an Incentive Stock Option.
(u
)
“
Officer
”
means a person who is an officer of the Company within the meaning
of Section 16 of the Exchange Act and the rules and
regulations promulgated thereunder.
(v
)
“
Option
”
means a Stock Option granted pursuant to the Plan.
(w
)
“
Option
Agreement
” means a written agreement between the
Company and an Optionholder evidencing the terms and conditions of
an individual Option grant. Each Option Agreement shall
be subject to the terms and conditions of the Plan.
(x
)
“
Optionholder
”
means a person to whom an Option is granted pursuant to the Plan
or, if applicable, such other person who holds an outstanding
Option.
(y
)
“
Outside
Director
” means a Director who either (i) is not
a current employee of the Company or an “affiliated
corporation” (within the meaning of Treasury Regulations
promulgated under Section 162(m) of the Code), is not a former
employee of the Company or an “affiliated corporation”
receiving compensation for prior services (other than benefits
under a tax-qualified pension plan), was not an officer of the
Company or an “affiliated corporation” at any time and
is not currently receiving direct or indirect remuneration from the
Company or an “affiliated corporation” for services in
any capacity other than as a Director or (ii) is otherwise
considered an “outside director” for purposes of
Section 162(m) of the Code.
(z
)
“
Participant
”
means a person to whom a Stock Award is granted pursuant to the
Plan or, if applicable, such other person who holds an outstanding
Stock Award.
(aa
)
“
Plan
”
means this Wrap Technologies, Inc. 2017 Equity Compensation
Plan.
(bb
)
“
Restricted
Stock
” means shares of Common Stock issued pursuant to
a Restricted Stock award under Section 7(b) of the
Plan.
(cc
)
“
Restricted
Stock Unit
” means a bookkeeping entry representing an
amount equal to the Fair Market Value of one share of Common Stock,
granted pursuant to Section 7(c). Each Restricted Stock
Unit represents an unfunded and unsecured obligation of the
Company.
(dd
)
“
Rule 16b-3
”
means Rule 16b-3 promulgated under the Exchange Act or any
successor to Rule 16b-3, as in effect from time to
time.
(ee
)
“
Securities
Act
” means the Securities Act of 1933, as
amended.
(ff
)
“
Stock
Award
” means any equity grant under the Plan,
including any grant of an Option, a Restricted Stock Unit, Common
Stock, or Restricted Stock.
(gg
)
“
Stock
Award Agreement
” means a written agreement between the
Company and a holder of a Stock Award evidencing the terms and
conditions of an individual Stock Award grant. Each
Stock Award Agreement shall be subject to the terms and conditions
of the Plan. In the case of a Stock Award consisting of Restricted
Stock, it shall mean a written agreement between the Company and a
Participant evidencing the terms and restrictions applying to an
individual grant of Restricted Stock, and in the case of a Stock
Award consisting of Restricted Stock Units, it shall mean a written
agreement between the Company and a Participant evidencing the
terms and restrictions applying to an individual grant of
Restricted Stock Units.
(hh
)
“
Stock
Award Transfer
Program
” means any program instituted by the Board
which would permit Participants the opportunity to transfer any
outstanding Stock Awards to a financial institution or other person
or entity approved by the Board.
(ii
)
“
Ten
Percent Stockholder
” means a person who owns (or is
deemed to own pursuant to Section 424(d) of the Code) stock
possessing more than ten percent (10%) of the total combined voting
power of all classes of stock of the Company or of any of its
Affiliates.
3. Administration.
(a
)
Administration by
Board
. The Board shall administer the Plan unless
and until the Board delegates administration to a Committee, as
provided in subsection 3(c).
(b
)
Powers of
Board
. The Board shall have the power, subject
to, and within the limitations of, the express provisions of the
Plan:
(i
)
To determine the
Fair Market Value;
(ii
)
To select the
persons to whom Stock Awards may be granted hereunder;
(iii
)
To determine the
number of shares of Common Stock to be covered by each Stock Award
granted hereunder;
(iv
)
To approve forms
of Stock Award Agreements for use under the Plan;
(v
)
To determine the
terms and conditions, not inconsistent with the terms of the Plan,
of any Stock Award granted hereunder. Such terms and
conditions include, but are not limited to, the exercise price, the
time or times when Stock Awards may be exercised (which may be
based on performance criteria), any vesting acceleration or waiver
of forfeiture restrictions, and any restriction or limitation
regarding any Stock Award or the shares of Common Stock relating
thereto, based in each case on such factors as the Board will
determine;
(vi
)
To determine the
terms and conditions of any, and to institute any, Stock Award
Transfer Program in accordance with Section 10(b);
(vii
)
To construe and
interpret the terms of the Plan and Stock Awards granted pursuant
to the Plan;
(viii
)
To prescribe,
amend and rescind rules and regulations relating to the Plan,
including rules and regulations relating to sub-plans established
for the purpose of satisfying applicable foreign laws;
(ix
)
To modify or amend
each Stock Award (subject to Section 13(e) of the Plan),
including but not limited to the discretionary authority to extend
the post-termination exercisability period of Stock Awards and to
extend the maximum term of an Option (subject to Section 6(a)
regarding Incentive Stock Options);
(x
)
To allow
Participants to satisfy withholding tax obligations in such manner
as prescribed in Section 11(f);
(xi
)
To authorize any
person to execute on behalf of the Company any instrument required
to effect the grant of a Stock Award previously granted by the
Board;
(xii
)
To allow a
Participant to defer the receipt of the payment of cash or the
delivery of shares of Common Stock that would otherwise be due to
such Participant under a Stock Award pursuant to such procedures as
the Board may determine; and
(xiii
)
To make all other
determinations deemed necessary or advisable for administering the
Plan.
(c
)
Delegation to
Committee
.
(i
)
General
. The Board may delegate administration of
the Plan to a Committee or Committees of one (1) or more members of
the Board, and the term “Committee” shall apply to any
person or persons to whom such authority has been
delegated. If administration is delegated to a
Committee, the Committee shall have, in connection with the
administration of the Plan, the powers theretofore possessed by the
Board, including the power to delegate to a subcommittee any of the
administrative powers the Committee is authorized to exercise (and
references in this Plan to the Board shall thereafter be to the
Committee or subcommittee), subject, however, to such resolutions,
not inconsistent with the provisions of the Plan, as may be adopted
from time to time by the Board. The Board may abolish
the Committee at any time and revest in the Board the
administration of the Plan.
(ii
)
Committee
Composition
. In the discretion of the Board, a
Committee may consist solely of two or more Outside Directors, in
accordance with Section 162(m) of the Code, and/or solely of
two or more Non-Employee Directors, in accordance with
Rule 16b-3. Within the scope of such authority, the
Board or the Committee may (1) delegate to a committee of one
or more members of the Board who are not Outside Directors the
authority to grant Stock Awards to eligible persons who are either
(a) not then Covered Employees and are not expected to be
Covered Employees at the time of recognition of income resulting
from such Stock Award or (b) not persons with respect to whom
the Company wishes to comply with Section 162(m) of the Code
and/or) (2) delegate to a committee of one or more members of
the Board who are not Non-Employee Directors the authority to grant
Stock Awards to eligible persons who are not then subject to
Section 16 of the Exchange Act.
(d
)
Effect of Board’s
and/or Committee’s Decision
. All
determinations, interpretations and constructions made by the Board
or the Committee in good faith shall not be subject to review by
any person and shall be final, binding and conclusive on all
persons.
4. Shares Subject To The Plan.
(a
)
Share
Reserve
. Subject to the provisions of
Section 12 relating to adjustments upon changes in Common
Stock, the total number of shares of Common Stock that may be
issued pursuant to Stock Awards shall not exceed in the aggregate
of 2,000,000 shares (the “
Reserved
Shares
”).
(b
)
Reversion of Shares to
the Share Reserve
. Subject to the provisions of
4(a) above, if any Stock Award shall for any reason expire or
otherwise terminate, in whole or in part, without having been
exercised in full, the shares of Common Stock not acquired under
such Stock Award shall revert to and again become available for
issuance under the Plan.
(c
)
Source of Shares
. The shares
of Common Stock subject to the Plan may be unissued shares or
reacquired shares, bought on the market or
otherwise.
5. Eligibility.
(a
)
Consultants
.
(i
)
A Consultant shall
not be eligible for the grant of a Stock Award if, at the time of
grant, either the offer or the sale of the Company’s
securities to such Consultant is not exempt under Rule 701 of
the Securities Act (“Rule 701”) because of the
nature of the services that the Consultant is providing to the
Company, or because the Consultant is not a natural person, or as
otherwise provided by Rule 701, unless the Company determines
that such grant need not comply with the requirements of
Rule 701 and will satisfy another exemption under the
Securities Act as well as comply with the securities laws of all
other relevant jurisdictions.
(ii
)
A Consultant shall
not be eligible for the grant of a Stock Award if, at the time of
grant, a Form S-8 Registration Statement under the Securities Act
(“Form S-8”) is not available to register either the
offer or the sale of the Company’s securities to such
Consultant because of the nature of the services that the
Consultant is providing to the Company, or because the Consultant
is not a natural person, or as otherwise provided by the rules
governing the use of Form S-8, unless the Company determines both
(i) that such grant (A) shall be registered in another
manner under the Securities Act (e.g., on a Form S-3 Registration
Statement) or (B) does not require registration under the
Securities Act in order to comply with the requirements of the
Securities Act, if applicable, and (ii) that such grant
complies with the securities laws of all other relevant
jurisdictions.
(iii
)
Rule 701 and
Form S-8 generally are available to consultants and advisors only
if (i) they are natural persons; (ii) they provide bona
fide services to the issuer, its parents, its majority-owned
subsidiaries or majority-owned subsidiaries of the issuer’s
parent; and (iii) the services are not in connection with the
offer or sale of securities in a capital-raising transaction, and
do not directly or indirectly promote or maintain a market for the
issuer’s securities.
6. Option Provisions.
Each
Option shall be in such form and shall contain such terms and
conditions as the Board shall deem appropriate. All
Options shall be non-statutory Stock Options at the time of
grant. The provisions of separate Options need not be
identical, but each Option shall include (through incorporation of
provisions hereof by reference in the Option or otherwise) the
substance of each of the following provisions:
(a
)
Term
. No Stock Option shall be exercisable after
the expiration of ten (10) years from the date it was
granted.
(b
)
Intentionally Left Blank
.
(c
)
Exercise Price of a Stock
Option
. The exercise price of each Stock Option
shall be not less than one hundred percent (100%) of the Fair
Market Value of the Common Stock subject to the Option on the date
the Option is granted. Notwithstanding the foregoing, a
Stock Option may be granted with an exercise price lower than that
set forth in the preceding sentence if such Option is granted
pursuant to an assumption or substitution for another option in a
manner satisfying the provisions of Section 424(a) of the
Code. Notwithstanding the foregoing,
the exercise price of an Incentive Stock Option
granted to any Ten Percent Stockholder shall in no event be less
than one hundred and ten percent (110%) of the Fair Market Value of
the stock covered by the Incentive Stock Option at the time the
Incentive Stock Option is granted. No Incentive Stock Option
granted to any Ten Percent Stockholder shall be exercisable more
than five (5) years after the date of
grant.
(d
)
Consideration
. The purchase price of Common Stock
acquired pursuant to an Option shall be paid, to the extent
permitted by applicable statutes and regulations, either
(i) in cash at the time the Option is exercised or
(ii) at the discretion of the Board at the time of the grant
of the Option (or subsequently in the case of a Non-statutory Stock
Option) (1) by delivery to the Company of other Common Stock,
(2) according to a deferred payment or other similar
arrangement with the Optionholder or (3) in any other form of
legal consideration that may be acceptable to the Board (which
includes a cashless exercise election). Unless otherwise
specifically provided in the Option, the purchase price of Common
Stock acquired pursuant to an Option that is paid by delivery to
the Company of other Common Stock acquired, directly or indirectly
from the Company, shall be paid only by shares of the Common Stock
of the Company that have been held for more than six (6) months (or
such longer or shorter period of time required to avoid a charge to
earnings for financial accounting purposes). At any time
that the Company is incorporated in Delaware, payment of the Common
Stock’s “par value,” as defined in the Delaware
General Corporation Law, shall not be made by deferred
payment.
In the
case of any deferred payment arrangement, interest shall be
compounded at least annually and shall be charged at the market
rate of interest necessary to avoid a charge to earnings for
financial accounting purposes.
In the
case of a cashless exercise, the following formula will be
used:
If
elected by the Holder, the Holder shall be entitled to receive a
certificate for the number of Option Shares equal to the quotient
obtained by dividing [(A-B) (X)] by (A), where:
(A) = the closing stock price (trade) or Fair Market Value
on the trading day immediately preceding the date of such
election,;
(B)
= the Exercise Price of the Option, as adjusted; and
(X)
= the number of Option Shares issuable upon exercise of the
Option in accordance with the terms of the Option by means of a
cash exercise rather than a cashless exercise.
Notwithstanding
anything herein to the contrary, on the Termination Date,
unexercised vested Options shall be automatically exercised via
cashless exercise pursuant to this Section 6(d).
(e) Vesting.
(i) The total
number of shares of Common Stock subject to an Option may, but need
not, vest and therefore become exercisable in periodic installments
that may, but need not, be equal. The Option may be
subject to such other terms and conditions on the time or times
when it may be exercised (which may be based on performance or
other criteria) as the Board may deem appropriate. The
vesting provisions of individual Options may vary. The
provisions of this subsection 6(e) are subject to any Option
provisions governing the minimum number of shares of Common Stock
as to which an Option may be exercised.
(f
)
Termination of Continuous
Service
. In the event an Optionholder’s
Continuous Service terminates, the Optionholder (or the
Optionholder’s heirs, executor or successors) may exercise
his or her Option (to the extent that the Optionholder was entitled
to exercise such Option as of the date of termination) but only
within such period of time ending on the earlier of (i) the
date three (3) months following the termination of the
Optionholder’s Continuous Service (or such longer period
specified in the Option Agreement), or (ii) the expiration of
the term of the Option as set forth in the Option
Agreement. If, after termination, the Optionholder does
not exercise his or her Option within the time specified in the
Option Agreement, the Option shall be exercised on a cashless basis
per section 6(d) or terminate.
(g
)
Extension of Termination
Date
. An Optionholder’s Option Agreement
may also provide that if the exercise of the Option following the
termination of the Optionholder’s Employment and/or
Continuous Service would be prohibited at any time solely because
the issuance of shares of Common Stock would violate the
registration requirements under the Securities Act, then the Option
shall terminate on the earlier of (i) the expiration of the
term of the Option set forth in Section 6(a) or (ii) the
expiration of a period of six (6) months after the termination of
the Optionholder’s Continuous Service during which the
exercise of the Option would not be in violation of such
registration requirements.
(h
)
Intentionally Left Blank.
(i
)
Intentionally Left Blank.
(j
)
Early
Exercise
. The Option may, but need not, include a
provision whereby the Optionholder may elect at any time before the
Optionholder’s Continuous Service terminates to exercise the
Option as to any part or all of the shares of Common Stock subject
to the Option prior to the full vesting of the
Option.
7. Provisions of Stock Awards other than
Options.
(a
)
Stock
Awards
. Each Stock Award Agreement with regard to
Common Stock shall be in such form and shall contain such terms and
conditions as the Board shall deem appropriate. The
terms and conditions of Stock Award Agreements for Common Stock may
change from time to time, and the terms and conditions of separate
Stock Award Agreements for Common Stock need not be identical, but
each Stock Award Agreement shall include (through incorporation of
provisions hereof by reference in the agreement or otherwise) the
substance of each of the following provisions:
(i
)
Consideration
. A Stock Award of Common Stock may
be awarded in consideration for past services actually rendered to
the Company or an Affiliate for its benefit.
(ii
)
Vesting
. Stock Awards other than Options shall
vest in accordance with the schedule determined by the Board, which
shall be set forth in the applicable Stock Award
Agreement.
(iii
)
Termination of
Participant’s Continuous Service
. In the
event a Participant’s Continuous Service terminates, the
Company may reacquire any or all of the shares of Common Stock held
by the Participant which have not vested as of the date of
termination under the terms of the Stock Award
Agreement.
(b
)
Restricted Stock
Awards
. Each Stock Award Agreement with regard to
Restricted Stock shall be in such form and shall contain such terms
and conditions as the Board shall deem appropriate. The
terms and conditions of the Stock Award Agreement may change from
time to time, and the terms and conditions of separate Stock Award
Agreement for Restricted Stock need not be identical, but each
Stock Award Agreement regarding Restricted Stock shall include
(through incorporation of provisions hereof by reference in the
agreement or otherwise) the substance of each of the following
provisions:
(i
)
Transferability
. Except as provided in this
Section 7(b) or Section 10, shares of Restricted Stock may not be
sold, transferred, pledged, assigned, or otherwise alienated or
hypothecated until such time as the shares of Restricted Stock have
vested.
(ii
)
Other
Restrictions
. The Board, in its sole discretion,
may impose such other restrictions on shares of Restricted Stock as
it may deem advisable or appropriate.
(iii
)
Removal of
Restrictions
. Except as otherwise provided in
this Section 7(b), shares of Restricted Stock covered by each
Restricted Stock grant made under the Plan will be released from
escrow as soon as practicable after the date the shares of
Restricted Stock vest or at such other time as the Board may
determine. The Board, in its discretion, may accelerate
the time at which any restrictions will lapse or be
removed.
(iv
)
Voting
Rights
. During the period in which the shares of
Restricted Stock are not transferable, Participants holding shares
of Restricted Stock granted hereunder may exercise full voting
rights with respect to those Shares, unless the Board determines
otherwise.
(v
)
Dividends and Other
Distributions
. During the period in which the
shares of Restricted Stock are not transferable, Participants
holding shares of Restricted Stock will be entitled to receive all
dividends and other distributions paid with respect to such shares,
unless the Board provides otherwise. If any such
dividends or distributions are paid in shares, the shares will be
subject to the same restrictions on transferability and
forfeitability as the shares of Restricted Stock with respect to
which they were paid.
(vi
)
Return of Restricted
Stock to the Company
. On the date set forth in
the Stock Award Agreement, the Restricted Stock for which
restrictions have not lapsed will revert to the Company and again
will become available for grant under the Plan.
(c
)
Restricted Stock
Units
. Restricted Stock Units may be granted at
any time and from time to time as determined by the
Board. After the Board determines that it will grant
Restricted Stock Units under the Plan, it shall advise the
Participant in a Stock Award Agreement for Restricted Stock Units
of the terms, conditions, and restrictions related to the grant,
including the number of Restricted Stock Units.
(i
)
Vesting Criteria and
Other Terms
. The Board shall set vesting criteria
in its discretion, which, depending on the extent to which the
criteria are met, will determine the number of Restricted Stock
Units that will be paid out to the Participant. The
Board may set vesting criteria based upon the achievement of
Company-wide, business unit, or individual goals (including, but
not limited to, continued employment), or any other basis
determined by the Board in its discretion.
(ii
)
Settlement of Restricted Stock
Units
. Restricted Stock Units shall be settled
within 10 business days after vesting, either by delivery to the
Participant of shares of Common Stock (with appropriate Securities
Act restrictive legends) or, at the election of the Company, by
delivery to the Participant of a cash payment based upon the Fair
Market Value of the Company’s Common Stock on the date of
vesting for each Restricted Stock Unit
vested.
8. Covenants of the Company.
(a
)
Availability of
Shares
. During the terms of the Stock Awards, the
Company shall keep available at all times the number of shares of
Common Stock required to satisfy such Stock Awards.
(b
)
Securities Law
Compliance
. The Company shall seek to obtain from
each regulatory commission or agency having jurisdiction over the
Plan such authority as may be required to grant Stock Awards and to
issue and sell shares of Common Stock upon exercise of the Stock
Awards;
provided, however
,
that this undertaking shall not require the Company to register
under the Securities Act the Plan, any Stock Award or any Common
Stock issued or issuable pursuant to any such Stock
Award. If, after reasonable efforts, the Company is
unable to obtain from any such regulatory commission or agency the
authority which counsel for the Company deems necessary for the
lawful issuance and sale of Common Stock under the Plan, the
Company shall be relieved from any liability for failure to issue
and sell Common Stock upon exercise of such Stock Awards unless and
until such authority is obtained.
9. Use of Proceeds from Stock
Proceeds from the
sale of Common Stock pursuant to Stock Awards shall constitute
general funds of the Company.
10. Transferability of Awards.
(a
)
General
. Unless determined otherwise by the
Board, a Stock Award may not be sold, pledged, assigned,
hypothecated, transferred, or disposed of in any manner other than
by will, by the laws of descent or distribution, to a revocable
trust, or as permitted by Rule 701, and may be exercised, during
the lifetime of the Participant, only by the
Participant. If the Board makes a Stock Award
transferable, such Stock Award will contain such additional terms
and conditions as the Board deems appropriate.
(b
)
Stock Award Transfer
Program
. Notwithstanding any contrary provision
of the Plan, the Board shall have all discretion and authority to
determine and implement the terms and conditions of any Stock Award
Transfer Program instituted pursuant to this Section 10(b) and
shall have the authority to amend the terms of any Stock Award
participating, or otherwise eligible to participate in, the Stock
Award Transfer Program, including (but not limited to) the
authority to (i) amend (including to extend) the expiration date,
post-termination exercise period and/or forfeiture conditions of
any such Stock Award, (ii) amend or remove any provisions of the
Stock Award relating to the Stock Award holder’s continued
service to the Company, (iii) amend the permissible payment methods
with respect to the exercise or purchase of any such Stock Award,
(iv) amend the adjustments to be implemented in the event of
changes in the capitalization and other similar events with respect
to such Stock Award, and (v) make such other changes to the terms
of such Stock Award as the Board deems necessary or appropriate in
its sole discretion.
11. Miscellaneous.
(a
)
Acceleration of
Exercisability and Vesting
. The Board shall have
the power to accelerate the time at which a Stock Award may first
be exercised or the time during which a Stock Award or any part
thereof will vest in accordance with the Plan, notwithstanding the
provisions in the Stock Award stating the time at which it may
first be exercised or the time during which it will
vest.
(b
)
Stockholder
Rights
. Except to the limited extent provided in
Section 7(b), no Participant (nor any beneficiary) shall have any
of the rights or privileges of a stockholder of the Company with
respect to any shares of Common Stock issuable pursuant to a Stock
Award (or exercise thereof), unless and until certificates
representing such shares shall have been issued, recorded on the
records of the Company or its transfer agents or registrars, and
delivered to the Participant (or beneficiary).
(c
)
No Employment or other
Service Rights
. Nothing in the Plan or any
instrument executed or Stock Award granted pursuant thereto shall
confer upon any Participant any right to continue to serve the
Company or an Affiliate in the capacity in effect at the time the
Stock Award was granted or shall affect the right of the Company or
an Affiliate to terminate (i) the employment of an Employee
with or without notice and with or without cause, (ii) the
service of a Consultant pursuant to the terms of such
Consultant’s agreement with the Company or an Affiliate or
(iii) the service of a Director pursuant to the Bylaws of the
Company or an Affiliate, and any applicable provisions of the
corporate law of the state in which the Company or the Affiliate is
incorporated, as the case may be.
(d
)
Intentionally Left Blank.
(e
)
Investment
Assurances
. The Company may require a
Participant, as a condition of exercising or acquiring Common Stock
under any Stock Award, (i) to give written assurances
satisfactory to the Company as to the Participant’s knowledge
and experience in financial and business matters and/or to employ a
purchaser representative reasonably satisfactory to the Company who
is knowledgeable and experienced in financial and business matters
and that he or she is capable of evaluating, alone or together with
the purchaser representative, the merits and risks of exercising
the Stock Award; and (ii) to give written assurances
satisfactory to the Company stating that the Participant is
acquiring Common Stock subject to the Stock Award for the
Participant’s own account and not with any present intention
of selling or otherwise distributing the Common
Stock. The foregoing requirements, and any assurances
given pursuant to such requirements, shall be inoperative if
(1) the issuance of the shares of Common Stock upon the
exercise or acquisition of Common Stock under the Stock Award has
been registered under a then currently effective registration
statement under the Securities Act or (2) as to any particular
requirement, a determination is made by counsel for the Company
that such requirement need not be met in the circumstances under
the then applicable securities laws. The Company may,
upon advice of counsel to the Company, place legends on stock
certificates issued under the Plan as such counsel deems necessary
or appropriate in order to comply with applicable securities laws,
including, but not limited to, legends restricting the transfer of
the Common Stock.
(f
)
Withholding
Obligations
. To the extent provided by the terms
of a Stock Award Agreement, the Participant may satisfy any
federal, state or local tax withholding obligation relating to the
exercise or acquisition of Common Stock under a Stock Award by any
of the following means,
if authorized
by the Board in its sole discretion, after considering any tax,
accounting and financial consequences
(in
addition to the Company’s right to withhold from any
compensation paid to the Participant by the Company), or by a
combination of such means: (i) tendering a cash payment;
(ii) authorizing the Company to withhold shares of Common
Stock from the shares of Common Stock otherwise issuable to the
Participant as a result of the exercise or acquisition of Common
Stock under the Stock Award,
provided, however
, that no shares of
Common Stock are withheld with a value exceeding the minimum amount
of tax required to be withheld by law; or (iii) delivering to
the Company owned and unencumbered shares of Common
Stock.
(g
)
Information
Obligation
. To the extent required by applicable
state law, the Company shall deliver financial statements to
Participants at least annually. This
subsection 10(g) shall not apply to key Employees whose duties
in connection with the Company assure them access to equivalent
information.
12. Adjustments upon Changes in
Stock.
(a
)
Capitalization
Adjustments
. If any change is made in the Common
Stock subject to the Plan, or subject to any Stock Award, without
the receipt of consideration by the Company (through merger,
consolidation, reorganization, recapitalization, reincorporation,
stock dividend, dividend in property other than cash, stock split,
liquidating dividend, combination of shares, exchange of shares,
change in corporate structure or other transaction not involving
the receipt of consideration by the Company), the Plan will be
appropriately adjusted in the class(es) and maximum number of
securities subject to the Plan pursuant to Section 4(a) and
the maximum number of securities subject to award to any person
pursuant to Section 5(c), and the outstanding Stock Awards
will be appropriately adjusted in the class(es) and number of
securities and price per share of Common Stock subject to such
outstanding Stock Awards. The Board shall make such
adjustments, and its determination shall be final, binding and
conclusive. (The conversion of any convertible
securities of the Company shall not be treated as a transaction
“without receipt of consideration” by the
Company.)
(b
)
Dissolution or
Liquidation
. In the event of a dissolution or
liquidation of the Company, then all outstanding Stock Awards shall
terminate immediately prior to such event.
(c
)
Asset Sale, Merger,
Consolidation or Reverse Merger
. In the event of
(i) a sale, lease or other disposition of all or substantially
all of the assets of the Company, (ii) a merger or
consolidation in which the Company is not the surviving corporation
or (iii) a reverse merger in which the Company is the
surviving corporation but the shares of Common Stock outstanding
immediately preceding the merger are converted by virtue of the
merger into other property, whether in the form of securities, cash
or otherwise (individually, a “Corporate Transaction”),
then any surviving corporation or acquiring corporation shall
assume any Stock Awards outstanding under the Plan or shall
substitute similar stock awards (including an award to acquire the
same consideration paid to the stockholders in the Corporate
Transaction) for those outstanding under the Plan. In
the event any surviving corporation or acquiring corporation
refuses to assume such Stock Awards or to substitute similar stock
awards for those outstanding under the Plan, then with respect to
Stock Awards held by Participants whose Continuous Service has not
terminated, the vesting of such Stock Awards (and, if applicable,
the time during which such Stock Awards may be exercised) shall be
accelerated in full, and the Stock Awards shall terminate if not
exercised (if applicable) at or prior to the Corporate
Transaction. With respect to any other Stock Awards
outstanding under the Plan, such Stock Awards shall terminate if
not exercised (if applicable) prior to the Corporate Transaction.
Notwithstanding the foregoing provisions of this paragraph,
Participants shall be allowed not less than six (6) months to
exercise Stock Awards so vested.
13. Amendment of the Plan and Stock
Awards.
(a
)
Amendment of
Plan
. The Board at any time, and from time to
time, may amend the Plan. However, except as provided in
Section 12 relating to adjustments upon changes in Common
Stock, no amendment shall be effective unless approved by the
stockholders of the Company to the extent stockholder approval is
necessary to satisfy the requirements of Section 422 of the
Code, Rule 16b-3 or any NASDAQ or securities exchange listing
requirements.
(b
)
Stockholder
Approval
. The Board may, in its sole discretion,
submit any other amendment to the Plan for stockholder approval,
including, but not limited to, amendments to the Plan intended to
satisfy the requirements of Section 162(m) of the Code and the
regulations thereunder regarding the exclusion of performance-based
compensation from the limit on corporate deductibility of
compensation paid to certain executive officers.
(c
)
Contemplated
Amendments
. It is expressly contemplated that the
Board may amend the Plan in any respect the Board deems necessary
or advisable to provide eligible Employees with the maximum
benefits provided or to be provided under the provisions of the
Code and the regulations promulgated thereunder relating to
Incentive Stock Options and/or to bring the Plan and/or Incentive
Stock Options granted under it into compliance
therewith.
(d
)
No Impairment of
Rights
. Rights under any Stock Award granted
before amendment of the Plan shall not be impaired by any amendment
of the Plan unless (i) the Company requests the consent of the
Participant and (ii) the Participant consents in
writing.
(e
)
Amendment of Stock
Awards
. The Board at any time, and from time to
time, may amend the terms of any one or more Stock Awards;
provided, however
, that the
rights under any Stock Award shall not be impaired by any such
amendment unless (i) the Company requests the consent of the
Participant, and (ii) the Participant consents in
writing.
14. Termination or Suspension of the
Plan.
(a
)
Plan
Term
. The Board may suspend or terminate the Plan
at any time. Unless sooner terminated, the Plan shall
terminate on the day before the tenth (10th) anniversary of the
date the Plan is adopted by the Board. No Stock Awards
may be granted under the Plan while the Plan is suspended or after
it is terminated.
(b
)
No Impairment of
Rights
. Suspension or termination of the Plan
shall not impair rights and obligations under any Stock Award
granted while the Plan is in effect except with the written consent
of the Participant.
15. Effective Date of Plan.
The
Plan shall become effective as of the date of approval by the
Board.
16. Choice of Law.
The law
of the State of Delaware shall govern all questions concerning the
construction, validity and interpretation of this Plan, without
regard to such state’s conflict of laws rules.
IN
WITNESS WHEREOF, the Company, by its duly authorized officer, has
executed this Plan on the date indicated below.
|
WRAP
TECHNOLOGIES, INC.
|
|
|
Dated:
March 31, 2017
|
/s/ James A.
Barnes
|
|
Name:
James A. Barnes
|
|
Title:
Chief Executive Officer
|
Approved By the Board of Directors on March 28, 2017
Approved By Stockholders: March 28, 2017
Termination Date: March 28, 2027
Exhibit 14.1
WRAP TECHNOLOGIES, INC.
CODE OF ETHICS
As a public company, it is of critical importance that filings with
the Securities and Exchange Commission by Wrap Technologies, Inc.
(the “
Company
”) be accurate and timely. Depending on
their position with the Company, employees may be called upon to
provide information to assure that the Company's public reports are
complete, fair, and understandable. The Company expects all of its
employees to take this responsibility seriously and to provide
prompt and accurate answers to inquiries related to the
Company’s public disclosure requirements.
The Company’s Finance and Accounting Department (the
“
Department
”) bears a special responsibility for
promoting integrity throughout the Company, with responsibilities
to stakeholders both inside and outside of the Company. The Chief
Executive Officer (“
CEO
”), Chief Financial Officer
(“
CFO
”), and the Department’s personnel
have a special role both to adhere to the principles of integrity
and also to ensure that a culture exists throughout the Company as
a whole that ensures the fair and timely reporting of the
Company’s results from operations and financial condition.
Because of this special role, the CEO, CFO, and all members of the
Department are bound by the Company’s Code of Ethics, and by
accepting the Code of Ethics, each agrees that they
will:
-
Act
with honesty and integrity, avoiding actual or apparent conflicts
of interest in personal and professional
relationships;
-
Provide
information that is accurate, complete, objective, relevant, timely
and understandable to ensure full, fair, accurate, timely, and
understandable disclosure in the reports and documents that the
Company files with, or submits to, government agencies and in other
public communications;
-
Comply
with the rules and regulations of federal, state and local
governments, and other appropriate private and public regulatory
agencies;
-
Act
in good faith, responsibly, with due care, competence and
diligence, without misrepresenting material facts or allowing one's
independent judgment to be subordinated;
-
Respect
the confidentiality of information acquired in the course of one's
work, except when authorized or otherwise legally obligated to
disclose. Confidential information acquired in the course of one's
work will not be used for personal advantage;
-
Share
job knowledge and maintain skills important and relevant to
stakeholders needs;
-
Proactively
promote and be an example of ethical behavior as a responsible
partner among peers, in the work environment and in the
community;
-
Achieve
responsible use of, and control over, all Company assets and
resources employed by, or entrusted to yourself, and your
department;
-
Receive
the full and active support and cooperation of the Company’s
officers, senior staff, and all employees in the adherence to this
Code of Ethics; and
-
Promptly
report to the CEO or CFO any conduct believed to be in violation of
law or business ethics or in violation of any provision of this
Code of Ethics, including any transaction or relationship that
reasonably could be expected to give rise to such a conflict.
Further, to promptly report to the Chair of the Company’s
Audit Committee or the Board of Directors prior to the
formation of the Audit Committee, such conduct if by the CEO or CFO
or if they fail to correct such conduct by others in a reasonable
period of time.
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM
We hereby consent to the use in this Registration Statement on Form
S-1 of Wrap Technologies, Inc. of our report dated March 29, 2017
relating to the financial statements of Wrap Technologies, LLC
which appears in such Registration Statement.
We also consent to the reference to us under the caption
“Experts” in this registration statement.
/s/ Rosenberg Rich Baker Berman & Company
Somerset, New Jersey
April 17, 2017